
<html lang="en"     class="pb-page"  data-request-id="5c6641da-a74d-461f-bef7-c72aa32a95ad"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01223;issue:issue:10.1021/jmcmar.2020.63.issue-1;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance" /></meta><meta name="dc.Creator" content="Zhikun  Liu" /></meta><meta name="dc.Creator" content="Meng  Wang" /></meta><meta name="dc.Creator" content="Hengshan  Wang" /></meta><meta name="dc.Creator" content="Lei  Fang" /></meta><meta name="dc.Creator" content="Shaohua  Gou" /></meta><meta name="dc.Description" content="Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated fro..." /></meta><meta name="Description" content="Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated fro..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 10, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01223" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01223" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01223" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01223" /></link>
        
    
    

<title>Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01223" /></meta><meta property="og:title" content="Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0017.jpeg" /></meta><meta property="og:description" content="Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rigosertib were designed. Among them, compound 29 showed the most potent antitumor activity in vitro with IC50 values at the nanomolar level against the tested tumor cell lines and 1000-fold higher than cisplatin against the multidrug resistant cells (A549/CDDP, A549/DOX, and SKOV-3/CDDP cells), while it showed only moderate cytotoxicity against normal cells (HEUVC cells). Compound 29 could clearly disturb signaling transduction between RAS and CRAF by directly bonding to CRAF and inhibit CRAF activation. Besides, the enhanced intracellular platinum level made 29 more potent than cisplatin in DNA damage, reactive oxygen species accumulation, and mitochondrial membrane potential decrease. Moreover, 29 induced apoptosis by the endogenous pathway and efficiently inhibited tumor growth in the A549 xenograft model without side effects." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01223"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01223">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01223&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01223&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01223&amp;href=/doi/10.1021/acs.jmedchem.9b01223" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 186-204</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00796" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01244" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Zhikun Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhikun Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhikun++Liu">Zhikun Liu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Meng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Meng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Meng++Wang">Meng Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Hengshan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengshan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengshan++Wang">Hengshan Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6474-8323" title="Orcid link">http://orcid.org/0000-0001-6474-8323</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lei Fang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#a5c9c0cc8bc3c4cbc2e5d6c0d08bc0c1d08bc6cb"><span class="__cf_email__" data-cfemail="bed2dbd790d8dfd0d9fecddbcb90dbdacb90ddd0">[emailÂ protected]</span></a> (L.F.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Fang">Lei Fang</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Shaohua Gou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaohua Gou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#582b3f372d182b3d2d763d3c2d763b36"><span class="__cf_email__" data-cfemail="4132262e34013224346f2425346f222f">[emailÂ protected]</span></a> (S.G.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaohua++Gou">Shaohua Gou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01223&amp;href=/doi/10.1021%2Facs.jmedchem.9b01223" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 186â204</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 10, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 July 2019</li><li><span class="item_label"><b>Published</b> online</span>10 December 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 January 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01223" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01223</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D186%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DZhikun%2BLiu%252C%2BMeng%2BWang%252C%2BHengshan%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D1%26contentID%3Dacs.jmedchem.9b01223%26title%3DPlatinum-Based%2BModification%2Bof%2BStyrylbenzylsulfones%2Bas%2BMultifunctional%2BAntitumor%2BAgents%253A%2BTargeting%2Bthe%2BRAS%252FRAF%2BPathway%252C%2BEnhancing%2BAntitumor%2BActivity%252C%2Band%2BOvercoming%2BMultidrug%2BResistance%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D204%26publicationDate%3DJanuary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01223"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1203</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01223" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Zhikun&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Meng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Hengshan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Fang&quot;},{&quot;first_name&quot;:&quot;Shaohua&quot;,&quot;last_name&quot;:&quot;Gou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;186-204&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01223&quot;},&quot;abstract&quot;:&quot;Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rigosertib were designed. Among them, compound 29 showed the most potent antitumor activity in vitro with IC50 values at the nanomolar level against the tested tumor cell lines and 1000-fold higher than cisplatin against the multidrug resistant cells (A549/CDDP, A549/DOX, and SKOV-3/CDDP cells), while it showed only moderate cytotoxicity against normal cells (HEUVC cells). Compound 29 could clearly disturb signaling transduction between RAS and CRAF by directly bonding to CRAF and inhibit CRAF activation. Besides, the enhanced intracellular platinum level made 29 more potent than cisplatin in DNA damage, reactive oxygen species accumulation, and mitochondrial membrane potential decrease. Moreover, 29 induced apoptosis by the endogenous pathway and efficiently in&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01223&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01223" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01223&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01223" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01223&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01223" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01223&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01223&amp;href=/doi/10.1021/acs.jmedchem.9b01223" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01223" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01223" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01223%26sid%3Dliteratum%253Aachs%26pmid%3D31820986%26genre%3Darticle%26aulast%3DLiu%26date%3D2020%26atitle%3DPlatinum-Based%2BModification%2Bof%2BStyrylbenzylsulfones%2Bas%2BMultifunctional%2BAntitumor%2BAgents%253A%2BTargeting%2Bthe%2BRAS%252FRAF%2BPathway%252C%2BEnhancing%2BAntitumor%2BActivity%252C%2Band%2BOvercoming%2BMultidrug%2BResistance%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D1%26spage%3D186%26epage%3D204%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/jmcmar.2020.63.issue-1/20200109/jmcmar.2020.63.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rigosertib were designed. Among them, compound <b>29</b> showed the most potent antitumor activity in vitro with IC<sub>50</sub> values at the nanomolar level against the tested tumor cell lines and 1000-fold higher than cisplatin against the multidrug resistant cells (A549/CDDP, A549/DOX, and SKOV-3/CDDP cells), while it showed only moderate cytotoxicity against normal cells (HEUVC cells). Compound <b>29</b> could clearly disturb signaling transduction between RAS and CRAF by directly bonding to CRAF and inhibit CRAF activation. Besides, the enhanced intracellular platinum level made <b>29</b> more potent than cisplatin in DNA damage, reactive oxygen species accumulation, and mitochondrial membrane potential decrease. Moreover, <b>29</b> induced apoptosis by the endogenous pathway and efficiently inhibited tumor growth in the A549 xenograft model without side effects.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mitogen-activated protein kinase (MAPK) signaling pathway is of great importance to cellular biological functions, which not only activates proliferative signals but also affects signals that are responsible for differentiation and apoptosis.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1â3)</a> The signal transmission is achieved by the conversation from RAS.GDP (inactive) to RAS.GTP (active) with the help of extracellular signals and in turn triggering several downstream cascades, including the RAF/MEK/ERK pathway.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Naturally, the MAPK pathway was frequently dysregulated in many cancer-harboring RAS mutations, resulting in constitutive activation of the pathway, uncontrolled proliferation, and decreased cellular sensitivity to agents that could originally induce apoptosis.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5â7)</a> Therefore, it will be attractive to inhibit the activation of RAS for the treatment of cancers. However, the lack of well-defined druggable pockets and cavities on the RAS surface made RAS an âundruggableâ target.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8â10)</a> In addition, the RAS genes in cancer cells mutated frequently, which made inhibition of RAS activation directly more challenging. Thus, alternatively, disturbing the signal transduction between RAS proteins and downstream effectors could serve as a new approach to develop novel RAS-driven therapies.</div><div class="NLM_p">In mammals, the RAF family contains three members: ARAF, BRAF, and CRAF, binding with RAS as the upstream activator and mediating the MAPK signaling transduction to the MEK as only the downstream effector. Among these three subtypes, CRAF plays an important role as a mediator in mutant KRAS-driven proliferation and tumor development.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> On the other hand, CRAF also affects the antitumor activity of BRAF inhibitors and MEK feedback-mediated pathway.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12â14)</a> Therefore, in consideration of inhibiting signaling transduction of RAS, inhibition of CRAF activation was proved to be an effective method to disturb RAS-driven tumorigenesis and feedback reactivation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Rigosertib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) belongs to the benzylstyryl sulphone compounds and can inhibit tumor cell proliferation in nanamole ranges, including some resistant cells.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> In in vitro study, Rigosertib acted as RAS analogues to bind to RAS effectors, resulting in their inability to bind to RAS, disrupting RAF activation, and inhibiting activation of the RAS/RAF/MEK pathway.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of Rigosertib and current Pt(II) drugs approved for worldwide use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the structureâactivity relationship point of view, the nature, number, and position of substituents on the two aromatic rings of Rigosertib, as described by Reddy et al.,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> are conservative and cannot tolerate significant structural modification. Thus, we have paid attention to the carboxyl group at the end of the side chain. In the past, the therapeutic potential of metal-based complexes has been widely used and investigated for cancer therapy because of the unique characteristics of metals, such as redox activity, lewis acid properties, and reactivity toward the organic substrate.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> A large number of metal-based complexes have been designed and synthesized, and among them several complexes were proved to be promising anticancer agents. For example, Ma et al. found a novel benzofuran-conjugated iridium(III) complex as a STAT3 and NF-kB dual inhibitor in prostate cancer cells.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Leung et al. found an enantiomeric iridium(III) metal-based compound as an efficient RAS/RAF interaction inhibitor, which could directly engage both H-Ras and Raf-1-RBD and efficiently disrupt the signaling between RAF/RAF/MEK/ERK.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Zhang et al. also summarized chirality metal-based agents in cancer research.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Therefore, metal-based complexes in cancer therapy has attracted a lot of interest. Platinum drugs, such as cisplatin (CDDP), carboplatin and oxaliplatin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), have been developed into an important part of clinical chemotherapy. As a kind of cytotoxic agents, platinum drugs mainly act on DNA and then cause death of tumor cells. This action mechanism is quite different from that of Rigosertib, suggesting that introduction of platinum pharmacophore to Rigosertib may give additional activity to the parent compound. On the other hand, the platinum drugs often suffer from the severe toxic side effects and the acquired resistance associated with the long-term application.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26 ref27">(22â27)</a> Given the good performance of RAS inhibitors against the multiple-resistance tumor cells, it may be anticipated that combination of Rigosertib and platinum drugs may overcome the resistance.</div><div class="NLM_p">In this context, we here made structural modifications to Rigosertib by conjugating a platinum(IV) complex, which can be considered as a stable prodrug of the classic platinum(II) drug<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> to carboxyl group via different linkers. The resulting conjugates were supposed to be relatively stable under the circulation condition, and the good lipophilicity,<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> as compared with the traditional platinum(II) complex, could be beneficial for the uptake by tumor cells. When entering the tumor cells, the conjugates could be effectively reduced by the reductive substances (e.g., glutathione, protein, and other biomoleculesn<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32">(28â32)</a>) in tumor cells to release Rigosertib and platinum(II) complex to exert antitumor activity via different pathways. Thus, enhancing activity and the potential to overcome the multidrug resistance can be expected. Our drug design idea is outlined in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural modification strategy and the drug design idea of the target compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Chemistry</h3><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, compound <b>8</b> was prepared according to previously reported procedures,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> which was further esterified and followed by a hydrolysis reaction to give compounds <b>13</b> and <b>14</b>. Pt(IV) complexes <b>15</b>, <b>16</b>, and <b>17</b> were obtained by oxidation of the corresponding Pt(II) complexes following known procedures.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32â34)</a> As for the synthesis of compound <b>26</b> (carboxyl acid form of Rigosertib), compound <b>8</b> was first treated with ethyl bromoacetate and then hydrolyzed to offer <b>26</b> in high yield. Finally, nine Pt(IV) derivatives were obtained via combining <b>15</b>, <b>16</b>, or <b>17</b> with compounds <b>13, 14</b>, and <b>26</b>, respectively, in the presence of <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyluronium tetrafluoroborate (TBTU). All of the target compounds were characterized with <sup>1</sup>H NMR, <sup>13</sup>C NMR, and ESIâMS techniques.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Pt(IV)Â Complexes <b>18â23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) NaBH<sub>4</sub>, MeOH; (c) PBr<sub>3</sub>, DCM; (d) mercapto acetic acid, NaOH, MeOH; (e) H<sub>2</sub>O<sub>2</sub>, AcOH; (f) piperidine, benzoic acid, toluene; (g) Fe, NH<sub>4</sub>Cl, EtOH, H<sub>2</sub>O; (h) oxalyl chloride, Et<sub>3</sub>N, DCM; (i) LiOHÂ·H<sub>2</sub>O, CH<sub>3</sub>OH, H<sub>2</sub>O; (j) TBTU, Et<sub>3</sub>N, <b>15</b>/<b>16</b>/<b>17</b>, DMF.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Pt(IV) Complexes <b>27â29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, KI, DMF; (b) LiOHÂ·H<sub>2</sub>O, CH<sub>3</sub>OH, H<sub>2</sub>O; (c) <b>15/16/17</b>, TBTU, Et<sub>3</sub>N, DMF.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  In Vitro Cytotoxicity Measurement</h3><div class="NLM_p">The cytotoxicity of the synthesized target compounds was evaluated by MTT methods, using <b>26</b> (carboxyl acid form of Rigosertib), cisplatin, and oxaliplatin as references. Different cancer cell lines, including A549 (nonsmall cell lung cancer cell line), MGC-803 (gastric cancer cell line), SKOV-3 (ovarian cancer cell line), and NCI-H460 (large cell lung cancer cell line) were used in this study. The results after 72 h drug exposure are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. All of these compounds tested showed moderate to strong antiproliferative activity against the cancer cells. It was found that the cytotoxicity of <b>19</b>, <b>21</b>, and <b>23</b> containing a four-methylene linker was higher than that of <b>18</b>, <b>20</b>, and <b>22</b> owning a three-methylene linker, but their IC<sub>50</sub> values are only at the level of cisplatin and oxaliplatin. Interestingly, when a glycine group was employed as the linker, the resulting complexes (i.e., <b>27</b>, <b>28</b>, <b>29</b>) showed much better activity than the above mentioned compounds. It was observed that all cancer cell lines tested were sensitive to complexes <b>27â29</b> with the IC<sub>50</sub> values comparable to those of compound <b>26</b> but much lower than those of cisplatin and oxaliplatin. Because the target complexes can be regarded as prodrugs, we assumed that the original styrylbenzylsulfone moiety was mainly responsible for their antitumor activity. Complexes <b>27â29</b> were capable of releasing <b>26</b>, a known potent antitumor agent. In contrast, complexes <b>18â23</b> were capable of releasing compounds <b>13</b> or <b>14</b>. Our MTT assay revealed that <b>13</b> or <b>14</b> showed only moderate cytotoxic activity with IC<sub>50</sub> values ranging from 10.81 to 17.31 Î¼M against the tested tumor cells (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), much lower than <b>26</b> whose IC<sub>50</sub> values ranged from 44 to 83 nM. Thus, it may be understandable why complexes <b>27â29</b> showed much better activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of the Tested Compounds toward Various Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center"><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">A549</th><th class="colsep0 rowsep0" align="center">MGC-803</th><th class="colsep0 rowsep0" align="center">SKOV-3</th><th class="colsep0 rowsep0" align="center">NCI-H460</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">10.81Â Â±Â 1.24</td><td class="colsep0 rowsep0" align="left">13.96Â Â±Â 1.23</td><td class="colsep0 rowsep0" align="left">17.31Â Â±Â 1.32</td><td class="colsep0 rowsep0" align="left">15.14Â Â±Â 0.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">13.82Â Â±Â 1.75</td><td class="colsep0 rowsep0" align="left">12.58Â Â±Â 1.67</td><td class="colsep0 rowsep0" align="left">14.58Â Â±Â 1.43</td><td class="colsep0 rowsep0" align="left">14.28Â Â±Â 1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">10.09Â Â±Â 0.83</td><td class="colsep0 rowsep0" align="left">5.70Â Â±Â 0.19</td><td class="colsep0 rowsep0" align="left">2.88Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="left">16.40Â Â±Â 1.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">6.91Â Â±Â 0.63</td><td class="colsep0 rowsep0" align="left">6.57Â Â±Â 0.25</td><td class="colsep0 rowsep0" align="left">2.81Â Â±Â 0.04</td><td class="colsep0 rowsep0" align="left">16.33Â Â±Â 1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">19.50Â Â±Â 1.18</td><td class="colsep0 rowsep0" align="left">4.03Â Â±Â 0.23</td><td class="colsep0 rowsep0" align="left">6.53Â Â±Â 0.32</td><td class="colsep0 rowsep0" align="left">23.39Â Â±Â 1.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">16.75Â Â±Â 0.88</td><td class="colsep0 rowsep0" align="left">4.68Â Â±Â 0.34</td><td class="colsep0 rowsep0" align="left">5.87Â±Â 0.25</td><td class="colsep0 rowsep0" align="left">13.99Â Â±Â 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">20.05Â Â±Â 1.74</td><td class="colsep0 rowsep0" align="left">11.39Â Â±Â 0.82</td><td class="colsep0 rowsep0" align="left">23.63Â Â±Â 1.14</td><td class="colsep0 rowsep0" align="left">25.55Â Â±Â 1.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">6.31Â Â±Â 0.75</td><td class="colsep0 rowsep0" align="left">5.83Â Â±Â 0.98</td><td class="colsep0 rowsep0" align="left">1.37Â Â±Â 0.47</td><td class="colsep0 rowsep0" align="left">4.89Â Â±Â 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">0.083Â Â±Â 0.023</td><td class="colsep0 rowsep0" align="left">0.054Â Â±Â 0.090</td><td class="colsep0 rowsep0" align="left">0.045Â Â±Â 0.190</td><td class="colsep0 rowsep0" align="left">0.044Â Â±Â 0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">0.094Â Â±Â 0.040</td><td class="colsep0 rowsep0" align="left">0.058Â Â±Â 0.120</td><td class="colsep0 rowsep0" align="left">0.079Â Â±Â 0.160</td><td class="colsep0 rowsep0" align="left">0.053Â Â±Â 0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">0.120Â Â±Â 0.130</td><td class="colsep0 rowsep0" align="left">0.062Â Â±Â 0.080</td><td class="colsep0 rowsep0" align="left">0.087Â Â±Â 0.070</td><td class="colsep0 rowsep0" align="left">0.089Â Â±Â 0.200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">0.006Â Â±Â 0.004</td><td class="colsep0 rowsep0" align="left">0.014Â Â±Â 0.008</td><td class="colsep0 rowsep0" align="left">0.050Â Â±Â 0.024</td><td class="colsep0 rowsep0" align="left">0.017Â Â±Â 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>CDDP/<b>26</b></td><td class="colsep0 rowsep0" align="left">0.076Â Â±Â 0.035</td><td class="colsep0 rowsep0" align="left">0.062Â Â±Â 0.049</td><td class="colsep0 rowsep0" align="left">0.050Â Â±Â 0.095</td><td class="colsep0 rowsep0" align="left">0.029Â Â±Â 0.010</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a>CDDP</td><td class="colsep0 rowsep0" align="left">8.22Â Â±Â 0.91</td><td class="colsep0 rowsep0" align="left">7.21Â Â±Â 0.83</td><td class="colsep0 rowsep0" align="left">5.45Â Â±Â 1.26</td><td class="colsep0 rowsep0" align="left">9.05Â Â±Â 0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a>oxa</td><td class="colsep0 rowsep0" align="left">11.95Â Â±Â 1.43</td><td class="colsep0 rowsep0" align="left">8.29Â Â±Â 0.76</td><td class="colsep0 rowsep0" align="left">12.06Â Â±Â 1.66</td><td class="colsep0 rowsep0" align="left">16.09Â Â±Â 2.44</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were presented as means Â± SD of three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">CDDP/<b>26</b>, cisplatin/<b>26</b> mixture (1:1, n/n); cisplatin.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">CDDP, cisplatin.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Oxa, oxaliplatin.</p></div></div></div><div class="NLM_p last">Among all of the target compounds, <b>29</b> showed the best activity, with the potency at least over 1000-fold higher than cisplatin and even 10-fold higher than <b>26</b> against A549. In contrast, the combination administration of <b>26</b> with cisplatin (i.e., equal molar <b>26</b>/cisplatin mixture) did not show significant improvement of the activity relative to the administration of <b>26</b> alone. Unexpectedly, compound <b>8</b> showed low cytotoxicity against these cancer cell lines tested, which may be attributed to the missing of the glycine group as well as its poor solubility in aqueous buffers and solutions.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, when the amino group was converted to glycine, the resulting compound <b>26</b> produced much better cytotoxic activity than compound <b>8</b> against all cancer cells used in this study. The enhanced activity of <b>26</b> illustrated that the glycine group was of great importance for the antiproliferative activity.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.3.  In Vitro Antiproliferative Activity of <b>29</b> Against CDDP/Doxorubicin-Resistant Cancer Cells and Normal Cells</h3><div class="NLM_p">Development of multidrug resistance to classical chemotherapeutic agents (e.g., cisplatin, doxorubicin) is the main reason for the failure of most first round chemotherapy. It was revealed that the overexpression of ATP binding cassette (ABC) transporters is responsible for the resistance because such transporters could enable the tumor cells to pump out drugs, thus reducing the intracellular drug concentrations. According to the previous report, Rigosertib was highly active against multidrug-resistant tumor cell lines that overexpress ABC transporters.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This is probably because the structure of Rigosertib cannot act as the substrate for ABC transport proteins and thus cannot be moved out the cell by ABC transport. Therefore, it will be interesting to investigate whether our target compounds, which are Rigosertib derivatives, could also overcome the multidrug resistance. Thus, the most active compound <b>29</b> was selected to test the cytotoxicity against CDDP-resistant A549 cells (A549/CDDP), doxorubicin-resistant A549 cells (A549/DOX), and CDDP-resistant SKOV3 cells (SKOV3/CDDP) as well as human umbilical vein endothelial cells (HUVECs), using <b>26</b> and CDDP as controls, respectively. To verify that these multidrug-resistant cancer cell lines were successfully constructed, we first performed MTT assays and Western blotting assays to identify whether they were drug-resistant or not. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S1</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Table S1</a>, the IC<sub>50</sub> values of A549/CDDP, A549/DOX, and SKOV3/CDDP were significantly increased when compared with those corresponding drug-sensitive A549 and SKOV-3 cancer cell lines. The resistant factors (RFs) of A549/CDDP, A549/DOX, and SKOV3/CDDP improved more than 4, 15, and 4 times than A549 and SKOV-3, respectively. Besides, Western blotting assays also revealed that P-glycoprotein (P-gp) in A549/CDDP, A549/DOX, and SKOV3/CDDP was also improved. Therefore, these drug-resistant cancer cell lines were successfully constructed. The results of <b>29</b> against the drug-resistant cancer cells are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. After 72 h co-incubation, both <b>26</b> and <b>29</b> showed high cytotoxicity to the drug-resistant tumor cells with very low IC<sub>50</sub> values from 0.008 to 0.094 Î¼M and the resistant factor not more than 1.5. In contrast, the activity of CDDP against A549/CDDP cells (IC<sub>50</sub> value was 35.77 Î¼M) and SKOV-3/CDDP cells (IC<sub>50</sub> value was 28.67 Î¼M) was significantly decreased as compared to that of nonresistant A549 and SKOV-3 tumor cells (RF values were 4.4 and 5.3, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). These results indicated that the A549/CDDP, A549/DOX, and SKOV3/CDDP cells showed obvious resistance to cisplatin but were sensitive to our designed compound <b>29</b>, meaning that <b>29</b> may overcome the multidrug resistance. Furthermore, in order to compare <b>29</b> with the combination administration of <b>26</b> with cisplatin, the cytotoxicity of <b>26</b>/cisplatin mixture (1:1, n/n) was also measured. It was found that its activity was comparable to that of <b>26</b>, but lower than <b>29</b>, especially to the A549 cells. Particularly, the mixture showed highest toxicity to human normal cells (IC<sub>50</sub> 0.78 Î¼M against HUVEC cells), suggesting a serious safety risk. In contrast, compound <b>29</b> showed only moderate cytotoxicity to human normal cells (IC<sub>50</sub> 8.74 Î¼M against HUVEC cells), at least 100-fold lower than that against tumor cells, indicating a good safety and a wide therapeutic window for compound <b>29</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values in Vitro of Tested Compounds in Various CDDP-Resistant Cancer Lines and Human Normal Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center"><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>IC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center"><b>26</b></th><th class="colsep0 rowsep0" align="center"><b>29</b></th><th class="colsep0 rowsep0" align="center">CDDP</th><th class="colsep0 rowsep0" align="center">CDDP/<b>26</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">0.083Â Â±Â 0.023</td><td class="colsep0 rowsep0" align="left">0.006Â Â±Â 0.004</td><td class="colsep0 rowsep0" align="left">8.22Â Â±Â 0.91</td><td class="colsep0 rowsep0" align="left">0.089Â Â±Â 0.055</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV-3</td><td class="colsep0 rowsep0" align="left">0.045Â Â±Â 0.009</td><td class="colsep0 rowsep0" align="left">0.050Â Â±Â 0.024</td><td class="colsep0 rowsep0" align="left">5.45Â Â±Â 1.26</td><td class="colsep0 rowsep0" align="left">0.051Â Â±Â 0.020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549/CDDP</td><td class="colsep0 rowsep0" align="left">0.094Â Â±Â 0.040</td><td class="colsep0 rowsep0" align="left">0.008Â Â±Â 0.011</td><td class="colsep0 rowsep0" align="left">35.77Â Â±Â 2.24</td><td class="colsep0 rowsep0" align="left">0.082Â Â±0Â .035</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV-3/CDDP</td><td class="colsep0 rowsep0" align="left">0.041Â Â±Â 0.039</td><td class="colsep0 rowsep0" align="left">0.038Â Â±Â 0.025</td><td class="colsep0 rowsep0" align="left">28.67Â Â±Â 2.24</td><td class="colsep0 rowsep0" align="left">0.050Â Â±Â 0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549/DOX</td><td class="colsep0 rowsep0" align="left">0.081Â Â±Â 0.020</td><td class="colsep0 rowsep0" align="left">0.009Â Â±Â 0.005</td><td class="colsep0 rowsep0" align="left">18.81Â Â±Â 0.95</td><td class="colsep0 rowsep0" align="left">0.076Â Â±Â 0Â .039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HUVEC</td><td class="colsep0 rowsep0" align="left">3.59Â Â±Â 0.55</td><td class="colsep0 rowsep0" align="left">8.74Â Â±Â 0.44</td><td class="colsep0 rowsep0" align="left">9.03Â Â±Â 0.78</td><td class="colsep0 rowsep0" align="left">0.78Â Â±Â 0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>RF1</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a>RF2</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a>RF3</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub>, values were presented as means Â± SD of three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">RF1, resistant factor = IC<sub>50</sub> (A549/CDDP)/IC<sub>50</sub> (A549).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">RF2, resistant factor = IC<sub>50</sub> (SKOV-3/CDDP)/IC<sub>50</sub> (SKOV-3).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">RF3, resistant factor = IC<sub>50</sub> (A549/DOX)/IC<sub>50</sub> (A549).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.4.  High-Performance Liquid Chromatography Analysis on the Release of Rigosertib Moiety under the Reduction of Ascorbic Acid</h3><div class="NLM_p">The target compounds, especially compound <b>29</b>, showed remarkable activity to both normal and drug-resistant tumor cells. This exciting result might be attributed to that the Pt(IV) part of the target compound could be reduced to release the corresponding Pt(II) part and the Rigosertib moiety under reduction, thus a synergistic effect can be achieved. In order to prove this drug design strategy, high-performance liquid chromatography (HPLC) analysis was performed for compound <b>29</b> which was cocultured with/without ascorbic acid (3.0 equiv) in a mixture of phosphate buffer saline (PBS) (pH = 7.4) and acetonitrile (90:10, v/v) and preserved at 37 Â°C water bath in dark. Compound <b>26</b> and ascorbic acid dissolved in the same solvent mentioned above were used as controls to match the peaks of compound <b>29</b> in the reduction process. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S2D</a>, compound <b>29</b> was stable in 72 h in the PBS (pH = 7.4) solution. In view of the acidic microenvironment of tumor cells, the stability of <b>29</b> in the PBS (pH = 5.5) was also investigated. The results in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S2E</a> showed that more than 90% percent of 29 remained stable in the solution within 24 h. However, when mixed with ascorbic acid, two peaks (i.e., ascorbic acid and compound <b>26</b> peaks) appeared as time passed. The peak of compound <b>29</b> gradually decreased with an increasing peak at the position of compound <b>26</b>, indicating that compound <b>29</b> could release compound <b>26</b> upon the reduction of ascorbic acid. Unsurprisingly, no peak of cisplatin was detected because of its weak chromophore under the tested condition. In all, compound <b>29</b> was stable under physiological condition and could be effectively reduced to release <b>26</b> within 5 h when exposed to ascorbic acid.</div><div class="NLM_p last">In order to verify that <b>29</b> can release <b>26</b> and CDDP in cells and detect the concentration of <b>26</b> in cancer cells, HPLC analysis was performed. Briefly, A549 cells was coincubated with <b>29</b> (10, 5, 2 Î¼M) for 24 h, washed with PBS, and lysed to obtain cell lysates. Supernatant fraction gained after centrifugation was recorded and analyzed with RP-HPLC (waters, e2695 system; 2489 UV/vis detector). The standard curve of <b>26</b> is displayed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S3</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Table S2</a>, and the results of cell lysates are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Table S3</a>. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S4</a>, no peak of <b>29</b> (Rt = 6.8 min) but only <b>26</b> (Rt = 8.1 min) was detected, illustrating that <b>29</b> was fully reduced to <b>26</b> in A549 cells in 24 h. The reduction of <b>29</b> in A549 cells was further proved with high-resolution mass spectrometry (HR-MS) in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S4D</a> (<b>26</b>, M + H = 452.1359) and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S4E</a> (CDDP, M + Na = 322.9356). As for the intracellular concentration of <b>26</b>, 0.77, 2.88, or 5.91 Î¼M of <b>26</b> could be detected after A549 cells co-incubated with 2, 5 or 10 Î¼M of <b>29</b>, respectively. Therefore, we conclude that <b>29</b> can be fully reduced in A549 cells in 24 h to release <b>26</b> and CDDP.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.5.  Cellular Uptake</h3><div class="NLM_p">Compound <b>29</b> showed excellent cytotoxicity in the cellular assays, which may, according to the former findings, be partly attributed to the improved cellular uptake.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32 ref33">(29â33)</a> Therefore, to testify this hypothesis, we used inductively coupled plasmaâmass spectrometry (ICPâMS) to measure the intracellular platinum content. After 12 h co-incubation with <b>29</b> (5 and 10 Î¼M) or CDDP (5 and 10 Î¼M), the platinum content in A549 cells was determined by ICPâMS after digestion with 65% nitric acid. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the accumulation of platinum of <b>29</b> was evidently enhanced compared with that of CDDP. Moreover, as the concentration increased, A549 cells internalized more platinum than those treated with CDDP at equal concentration (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This may be associated with the hydrophobic ligands which increased the lipophilicity of the Pt(IV) complexes and contributed to the transportation through the cell membrane. The more uptake of <b>29</b> also corresponds to the increased antitumor activity in vitro in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell uptake of 26 in A549 cells treated with <b>29</b> for 12 h at the concentration of 5 and 10 Î¼M. Platinum content was measured by ICPâMS after digestion with 65% HNO<sub>3</sub>. Data represented the mean Â± SD of at least three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.6.  Effect of 29 on RAS/RAF Interaction</h3><div class="NLM_p">Originally, Rigosertib was reported to be a non-ATP competitive Plk1 inhibitor in nanomole concentration.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, subsequent experiments of Plk1 kinase activity test indicated that Rigosertib, <b>20</b>, and <b>26</b> had little effect on kinase activity (data were not shown).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Later, Reddy and co-workers reported that Rigosertib acted as RAS mimetic blocking signals that associated with downstream effector proteins.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Therefore, in order to determine whether our target compounds could also block the RAS/RAF/MEK/ERK signaling pathway, we conducted a series of Western blot to study the effect of <b>26</b> and <b>29</b> on the RAS/RAF complex and MAPK signaling cascade. Briefly, A549 cells were co-incubated with <b>26</b> (5 Î¼M) and <b>29</b> (5 Î¼M) for 24 h, and then the coprecipitation obtained using VE-cadherin (containing anti-RAS antibody) was further purified with protein G agarose and subjected to Western blot to determine the levels of its associated CRAF. For the analysis of effects on the phosphorylation and expression of MEK and ERK, A549 cells were treated with CDDP (5 Î¼M) or different concentrations of <b>26</b> and <b>29</b> for 24 h, and then the levels of phosphorylation and expression of MEK and ERK were measured, using GAPDH as the loading control. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B, the levels of CRAF proteins, which were associated with RAS proteins, were reduced in the input group, whereas little effect on the expression of RAS was observed. This result suggested that <b>26</b> and <b>29</b> did disturb the interaction between RAS and CRAF, which was consistent with the result reported previously.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Moreover, the levels of RAS/CRAF complexes of cells treated with <b>26</b> and <b>29</b> in the IP group were significantly decreased when compared to those of the control group (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B). Interestingly, the disruption of RAS and CRAF interaction may raise a question whether <b>29</b> directly targets either RAS protein or CRAF protein or both. We thereby carried out microscale thermophoresis (MST) assay and cellular protein thermal shift assay (CETSA) for further studies. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D, <b>29</b> can directly target CRAF protein with high affinity at nanomolar concentration (affinity constant of <i>K</i><sub>d</sub> value was 149 nM), whereas the <i>K</i><sub>d</sub> value between <b>29</b> and K-RAS, N-RAS, or H-RAS cannot be detected, even with the initial concentration was increased to 125 Î¼M, indicating the poor affinity of <b>29</b> to K-RAS, N-RAS, or H-RAS (results are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S5CâH</a>). The obvious difference of the affinity explained our design concept that as a derivative of styrylbenzylsulfones compound <b>29</b> still possessed the ability to target CRAF protein and acted as an inhibitor of the protein. Similarly, as the positive control, <b>26</b> also displayed high affinity with the <i>K</i><sub>d</sub> value of 124 nM (results are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S5A,B</a>). Moreover, the results of CETSA assays (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E,F) also showed that the level of CRAF remaining in the soluble fraction quickly decreased when the A549 cell lysates were heated from 47 to 67 Â°C. In contrast, when A549 cell lysates were treated with <b>26</b> or <b>29</b>, the melting temperature of CRAF from 51 to 67 Â°C significantly increased, indicating that the tested compounds can effectively bind and stabilize CRAF. However, as for RAS, the melting temperature of RAS hardly changed when A549 cell lysates were treated with <b>26</b> or <b>29</b> as compared with the negative DMF treatment group (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S6A,B</a>). Besides, the results of GAPDH in the CETSA assay showed that both <b>26</b> and <b>29</b> had no effect on the thermal stability of GAPDH (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S6C,D</a>). From these results, we could conclude that <b>29</b> could directly bind to CRAF protein rather than RAS protein and disrupt the signaling transferred from RAS to CRAF.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>29</b> interfered with the interaction of Ras/Raf and MEK/ERK activation. (A) Cell lysates collected from A549 cells that were pretreated with <b>29</b> (5 Î¼M) and <b>26</b> (5 Î¼M) for 24 h were subjected to immunoprecipitation with anti-Ras antibodies and determined the associated CRAF with Western blot. (B) Statistics of gray intensity were normalized with input. Data were presented as the mean Â± SD of three independent experiments. (C): MST trace lines of <b>29</b> binding to CRAF-RBD protein. (D): MST results of <b>29</b> binding to CRAF protein. Results provided above showed that <b>29</b> binds to the CRAF protein (<i>K</i><sub>d</sub> values was 149 nM). (E) Thermal stability of RAS; (F) statistics of gray intensity were normalized with gray intensity of 47 Â°C. Data were presented as the mean Â± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">RAF kinases were essential for RAS/RAF/MEK/ERK pathway signaling. The RAF kinases can form dimers just like other protein kinases, which were RAS-dependent. Under normal signaling transduction condition, the dimers occurred in plasm and disassociated by the feedback of activation of ERK.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35â37)</a> Thus, we conducted Western blotting to detect the activation of BRAF in A549 cells, which were pretreated with CDDP (5 Î¼M), <b>26</b> (2, 5 Î¼M), and <b>29</b> (2 Î¼, 5 Î¼M) for 24 h by using BRAF antibodies. The results in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S7A,B</a> showed that <b>26</b> and <b>29</b> could inhibit the activation BRAF in a dose-dependent manner while <b>29</b> (2 Î¼M) was weaker than <b>26</b> (2 Î¼M) in this assay. Thereafter, to detect the effects of <b>29</b> on the RAS-mediated signaling, heterodimerization of endogenous CRAF and BRAF with the stimulation of EGF was investigated by co-immunoprecipitation assays, using CRAF antibodies to detect the levels of associated BRAF. The results are displayed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S7C,D</a>, from which we could see that no BRAF protein in the IP group was detected when A549 cells were treated with control (DMF without EGF), though BRAF protein existed in input group.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The formation of CRAF and BRAF dimers was found upon the stimulation of EGF. However, significant decrease occurred in their dimers after 24 h co-incubation of A549 cells with <b>26</b> (5 Î¼M) or <b>29</b> (5 Î¼M), revealing that both <b>26</b> and <b>29</b> could also disrupt the interaction of CRAF and BRAF by interrupting the signaling between RAS and RAF. Not surprisingly, CDDP had no activity in both assays. In all, <b>29</b> could inhibit the activation of BRAF and disrupt the signaling transduction from RAS to CRAF.</div><div class="NLM_p">As for the classical MAPK signaling cascade, the block signaling between RAS and RAF usually led to the down-regulation of phosphorylation of MEK and ERK. Indeed, the inhibition of phosphorylation was observed in our study, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B. As expected, treatment with <b>26</b> or <b>29</b> resulted in reduced phospho-MEK and phospho-ERK levels in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). However, little effect on phosphorylation of MEK and ERK was found in the CDDP-treated group, which explained indirectly that antitumor activity of CDDP was not involved in this signaling pathway. In summary, these findings supported our hypothesis that <b>29</b>, similar to Rigosertib, could disturb the MAPK signaling transduction by inhibiting the formation of RAS/RAF complexes.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Phosphorylation and expression of the indicated proteins determined by Western blot in A549 cells after treatment with CDDP or increasing concentrations of <b>29</b> and <b>26</b>. (B) Signals obtained from Western blot and normalized with GAPDH. Data were presented as the mean Â± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.7.  A549 Apoptosis Induced by <b>29</b></h3><div class="NLM_p">To further investigate whether compound <b>29</b> produced cytotoxicity by inducing apoptosis of tumor cells, cell apoptosis analysis was carried out. A549 cells were first treated with compound <b>29</b> (5 Î¼M), compound <b>26</b> (5 Î¼M), and CDDP (5 Î¼M) which was used as the positive control for 24 h. Thereafter, the tumor cells were costained with Annexin-V FITC and propidium iodide (PI), and the apoptotic cells were analyzed with flow cytometry. The result of apoptotic value is shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, from which four states of cells were found: necrotic cells (Q1), late apoptotic (Q2), early apoptotic cells (Q3), and living cells (Q4). A great difference of the apoptotic value was presented clearly. One hand, compound <b>29</b>, compound <b>26</b>, and CDDP could efficiently induce apoptosis in A549 cells at the concentration of 5 Î¼M, and the apoptotic values (including the early and late apoptosis states) are 40.6, 37.2, and 15.55%, respectively. On the other hand, the apoptotic value (40.6%) of compound <b>29</b> was more superior to that of compound <b>26</b> (37.2%), and CDDP (15.55%), which revealed that compound <b>29</b> could induce more apoptosis of A549 cells than that of compound <b>26</b> and cisplatin at the same concentration. Because of apoptosis, data of A549 cells were obtained after 24 h co-incubation with high concentration of <b>29</b> (5 Î¼M), <b>26</b> (5 Î¼M), and CDDP (5 Î¼M), we further investigated the apoptosis-inducing ability of <b>29</b>, <b>26</b>, and CDDP with the concentration at the IC<sub>50</sub> value level and total 72 h drug exposure. From <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Table S4</a>, we could find that <b>26</b> and <b>29</b> did not cause significant apoptosis in the first 24 h. However, when A549 was exposed to <b>29</b>, <b>26</b>, and CDDP for 72 h, much more cells were in the apoptotic state even at the concentration of IC<sub>50</sub> values (the results are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S8</a>). Altogether, <b>29</b> showed a similar antitumor behavior by inducing apoptosis of tumor cells as compound <b>26</b> and CDDP did, but its potency was much higher than the others.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Annexin V-FITC and PI staining to evaluate apoptosis in A549 cells treated with various compounds. A549 cells were co-incubated with DMF, cisplatin (5 Î¼M), compound <b>26</b> (5 Î¼M), and compound <b>29</b> (5 Î¼M) and stained with Annexin V-FITC and PI and analyzed with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.8.  Cell Cycle Arrest Analysis</h3><div class="NLM_p">It was well demonstrated that <b>29</b> and cisplatin produced cytotoxicity by inducing apoptosis. Therefore, to study the effect of the target complexes on the tumor cell cycle, <b>26</b> (5 Î¼M) and <b>29</b> (5 Î¼M) were incubated with A549 cells overnight using CDDP (5 Î¼M) and DMF as positive and negative controls, respectively. As the results of cell arrest shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, CDDP mainly arrested A549 cells in the S phase when compared to that of the control group, whose value increased from 24.25 to 32.47%. However, the cells treated with <b>26</b> (5 Î¼M) were mainly arrested in the G2/M phase with the percentage of 68.83%, whereas the values were 12.25 and 7.72% for control and cisplatin respectively. Interestingly, when the tumor cells were treated with the same concentration of compound <b>29</b> (5 Î¼M), the percentage of cells arrested in G2/M phase was larger than that of compound <b>26</b> (5 Î¼M) and control. In conclusion, compound <b>26</b> and <b>29</b> could produce cytotoxicity by introducing cell arrest in the G2/M phase.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle arrest was analyzed after 24 h being treated with various compounds. A549 cells were treated with DMF, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), stained with PI, and analyzed with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.9.  DNA Damage Induced by <b>29</b></h3><div class="NLM_p">It is well known that Pt(IV) complexes exert antitumor activity mainly depending on the release of Pt(II) complexes.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34â37)</a> Previously, we proved that <b>29</b> could release <b>26</b> and CDDP under the reductive condition in cells. Therefore, we performed comet assays and Western blotting assays to verify whether <b>29</b> could also cause DNA damage. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, A549 cells were induced apparent DNA damage after 24 h co-incubation with CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), which was characterized by the tail DNA. Normally, the number and length of tail DNA were in positive correlation with the degree of DNA damage. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, more and longer tail DNA existed in A549 cells treated with <b>29</b>, whereas less and shorter DNA tails were found in the CDDP-treated group and <b>26</b>-treated group. This indicated that <b>29</b> induced stronger DNA damage than <b>26</b> and CDDP. Usually, the DNA damage induced by CDDP was along with double-strand break (DSB).<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38â40)</a> Therefore, we detected the expression of H2AX phosphorylation (Î³H2AX), a hallmark of DNA DSB. As indicated in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S9A,B</a>, after 24 h co-incubation of A549 cells with <b>29</b> (2, 5 Î¼M) and CDDP (5 Î¼M), the level of Î³H2AX was significantly increased when compared with the control group. The <b>29</b>-treated group produced higher level of discrete Î³H2AX in a dose-dependent manner than CDDP-treated group, which explained that <b>29</b> increased the extent of DSB. Subsequently, the increased DSB in A549 cells also promote the expression of p53 protein, which usually occurred in an activation of the mitotic checkpoint following drug exposure.<a onclick="showRef(event, 'cit34a'); return false;" href="javascript:void(0);" class="ref cit34a">(34a)</a> In <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S9A,B</a>, higher level of p53 was induced in A549 cells by <b>29</b> (2, 5 Î¼M) than CDDP (5 Î¼M) in a dose-dependent manner. This also indicated that <b>29</b> can not only arrest A549 cells in G2/M phase but induced DNA damage and finally induced more apoptosis as just shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">S8</a>.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. After 24 h treatment with vehicle, cisplatin (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were transferred onto the comet slide and treated according to the method reported previously.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Images were analyzed and recorded with a laser confocal microscope. Tail DNA was marked with a white arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.10.  Detection of Reactive Oxygen Species Active Oxygen</h3><div class="NLM_p">According to previous reports,<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32â34)</a> the metal complex broke the balance of intracellular redox to induce excess reactive oxygen species (ROS) accumulation. Therefore, in order to study the accumulation of intracellular ROS, A549 cells were incubated with following compounds: vehicle (DMF), CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M). After 24 h treatment, the tumor cells were stained with DCFH-DA (Molecular Probe, Beyotime, Haimen, China) and were observed and recorded with a fluorescence microscope. The results are shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, from which we could see that the treatment with cisplatin significantly increased the level of intracellular ROS. Similarly, complex <b>26</b> and <b>29</b> also caused the increased level of ROS, and the fluorescence intensity of later two was higher than that of cisplatin, suggesting higher ROS levels caused by <b>26</b> and <b>29</b>. It is widely accepted that high-level ROS produces high cytotoxicity. Thus, these results were consistent with former findings.<a onclick="showRef(event, 'ref34 cit41a'); return false;" href="javascript:void(0);" class="ref ref34 cit41a">(34,41a)</a></div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. After 24 h treatment with vehicle, cisplatin (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were incubated with fluoresce probe DCFH-DA. Images were analyzed and recorded with a fluorescence microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Generally, mitochondria are responsible for production of ATP and provide the energy using for cellular biological functions. In the mitochondrial electron transport chain, only 1â2% of molecular oxygen consumed by mammalian cells turned into ROS via electron leakage.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41â43)</a> Therefore, the endogenous ROS was mainly from mitochondria in human and animal cells. Given the significant accumulation of ROS in A549 cells displayed in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> after co-incubation with <b>26</b>, <b>29</b>, and CDDP, we observed the cellular location of ROS in A549 cells to confirm the distribution of ROS and to verify the source of ROS. The ROS was traced with DCHF-DA as green fluorescence (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S10A2âD2</a>), while the mitochondria were highlighted by Mito Tracker RED as red fluorescence (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S10A3âD3</a>). In <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S10A3</a>, without drug treatment, the red mitochondria were regularly distributed around the cell nucleus, and only a little green fluorescence was detected. However, much more ROS in A549 cells with green fluorescence was detected and distributed in the whole cell cytoplasm upon treated with <b>26</b>, <b>29</b>, or <b>CDDP</b> with the same concentration. However, the merging images in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S10A4âD4</a> displayed that the location of ROS and mitochondria did not overlap well. The Pearsonâs <i>R</i> value analyzed according to the 2D intensity histogram by ImageJ lab program is shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S10A4-1âD4-1</a>, from which we could see that ROS was irrelevant to mitochondria. Thus, the results suggested that the production of ROS may not come from mitochondria itself.</div><div class="NLM_p last">To confirm whether intrinsic luminescence of compounds that would interfere with the results of the luminescence of ROS tracker, we next tested the fluorescence emission spectra of <b>26</b> and <b>29</b> in various solutions (Î»<sub>ex</sub> = 315 nm, Î»<sub>ex</sub> = 494 nm, Î»<sub>ex</sub> = 535 nm). Not surprisingly, negligible fluorescence emission spectra were obtained (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S11</a>).</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.11.  Decreasing of Mitochondrial Membrane Potential Induced by <b>29</b></h3><div class="NLM_p">As we have found that <b>26</b> and <b>29</b> could induce the accumulation of ROS in cells, it will be interesting to investigate whether the enhanced formation of ROS in cells could make the decrease of mitochondrial membrane potential (MMP),<a onclick="showRef(event, 'cit41a ref44 ref45'); return false;" href="javascript:void(0);" class="ref cit41a ref44 ref45">(41a,44,45)</a> which was the notable hallmark of classical mitochondrial apoptosis pathway. Therefore, A549 cells were incubated with <b>26</b> (5 Î¼M), <b>29</b> (5 Î¼M), or CDDP (5 Î¼M), using equal DMF as the negative control. After 24 h treatment, cells were stained with JC-1 test kit, analyzed, and recorded with flow cytometry. The result of MMP is shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, from which we could see that the ÎÏm of cells treated with three compounds mentioned above was decreased relative to control, indicating the damage of the cells which eventually resulted in apoptosis.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. After 24 h treatment with vehicle, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were stained with a JC-1 probe. MMP (ÎÏ<sub>m</sub>) was analyzed and recorded with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.12.  Cell Morphology of Apoptosis Induced by <b>29</b></h3><div class="NLM_p">In order to investigate the cell morphology of apoptosis, A549 tumor cells were treated with various compounds: <b>26</b> (5 Î¼M), <b>29</b> (5 Î¼M), CDDP (5 Î¼M), and vehicle (DMF) for 24 h. Then, the cells were costained with AO (6 Î¼g/mL) and EB (6 Î¼g/mL), and apoptotic morphology was analyzed with a fluorescence microscope. The result is shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, from which different nuclear morphology could be found. The cells with different treatment was colored in green or orange, especially for that of cisplatin, <b>26</b>, and <b>29</b> groups, whose brightness was enhanced, indicating the happening of apoptosis induced by these three compounds. In addition, the tumor cells treated with <b>26</b> or <b>29</b> showed clear apoptotic state with decreased cell density, reduced cell volume, and concentrated cytoplasm, which was consistent with that of cells treated with cisplatin at the same concentration. Therefore, compound <b>29</b> could induce apoptosis just as <b>26</b> and CDDP did.</div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Morphological changes of A549 cells induce by <b>29</b>. After 24 h treatment with DMF, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were stained with AO/EB. Results were analyzed and recorded with a Nikon Te2000 deconvolution microscope (magnification 200Ã).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">2.13.  <b>26</b> and <b>29</b> Regulated Apoptotic-Related Proteins</h3><div class="NLM_p">To elucidate the mechanisms involved in the potent apoptotic pathway induced by <b>26</b> (2, 5 Î¼M), <b>29</b> (2, 5 Î¼M), and CDDP (5 Î¼M), several apoptotic-related proteins, including pro- or/and anti-apoptotic proteins, such as Bax and Bcl-2 were analyzed with Western blot assay. The results are shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A,B. Treatment with <b>29</b> (5 Î¼M) for 24 h induced down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax in A549 cells, which deeply caused the decrease of MMP studied above. Then, the collapsed MMP activated the release of Cyt <i>c</i> and subsequently led to the activation of downstream caspase cascade. As is shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A,B, A549 cells exposed to <b>29</b> showed statistically up-regulated level of cleaved-caspase 9 and cleaved-caspase 3 along with the down-regulated level of pro-caspase 9 and pro-caspase3, which also contributed to the up-regulation of cleaved-poly ADP-ribose polymerase (PARP) level. It is noted that this protein-regulating activity of <b>29</b> was in a dose-dependent manner. Not surprisingly, similar effects were also observed when A549 cells were treated with <b>26</b>. Besides, as the positive control, CDDP (5 Î¼M) also showed the same activity to regulate the expression of the tested proteins, however, its potency was not comparable to that of <b>26</b> or <b>29</b> at the concentration of 2 or 5 Î¼M.</div><figure id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. After 24 h treatment of A549 cells with <b>26</b> (5 Î¼M) and <b>29</b> (5 Î¼M), (A) Western blot analysis of Cyt <i>c</i>, Bcl-2, Bax, pro-caspase 9, caspase-9, pro-caspase 3, caspase-3, total-PARP, and cleaved PARP were analyzed, using Î²-actin antibody was used as the reference control. (B) Expression levels of (A) shown as percentages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Because prolyl-isomerase 1 (Pin 1), overexpressed in many cancers such as prostate, breast, and lung cancers, can also regulate the process of apoptosis,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> we detected the expression of Pin 1 in A549 cells after 24 h treatment of <b>26</b> (2 Î¼M), <b>26</b> (5 Î¼M), <b>29</b> (2 Î¼M), <b>29</b> (5 Î¼M), and CDDP (5 Î¼M). As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Figure S12</a>, the level of Pin 1 changed little when A549 cells were treated with tested compounds, except for the treatment of higher concentration of <b>29</b>, which caused moderate down-regulation of Pin 1. The weak effect of the tested compounds on Pin 1 may be attributed to the lack of effective binding domain in Pin 1. Thus, the obtained results clearly illustrated that <b>29</b> could effectively bind to CRAF and disrupt the signaling transduction between RAS and CRAF other than other protein, such as the Pin 1-mediated pathway.</div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.14.  In Vivo Evaluation of <b>29</b> on A549 Xenograft Models</h3><div class="NLM_p">On the basis of its superior in vitro antitumor activities, <b>29</b> was selected for an in vivo xenograft mouse study. A549 cells (3 Ã 106 in 100 Î¼L) were injected subcutaneously into the flank of the nude mice to establish tumor xenograft models. Once the tumors reached to 150â250 mm<sup>3</sup>, these mice were divided randomly into four different groups (three mice per group) and treated via injecting intravenously following: (1) <b>29</b> (6 Î¼mol/kg, on days 0, 2 and 4), Rigosertib (6 Î¼mol/kg, on days 0, 2 and 4), CDDP (6 Î¼mol/kg, on days 0, 2 and 4), and vehicle (equivalent volume of normal saline injection, on days 0, 2 and 4). As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, compound <b>29</b> caused statistically significant inhibition of tumor growth with 52.1% (percentage of inhibition ration [IR] value, <a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">Table S5</a>) as compared with that of the untreated control. In addition, compound <b>29</b> (IR, 52.1%) showed better potential antitumor activity than that of positive drug CDDP (IR, 36.7%) and Rigosertib (IR, 38.0%) at equal molecular dose. The curves of <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A,B showed the same trend. It should be noted that though Rigosertib showed strong antitumor activity at nanomolar concentrations in vitro, it only exhibited moderate tumor growth inhibition in vivo. This may be because of the low dosage used in the study.<a onclick="showRef(event, 'ref16 ref34'); return false;" href="javascript:void(0);" class="ref ref16 ref34">(16,34)</a> Importantly, no evident side effects such as body weight loss or animal death were observed in groups treated with compound <b>29</b> and Rigosertib, as shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C. On the contrary, the CDDP-treated group showed serious toxicity as reflected by the big body weight loss, especially during the days of 6â12 after intravenous injection of CDDP. These results showed that compound <b>29</b> was efficacious against A549 tumor xenografts with good safety.</div><figure id="fig13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Antitumor activity of compound <b>29</b> on A549 xenograft models. Nude mice implanted with A549 cells in the flank were dosed via injecting intravenously of <b>29</b> (6 Î¼mol/kg), Rigosertib (6 Î¼mol/kg), CDDP (6 Î¼mol/kg), and vehicle (equivalent volume of normal saline injection) on days 0, 2, and 4. The mice were sacrificed and made mathematical statistics. (A) Tumor pictures obtained after sacrifice of the mice treated with <b>29</b>, Rigosertib, CDDP, and vehicle. (B) The RTV (relative tumor volume) (Â±SEM) is graphed with error bars representing the standard deviation. (c) The average body weights (Â±SEM) were plotted after sacrifice of the mice treated with <b>29</b>, Rigosertib, CDDP, and vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rigosertib were designed, synthesized, and tested for their biological activity. The results of MTT activity test in vitro showed that all of the synthesized target compounds showed good anti-proliferative activity against the tested cancer cells; among them compound <b>29</b> was most active with the potency higher than the positive control cisplatin and Rigosertib. Significantly, compound <b>29</b> could also inhibit the multidrug-resistant tumor cells at nanomolar concentration. This unique merit of <b>29</b> may be attributed to the enhancement of cellular uptake as well as its multifunctional antitumor mechanism. As our studies revealed that <b>29</b> could effectively release Rigosertib and the corresponding Pt(II) moiety upon the reducing substances, thus the active components could exert the antitumor effect via different pathways. Indeed, we have found that <b>29</b> could, on the one hand, disturb signaling transduction between RAS and CRAF via directly binding to CRAF protein and finally induce downregulation of phosphor-MEK and phosphor-ERK; On the other hand, <b>29</b> could also induce apoptosis and clearly arrest the A549 cells at the G2/M phase. Furthermore, the study of apoptotic pathway showed that massive ROS was produced when the cancer cell was treated with <b>29</b>. All of these performances of <b>29</b> are quite similar to that of platinum-based agents, suggesting that <b>29</b> maintained the cisplatin-like activity. Thus, we can summarize that <b>29</b> could inhibit the proliferation of tumor cells via two different pathways: the RAF/MEK/ERK pathway and the platinum-based cytotoxicity pathway, as outlined in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>. Because of this multifunctional character, <b>29</b> could efficiently inhibit tumor growth in the A549 xenograft model, and no obvious side effects were observed during the test. In all, these excellent performances in the pharmacological tests both in vitro and in vivo made compound <b>29</b> possible for âefficient and hypotoxicâ antineoplastic candidate.</div><figure id="fig14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Proposed antitumor action mode of <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.1.  Materials and Instruments</h3><div class="NLM_p last">All chemical reagents and solvents were purchased commercially from Aladdin, Energy Chemical or Adamas-beta and used without further purification. Potassium tetrachloroplatinate(II) was purchased from commercial sources (Lingfeng Chemical Ltd.). <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained from with a Bruker 300, 400, or 600 MHz spectrometer in DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub>, and tetramethylsilane (TMS) was used as the reference. Mass spectra were measured by an Agilent 6224 ESI/TOF MS instrument. All of the compounds submitted for biological studies were at least 95% purity by RP-HPLC on the ODS column (250 Ã 4.6 mm, 5 Î¼m) with an eluent of acetonitrile/water (45:55, V/V) (0.1% trifluoroacetic acid in water). Besides, all cells used in this article were obtained from KeyGEN BioTECH Corp. Besides, Mitochondrion Red (KGMP0071) and ROS tracker were obtained from KeyGEN BioTECH Corp. Bax, Bcl-2, cytochrome <i>c</i>, pro-caspase-3/9, cleaved-caspase-3/9, total-PARP, and cleaved-PARP antibodies were purchased from Imgenex, USA. Antibodies directed against p-MEK, MEK, p-ERK, ERK, Pin 1 (#3722), and p53 were purchased from Cell Signaling Technology. The CRAF antibody was purchased from Affinity Biosciences, whereas RAS antibody and BRAF antibody (ab124794) were purchased from Abcam. Secondary antibody (1:2000) labeled with horseradish peroxidase was obtained from Santa Cruz Biotechnologies</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">4.2.  Synthesis and Characterization of Intermediates</h3><div class="NLM_p">Compound <b>1</b>: To a solution of compound <b>SM</b><sub><b>1</b></sub> (3.01 g, 18.01 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (6.22 g, 45.03 mmol) in DMF (30 mL) was added CH<sub>3</sub>I (3.83 g, 27.02 mmol) at room temperature and stirred overnight at the same temperature. Progress of the reaction was monitored with thin layer chromatography (TLC). After completion of the reaction, the solvent was evaporated under reduced pressure to obtain a crude yellow solid. After this, DCM (300 mL) was added to dissolve the residue and washed with NaOH solution (1 N), sat. NaCl (100 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum to give a pale white solid (3.05 g). Yield: 93.7%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): Î´ 9.94 (s, 1H), 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 8.09 (dd, <i>J</i> = 8.7, 2.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.7 Hz, 1H), 4.07 (s, 3H).</div><div class="NLM_p">Compound <b>2</b>: To a solution of compound <b>1</b> (1.01 g, 5.58 mmol) in MeOH (20 mL) at 0 Â°C was added NaBH<sub>4</sub> (0.27 g, 7.25 mmol) gradually and stirred at the same temperature for 20 min. Progress of the reaction was monitored with TLC. The reaction was worked up by quenching with HCl solution (1 N) at 0 Â°C and removed the solvent to obtain a white solid under reduced pressure. After this, DCM (300 mL) was added to dissolve the residue and washed with sat. NaCl (3 Ã 100 mL). The combined organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum to give a white solid (1.02 g). Yield: 100%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): Î´ 7.83 (d, <i>J</i> = 2.1 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 7.07 (d, <i>J</i> = 8.6 Hz, 1H), 4.68 (s, 2H), 3.96 (s, 3H), 2.06 (s, 1H).</div><div class="NLM_p">Compound <b>3</b>: To a solution of compound <b>2</b> (0.50 g, 2.73 mmol) in DCM (15 mL) at 0 Â°C was added PBr<sub>3</sub> (1.10 g, 4.10 mmol) gradually and stirred at the same temperature for 2 h. The reaction was monitored with TLC and quenched with NaHCO<sub>3</sub> (1 M) solution at 0 Â°C. After this, DCM (300 mL) was added to dissolve the residue and washed with sat. NaCl (3 Ã 100 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuum to give a white solid (0.67 g). Yield: 99.7%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): Î´ 7.88 (d, <i>J</i> = 2.2 Hz, 1H), 7.57 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 7.07 (d, <i>J</i> = 8.7 Hz, 1H), 4.46 (s, 2H), 3.97 (s, 3H).</div><div class="NLM_p">Compound <b>4</b>: To a solution of NaOH (162.4 mg, 4.06 mmol) in MeOH (15 mL) at 0 Â°C was added TGA (224.6 mg, 2.43 mmol) gradually and stirred at the same temperature for 10 min. Then, compound <b>3</b> (0.50 g, 2.03 mmol) in 10 MeOH (10 mL) was dropped slowly into the solution. The reaction was monitored with TLC. After completion of the reaction, the solvent was removed under reduced pressure to obtain a pale yellow solid. After this, water (50 mL) was added to dissolve the residue and adjusted the PH to 4â5 with HCl (1 N) solution. The precipitate was filtered to obtain a pale yellow solid (469.8 mg). Yield: 90.0%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.53 (s, 1H), 7.82 (d, <i>J</i> = 2.1 Hz, 1H), 7.60 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 7.32 (d, <i>J</i> = 8.6 Hz, 1H), 3.91 (s, 3H), 3.83 (s, 2H), 3.14 (s, 2H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>10</sub>H<sub>11</sub>NO<sub>5</sub>S [M â H], 256.0358; found, 256.0359.</div><div class="NLM_p">Compound <b>5</b>: To a solution of compound <b>4</b> (257.3 mg, 1.94 mmol) in AcOH (15 mL) at room temperature was added H<sub>2</sub>O<sub>2</sub> (661.0 mg, 19.40 mmol) and stirred at the 50 Â°C for 3 h. The reaction was monitored with TLC. After the completion of the reaction, the solvent was removed under reduced pressure to attain a crude product. The residue was further purified with silica gel chromatography with the eluent of DCM and MeOH (100:0â30:1) to give a pale yellow solid (413.0 mg). Yield: 73.7%. <sup>1</sup>H NMR (500 MHz, DMSO): Î´ 13.48 (s, 1H), 7.92 (d, <i>J</i> = 2.1 Hz, 1H), 7.68 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 7.43 (d, <i>J</i> = 8.7 Hz, 1H), 4.68 (s, 2H), 4.20 (s, 2H), 3.95 (s, 3H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>10</sub>H<sub>11</sub>NO<sub>5</sub>S [M â H], 288.0250; found, 288.0254.</div><div class="NLM_p">Compound <b>7</b>: To a solution of compound <b>5</b> (3.0 g, 10.37 mmol) in toluene (30 mL) at 40 Â°C was added piperidine (823.8 Î¼L, 8.30 mmol) and stirred at the same temperature for 10 min. Then, benzoic acid (1.3 g, 10.37 mmol) and compound <b>6</b> (2.2 g, 11.42 mmol) were added to the solution and heated to reflux overnight. Progress of reaction was monitored with TLC. After the completion of the reaction, the solution was cooled to room temperature and filtered to obtain a yellow crude product. The precipitate was recrystallized with MeOH (20 mL) to get a yellow solid (1.5 g). Yield: 34.1%. <sup>1</sup>H NMR (300 MHz, DMSO): Î´ 7.88 (s, 1H), 7.64 (d, <i>J</i> = 8.6 Hz, 1H), 7.51 (d, <i>J</i> = 15.6 Hz, 1H), 7.38 (d, <i>J</i> = 8.6 Hz, 1H), 7.09 (d, <i>J</i> = 15.6 Hz, 1H), 6.29 (s, 2H), 4.54 (s, 2H), 3.93 (s, 3H), 3.85 (s, 9H).</div><div class="NLM_p">Compound <b>8</b>:To a solution of compound <b>7</b> (1.80 g, 4.25 mmol) in EtOH (20 mL) was added H<sub>2</sub>O (5.0 mL), NH<sub>4</sub>Cl (136.4 mg, 2.55 mmol), and Fe (1.43 g, 25.50 mmol) and heated to 70 Â°C for 4 h. Progress of reaction was monitored with TLC. After the completion of the reaction, the insoluble content was removed by filtration. The solvent of the reaction was finally evaporated under reduced pressure to give a yellow solid (1.5 g). Yield: 88.2%. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): Î´ 7.59 (d, <i>J</i> = 15.6 Hz, 1H), 7.08 (d, <i>J</i> = 15.6 Hz, 1H), 6.75 (d, <i>J</i> = 8.1 Hz, 1H), 6.64 (s, 1H), 6.50 (d, <i>J</i> = 8.1 Hz, 1H), 6.29 (s, 2H), 4.76 (s, 2H), 4.20 (s, 2H), 3.85 (s, 9H), 3.75 (s, 3H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>19</sub>H<sub>23</sub>NO<sub>6</sub>S [M + H], 394.1246; found, 394.1230.</div><div class="NLM_p">Compound <b>11</b>: (1) To a solution of compound <b>9</b> (612.9 mg, 4.21 mmol) in anhydrous DCM (10 mL) was added oxalyl chloride (1.8 mL) at 0 Â°C and stirred at room temperature overnight. After completion of the reaction, the solvent was removed under reduced pressure to obtain colorless oil. The crude product was used for the next step without further treatment. (2) To a solution of compound <b>8</b> (1.50 g, 3.83 mmol) in anhydrous DCM (15 mL) at 0 Â°C was added the compound obtained previously in DCM (5 mL) at the same temperature and stirred at room temperature for 10 min. After this, Et<sub>3</sub>N (507.8 mg, 699 Î¼L) in DCM (5 mL) was added to the solution and stirred for another 2 h. After completion of the reaction, the residue was dissolved in DCM (300 mL) and washed with water (100 mL), sat. NaCl (3 Ã 100 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude product was further purified with silica gel chromatography with the eluent of DCM and PE (2:1) to get a pale yellow solid (1.62 g). Yield: 85.0%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.04 (s, 1H), 7.98 (s, 1H), 7.59 (d, <i>J</i> = 15.7 Hz, 1H), 7.11 (d, <i>J</i> = 15.7 Hz, 1H), 7.04 (s, 1H), 7.01 (d, <i>J</i> = 8.4 Hz, 1H), 6.29 (s, 2H), 4.35 (s, 2H), 3.86 (s, 9H), 3.83 (s, 3H), 3.60 (s, 3H), 2.46â2.29 (m, 4H), 1.86â1.76 (m, 2H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>31</sub>NO<sub>9</sub>S [M + H], 522.1792; found, 522.1721.</div><div class="NLM_p">Compound <b>12</b>: Compound <b>8</b> (751.0 mg, 1.91 mmol), compound <b>10</b> (160.2 mg, 2.10 mmol), oxalyl chloride (1.0 mL), Et<sub>3</sub>N (249.5 mg, 344 Î¼L), and DCM (25 mL) were used following the procedure described for synthesis of compound <b>11</b> and attained a pale yellow solid (0.85 g). Yield: 84.9%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 8.37 (s, 1H), 7.84 (d, <i>J</i> = 15.6 Hz, 1H), 7.72 (s, 1H), 7.15 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.11 (d, <i>J</i> = 15.6 Hz, 1H), 6.87 (d, <i>J</i> = 8.4 Hz, 1H), 6.08 (s, 2H), 4.21 (s, 2H), 3.88 (s, 3H), 3.84â3.83 (m, 9H), 3.67 (s, 3H), 2.40â2.35 (m, 4H), 1.74â1.69 (m, 4H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>33</sub>NO<sub>9</sub>S [M + H], 536.1954; found, 536.1902.</div><div class="NLM_p">Compound <b>13</b>: To a solution of compound <b>10</b> (1.2 g, 2.30 mmol) in EtOH (10 mL) and pure water (5 mL) was added LiOHÂ·H<sub>2</sub>O (243.6 mg, 5.75 mmol) at room temperature and stirred at room temperature overnight. Progress of the reaction was monitored by TLC. After the completion of reaction, the solvent was removed under reduced pressure to obtain a pale yellow solid. The residue was dissolved with 30 mL pure water and adjusted the pH of the solution to 5 with HCl solution (1 N) and then filtered to give a pale yellow solid (1.0 g). Yield: 91.0%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.02 (s, 1H), 7.98 (s, 1H), 7.59 (d, <i>J</i> = 15.7 Hz, 1H), 7.10 (d, <i>J</i> = 15.7 Hz, 1H), 7.05 (d, <i>J</i> = 8.2 Hz, 1H), 7.01 (d, <i>J</i> = 8.2 Hz, 1H), 6.29 (s, 2H), 4.34 (s, 2H), 3.85 (s, 9H), 3.82 (s, 3H), 2.43â2.37 (m, 2H), 2.27â2.25 (m, 2H), 1.79â1.76 (m, 2H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>24</sub>H<sub>29</sub>NO<sub>9</sub>S [M + H], 508.1436; found, 508.1460.</div><div class="NLM_p last">Compound <b>14</b>: Compound <b>12</b> (850.0 mg, 1.58 mmol), LiOHÂ·H<sub>2</sub>O (166.6 mg, 3.97 mmol), EtOH (10 mL), and pure water (5 mL) were used following the procedure described for synthesis of compound <b>11</b> and obtained a pale yellow solid (746.5 g). Yield: 90.0%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 11.98 (s, 1H), 9.03 (s, 1H), 7.99 (s, 1H), 7.59 (d, <i>J</i> = 15.7 Hz, 1H), 7.11 (d, <i>J</i> = 15.7 Hz, 1H), 7.05 (d, <i>J</i> = 8.5 Hz, 1H), 7.01 (d, <i>J</i> = 8.5 Hz, 1H), 6.30 (s, 2H), 4.34 (s, 2H), 3.86 (s, 9H), 3.83 (s, 3H), 2.43â2.33 (m, 2H), 2.26â2.22 (m, 2H), 1.60â1.49 (m, 4H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>31</sub>NO<sub>9</sub>S [M â H], 520.1647; found, 520.1751.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.3.  General Procedures for Preparing Compounds <b>18â23</b></h3><div class="NLM_p">To a solution of compound <b>13</b> or <b>14</b> (0.33 mmol) in DMF (3 mL) was added compound TBTU (0.50 mmol) and stirred at room temperature for 5 min. Then, Et<sub>3</sub>N (68.0 Î¼L, 0.50 mmol) was added to the solution under the protection of nitrogen and stirred for 5 min at the same temperature. After this, compound <b>15</b>, <b>16</b>, or <b>17</b>(0.36 mmol) was added to the solution under the protection of nitrogen and stirred for 2 h at 35 Â°C. Progress of the reaction was monitored with TLC. After the completion of the reaction, DCM (250 mL) was added to the solution and washed with sat. NaCl (150 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to obtain crude product. The crude product was further purified with silica gel chromatography with the eluent of DCM and MeOH (60:1â20:1) to give a target product.</div><div class="NLM_p">Compound <b>18</b>: Yield: 36.2%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.58 (s, 1H), 8.94 (s, 1H), 8.13 (s, 1H), 8.02 (s, 1H), 7.78 (s, 1H), 7.59 (d, <i>J</i> = 15.6 Hz, 1H), 7.41 (s, 1H), 7.10 (d, <i>J</i> = 15.6 Hz, 1H), 7.03â6.99 (m, 2H), 6.29 (s, 2H), 4.34 (s, 2H), 3.85 (s, 9H), 3.82 (s, 3H), 2.83â2.71 (m, 2H), 2.44â2.39 (m, 2H), 2.32â2.28 (m, 2H), 2.21â2.16 (m, 1H), 2.08â2.04 (m, 1H), 1.81â1.76 (m, 2H), 1.56â1.49 (m, 3H), 1.33â1.25 (m, 1H), 1.11â1.03 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 183.39, 171.29, 163.99, 160.89 (C Ã 2), 149.89, 133.37, 127.68, 127.50, 124.82, 123.98, 120.88, 111.02, 102.88, 91.40 (C Ã 2), 63.71, 62.91, 60.06, 56.55 (C Ã 2), 56.23, 56.12, 37.12, 35.82, 31.36, 31.30, 24.16 (C Ã 2), 22.28. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>30</sub>H<sub>42</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>9</sub>PtS [M â H], 920.1480; found, 920.1414.</div><div class="NLM_p">Compound <b>19</b>: Yield: 33.6%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.61 (s, 1H), 8.99 (s, 1H), 8.12 (s, 1H), 8.00 (s, 1H), 7.77 (s, 1H), 7.59 (d, <i>J</i> = 15.5 Hz, 1H), 7.41 (s, 1H), 7.11 (d, <i>J</i> = 15.5 Hz, 1H), 7.02 (s, 2H), 6.30 (s, 2H), 4.34 (s, 2H), 3.85 (s, 9H), 3.83 (s, 3H), 2.39â2.35 (m, 2H), 2.30â2.25 (m, 2H), 2.21â2.02 (m, 3H), 1.55â1.48 (m, 7H), 1.30â1.24 (m, 1H), 1.16â0.96 (m, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 183.57, 171.94, 164.28, 161.31 (C Ã 2), 149.97, 133.34, 127.70, 127.45, 124.91, 124.04, 121.09, 111.17, 103.05, 91.41 (C Ã 2), 63.91, 62.62, 60.35, 56.55 (C Ã 2), 56.23, 56.12, 37.43, 36.18, 31.37, 31.29, 25.53 (C Ã 2), 25.15, 24.00. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>31</sub>H<sub>44</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>9</sub>PtS [M â H], 934.1282; found, 934.1586.</div><div class="NLM_p">Compound <b>20</b>: Yield: 39.0%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.98 (s, 1H), 8.32 (s, 3H), 8.03 (d, <i>J</i> = 28.2 Hz, 1H), 7.59 (d, <i>J</i> = 15.7 Hz, 2H), 7.14 (t, <i>J</i> = 20.0 Hz, 1H), 7.02 (s, 2H), 6.29 (s, 2H), 4.34 (s, 2H), 3.85 (s, 9H), 3.82 (s, 3H), 2.66â2.55 (m, 2H), 2.39â2.22 (m, 4H), 2.11â1.92 (m, 2H), 1.801â1.68 (m, 2H), 1.55â1.30 (m, 4H), 1.18â1.04 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 180.44, 171.38, 164.11, 163.75, 161.41 (C Ã 2), 160.73, 150.00, 133.38, 127.76, 124.95, 124.00 (C Ã 2), 121.07, 111.27, 103.01, 91.40 (C Ã 2), 62.00, 61.78, 60.27, 56.52 (C Ã 2), 56.22, 56.10, 36.40, 35.77, 31.40, 31.04, 23.97 (C Ã 2), 21.95. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>32</sub>H<sub>42</sub>ClN<sub>3</sub>O<sub>13</sub>PtS [M â H], 938.1700; found, 938.1862.</div><div class="NLM_p">Compound <b>21</b>: Yield: 39.0%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.61 (s, 1H), 8.99 (s, 1H), 8.12 (s, 1H), 8.00 (s, 1H), 7.77 (s, 1H), 7.59 (d, <i>J</i> = 15.5 Hz, 1H), 7.41 (s, 1H), 7.11 (d, <i>J</i> = 15.9 Hz, 1H), 7.02 (s, 2H), 6.30 (s, 2H), 4.34 (s, 2H), 3.85â3.82 (m, 9H), 3.83 (s, 3H), 2.35â2.30 (m, 4H), 2.12â2.09 (m, 3H), 1.52â1.35 (m, 8H), 1.24 (s, 1H), 1.16â0.96 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 181.21, 175.25, 171.48, 164.18, 163.64, 161.42 (C Ã 2), 150.08, 133.45, 127.68, 127.50, 124.97, 124.03, 121.08, 111.26, 103.12, 91.42 (C Ã 2), 62.02, 61.87, 60.48, 56.53 (C Ã 2), 56.23, 56.09, 36.68, 36.11, 31.41, 31.08, 25.41 (C Ã 2), 25.14, 24.09. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>33</sub>H<sub>44</sub>ClN<sub>3</sub>O<sub>13</sub>PtS [M â H], 952.1857; found 952.2023.</div><div class="NLM_p">Compound <b>22</b>: Yield: 27.8%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.94 (s, 1H), 8.01 (s, 1H), 7.59 (d, <i>J</i> = 15.6 Hz, 1H), 7.11 (d, <i>J</i> = 15.6 Hz, 1H), 7.13â7.02 (m, 2H), 6.29 (s, 2H), 6.39â5.89 (m, 6H), 4.34 (s, 2H), 3.84 (d, <i>J</i> = 7.2 Hz, 9H), 3.83 (s, 3H), 2.43â2.39 (m, 2H), 2.31â2.27 (m, 2H), 1.79â1.77 (m, 2H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 180.49, 171.93, 164.23, 161.24 (C Ã 2), 149.99, 133.21, 127.59, 127.49, 124.90, 124.33, 121.30, 110.95, 103.31, 91.15 (C Ã 2), 60.10, 56.56 (C Ã 2), 56.24, 56.13, 36.10, 35.96, 22.18. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>24</sub>H<sub>34</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>9</sub>PtS [M â H], 840.0637; found, 840.0766.</div><div class="NLM_p">Compound <b>23</b>: Yield: 29.4%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.99 (s, 1H), 8.01 (s, 1H), 7.58 (d, <i>J</i> = 15.7 Hz, 1H), 7.11 (d, <i>J</i> = 15.6 Hz, 1H), 7.07â6.95 (m, 2H), 6.52â5.90 (m, 8H), 4.34 (s, 2H), 3.85 (s, 9H), 3.82 (s, 3H), 2.38â2.34 (m, 2H), 2.26â2.24 (m, 2H), 1.60â1.48 (m, 4H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 180.93, 171.72, 164.11, 161.43 (C Ã 2), 149.83, 133.31, 127.81, 127.46, 124.91, 123.91, 120.99, 111.14, 103.06, 91.23 (C Ã 2), 60.32, 56.55 (C Ã 2), 56.25, 56.12, 36.52, 36.28, 25.52, 25.18. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>36</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>9</sub>PtS [M â H], 855.0815; found, 854.0934.</div><div class="NLM_p">Compound <b>25</b>: To a solution of compound <b>8</b> (1.50 g, 3.81 mmol) in DMF (15 mL) was added K<sub>2</sub>CO<sub>3</sub> (1.3 g, 9.52 mmol) and compound <b>24</b> (2.55 g, 15.24 mmol) and then the solution was stirred at 50 Â°C for 3 h. Process of the reaction was monitored by TLC. After the completion of reaction, the solvent was removed under reduced pressure and then DCM (250 mL) was added to dissolve the residue and washed with water and sat. NaCl (3 Ã 100 mL). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified with silica gel chromatography with the eluent of DCM and EA (100:0â100:1) to get white solid 1.51 g. Yield 83.3%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 7.56 (d, <i>J</i> = 15.7 Hz, 1H), 7.10 (d, <i>J</i> = 15.7 Hz, 1H), 6.81 (d, <i>J</i> = 8.2 Hz, 1H), 6.59 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 6.39 (d, <i>J</i> = 1.8 Hz, 1H), 6.30 (s, 2H), 5.25 (s, 1H), 4.26 (s, 2H), 4.09 (q, <i>J</i> = 7.1 Hz, 2H), 3.85 (d, <i>J</i> = 2.6 Hz, 9H), 3.81 (d, <i>J</i> = 5.9 Hz, 5H), 1.19 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p last">Compound <b>26</b>: To a solution of compound 25 (1.50 g, 3.12 mmol) in EtOH (10 mL) and pure water (5 mL) was added LiOHÂ·H<sub>2</sub>O (327.6 mg, 7.82 mmol) at room temperature and stirred at the same temperature for 3 h. Progress of the reaction was monitored by TLC. The reaction was worked up with removal the solvent under reduced pressure after the completion of the reaction and obtained a pale yellow solid. Pure water (30 mL) was added to dissolve the residue and adjusted the pH of the solution to 5 with HCl (1 M). The residue was filtered and dried at 45 Â°C to give a white solid (1.2 g). Yield 85.0%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 12.71 (s, 1H), 7.56 (d, <i>J</i> = 15.7 Hz, 1H), 7.12 (d, <i>J</i> = 15.7 Hz, 1H), 6.78 (d, 8.1 Hz, 1H), 6.59 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 6.42 (d, <i>J</i> = 1.6 Hz, 1H), 6.30 (s, 2H), 5.77 (s, 1H), 4.27 (s, 2H), 3.85 (s, 9H), 3.80 (s, 3H), 3.72 (s, 2H). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>25</sub>NO<sub>8</sub>S [M â H], 450.1228; found, 450.1272.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.4.  General Procedures for Preparing Compounds <b>27â29</b></h3><div class="NLM_p">Compound <b>26</b> (0.33 mmol), compound <b>15</b>, <b>16</b> or <b>17</b> (0.37 mmol), TBTU (0.50 mmol) and Et<sub>3</sub>N (0.50 mmol) in DMF (3 mL) was used for preparing compounds <b>17â29</b>, following the general procedure of synthesis of compounds <b>18â23</b>.</div><div class="NLM_p">Compound <b>27</b>: Yield: 18.8%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.28 (d, <i>J</i> = 9.2 Hz, 1H), 8.19 (s, 1H), 7.87 (s, 1H), 7.53 (d, <i>J</i> = 15.6 Hz, 2H), 7.12 (d, <i>J</i> = 15.6 Hz, 1H), 6.79 (d, <i>J</i> = 8.0 Hz, 1H), 6.58 (d, <i>J</i> = 8.0 Hz, 1H), 6.45 (s, 1H), 6.29 (s, 2H), 5.20 (s, 1H), 4.33â4.21 (m, 2H), 3.86 (s, 9H), 3.79 (s, 5H), 2.74 (s, 1H), 2.08 (m, 2H), 1.57â1.39 (m, 3H), 1.32â0.98 (m, 3H), 0.91â0.87 (m, 1H).<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 180.51, 164.19, 161.37 (C Ã 2), 146.91, 137.54, 133.10, 124.02, 121.87, 119.47, 112.81, 109.96, 103.05, 91.46 (C Ã 2), 63.91, 62.80, 60.69, 56.61 (C Ã 2), 56.11, 55.92, 47.33, 31.40, 31.32, 23.93 (C Ã 2). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>27</sub>H<sub>38</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>8</sub>PtS [M â H], 864.1060; found, 864.1065.</div><div class="NLM_p">Compound <b>28</b>: Yield: 19.2%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.34 (d, <i>J</i> = 5.8 Hz, 1H), 8.26 (d, <i>J</i> = 5.8 Hz, 1H), 8.05 (t, <i>J</i> = 9.9 Hz, 1H), 7.66 (t, <i>J</i> = 9.9 Hz, 1H), 7.58 (d, <i>J</i> = 15.7 Hz, 1H), 7.12 (d, <i>J</i> = 15.7 Hz, 1H), 6.78 (d, <i>J</i> = 8.1 Hz, 1H), 6.57 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 6.44 (d, <i>J</i> = 1.3 1H), 6.29 (s, 2H), 5.11 (t, <i>J</i> = 5.5 Hz, 1H), 4.35â4.23 (m, 2H), 3.85 (s, 9H), 3.78 (s, 5H), 2.56â2.53 (m, 1H), 2.47â2.44 (m, 1H), 2.08â2.05 (m, 1H), 1.98â1.95 (m, 1H), 1.60â1.40 (m, 3H), 1.35â1.27 (m, 1H), 1.15â0.97 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 177.49, 164.07, 163.87, 161.39 (C Ã 2), 146.88, 143.04, 137.43, 133.09, 124.18, 121.77, 119.55, 112.72, 110.01, 103.06, 91.44 (C Ã 2), 62.13, 61.50, 60.67, 56.53 (C Ã 2), 56.10, 55.89, 46.81, 31.33, 31.00, 23.95 (C Ã 2). HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>29</sub>H<sub>38</sub>ClN<sub>3</sub>O<sub>12</sub>PtS [M â H], 882.1437; found, 882.1515.</div><div class="NLM_p last">Compound <b>29</b>: Yield: 21.2%.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 7.56 (d, <i>J</i> = 15.7 Hz, 1H), 7.12 (d, <i>J</i> = 15.7 Hz, 1H), 6.78 (d, <i>J</i> = 8.2 Hz, 1H), 6.56 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 6.49 (d, <i>J</i> = 1.6 Hz, 1H), 6.24 (m, 8H), 4.94 (t, <i>J</i> = 5.1 Hz, 1H), 4.28 (s, 2H), 3.86â3.85 (m, 9H), 3.78 (s, 3H), 3.74 (d, <i>J</i> = 5.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 177.53, 164.05, 161.37 (C Ã 2), 146.72, 137.50, 133.11, 124.02, 121.99, 119.35, 113.05, 109.80, 103.03, 91.46 (C Ã 2), 60.88, 56.64 (C Ã 2), 56.12, 55.91, 46.59. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>21</sub>H<sub>30</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>8</sub>PtS [M â H], 784.0374; found, 784.0453.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.5.  Cell Culture</h3><div class="NLM_p last">All adherent cells used in this article were cultured in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air at 37.0 Â°C, including A549 (nonsmall cell lung cancer cell line), MGC-803 (gastric cancer cell line), SKOV-3 (ovarian cancer cell line), NCI-H460 (large cell lung cancer cell line), A549/CDDP (cisplatin-resistant nonsmall cell lung cancer cell line), A549/DOX (doxorubicin-resistant nonsmall cell lung cancer cell line), SKOV-3/CDDP (CDDP-resistant ovarian cancer cell line), and HEUVC. The cells were grown monolayer in Dulbeccoâs modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 Î¼g/mL), and streptomycin (100 Î¼g/mL) solution. The A549/CDDP, A549/DOX, and SKOV-3/CDDP cells were constructed following the method reported previously.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Briefly, A549/CDDP or SKOV-3/CDDP cell lines survived intermittently by exposure to 8, 20, or 40 Î¼M cisplatin in monolayer culture. Initially, A549 or SKOV-3 cell lines were co-incubated with cisplatin at a concentration of 3 nM and were continuously exposed at the same concentration of cisplatin three times for 3-day periods during a 3â6-week period. These cell lines were allowed for growth recovery between cycles. Upon the completion of three or four cycles of drug, the concentration of cisplatin was doubled and repeated the procedure during the following long period until the noted drug levels were achieved. To verify the success of the construction of cisplatin-resistant cells, MTT assays were carried out to detect the resistance factor (RF) of cisplatin until reached experimental requirements. Similarly, A549/DOX was obtained with the same method provided above, using 0.002 and 0.2 Î¼g/mL as initial and final concentrations, respectively.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">4.6.  In Vitro Cytotoxicity Test of Compounds</h3><div class="NLM_p last">The cytotoxicity of compounds synthesized in this article was tested with MTT methods. A549, MGC-803, SKOV-3, NCI-H460, HUVEC, A549/CDDP, A549/DOX, and SKOV3/CDDP were grown on 96-well plates at a cell density of 1 Ã 10<sup>5</sup> cells/mL/well and incubated at an atmosphere of 5% CO<sub>2</sub> and 95% air at 37.0 Â°C for overnight. After that, compounds dissolved in DMF and diluted to various concentrations with medium were added to those different cells culture medium respectively. After 72 h treatment, the incubation was work up by the addition of MTT (5 mg/mL). Then, the cells were incubated for another 4 h. Finally, the medium was replaced with DMSO (150 Î¼L), the O.D. The value was read with a 570/630 nm enzyme-labeling instrument. The IC<sub>50</sub> value of each compound was calculated by SPSS software with three parallel experiments.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.7.  Release of Compound <b>26</b> under the Reduction of Ascorbic Acid, the Stability of <b>29</b> at Acidic Condition and in A549 Cells</h3><div class="NLM_p">The stability or reduction reaction at different atmospheres was detected with RP-HPLC (waters, 2545 system). The stability of Pt(IV) was prepared a solution of compound <b>29</b> (2.0 mg, 0.5 mM) in PBS (PH = 7.4) and acetonitrile (5 mL, 90:10, V/V). The reduction of Pt(IV) was a mixture of compound <b>29</b> (2.0 mg, 0.5 mM) and ascorbic acid (1.3 mg, 1.5 mM) in PBS (PH = 7.4) and acetonitrile (5 mL, 90:10, V/V). All the solutions were preserved at 37 Â°C water bath in dark, detected and recorded by RP-HPLC on the ODS column (250 Ã 4.6 mm, 5 Î¼m) at different time points with an eluent of acetonitrile/water (45:55, v/v) (0.1% trifluoroacetic acid in water). Similarly, compound <b>26</b> and ascorbic acid were used as the control to match the peaks of compound <b>29</b> in a reduced atmosphere. The flow rate was 1.0 mL/min, and the volume of sample injection was more than 20.0 Î¼L. All of the compounds tested with RP-HPLC were purified with a 0.45 Î¼m filter. The wavelength for testing was 254 nm. Besides, the stability of <b>29</b> under acidic condition was also investigated by using a solution of <b>29</b> (0.5 mg) in PBS (pH = 5.5) and acetonitrile (5 mL, 90:10, V/V) and was incubated at 37 Â°C in a water bath in dark for 36 h. The results were detected and recorded with RP-HPLC (waters, e2695 system; 2489 UV/vis detector) on the ODS column (250 Ã 4.6 mm, 5 Î¼m), using a wavelength of 254 nm and an eluent of acetonitrile/water (45:55, V/V) (0.05% trifluoroacetic acid inwater).</div><div class="NLM_p last">The release of <b>26</b> from <b>29</b> in A549 cells was also conducted. Briefly, A549 cells were co-incubated with <b>29</b> (2, 5, 10 Î¼M) for 24 h, washed with PBS, and lysed to obtain cell lysates. Supernatant fraction gained after centrifugation was filtered with a microporous filter membrane (0.22 Î¼m), recorded, and analyzed with RP-HPLC (waters, e2695 system; 2489 UV/vis detector). The other conditions of HPLC were the same as description mentioned above.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.8.  Cellular Uptake Assay</h3><div class="NLM_p last">The content of cellular uptake of CDDP and <b>29</b> was measured on A549 cells. Briefly, A549 cells were seeded in 96-well plates until reached about 80% confluence and then incubated with <b>29</b> (5 and 10 Î¼M) and CDDP (5 and 10 Î¼M) at 37 Â°C in standard culture conditions. After 12 h co-incubation, the cells were harvested, washed with ice cold PBS (3 Ã 3 mL), centrifuged at 1000 g, and resuspended in PBS (1 mL). The cell numbers were counted by using 100 Î¼L suspension, and the rest cells were digested with 65% nitric acid for ICPâMS to obtain the platinum content.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.9.  Co-Immunoprecipitation</h3><div class="NLM_p last">To investigate the effect of <b>29</b> on the signaling transduction between RAS and RAF, co-immunoprecipitation assays were carried out. Briefly, A549 cells (at a density of 2 Ã 10<sup>6</sup> cells/mL) were seeded in six-well plates and incubated for overnight. Then the cells were co-incubated with the same concentration (5 Î¼M) of <b>26</b> and <b>29</b>, respectively. After 24 h treatment, cells were harvested, washed with fresh ice PBS, treated with trypsin, and lysed in lysis buffer (KGP701, KeyGEN BioTECH). Subsequently, the clarified cell lysates were divided into two groups of input group and IP group. The lysates of input group were subjected to Western blot, following the method in 4.16. As for the IP group, lysates were incubated with VE-cadherin (contains primary antibody) at 4 Â°C overnight. The resulting proteins were precipitated with protein G agarose and co-incubated 4 Â°C for 3 h. The protein sediment obtained after centrifugation was washed with cold PBS buffer, resolved with 1 Ã sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and subjected to Western blot analysis, according to the method mentioned in 4.12, using the indicated antibodies. The co-immunoprecipitation assays of CRAF and BRAF were carried out following the illustrations mentioned above, using CRAF antibody (Genetex, GTX 24767) and BRAF antibody (abcam, Ab33899).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.10.  Microscale Thermophoresis</h3><div class="NLM_p">H-Ras protein (Sino Biological Inc.), K-RAS (Sino Biological Inc.), N-RAS (Sino Biological Inc.), and human recombinant Raf-1-RBD (EMD Millipore) were used for MST assays. First, H-RAS, K-RAS, and N-RAS proteins were N-terminally labeled using the Monolith NT Protein Labeling Kit RED-NHS (NanoTemper Technologies, MÃ¼nchen, Germany), following the illustrations of manufacturer. Also, the CRAF was labeled with FITC by FITC-OSu in PBS (PH = 7.4) solution and the protein eluted in 0.5 mL of binding buffer (25 mM TrisâHCl, pH 8.0/300 mM NaCl).<a onclick="showRef(event, 'cit8a'); return false;" href="javascript:void(0);" class="ref cit8a">(8a)</a></div><div class="NLM_p last">To carried out the MST assays <b>26</b> (5â0.000153 Î¼M) or <b>29</b> (5â0.000153 Î¼M), K-/H-/N-RAS (100 nM) were co-incubated for 30 min at room temperature in binding buffer (25 mM TrisâHCl, pH 8.0/300 mM NaCl).<a onclick="showRef(event, 'cit8e'); return false;" href="javascript:void(0);" class="ref cit8e">(8e)</a> Then, the binding data were recorded and analyzed with Monolith NT.115 (Nano Temper Technologies).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.11.  Cellular Thermal Shift Assay</h3><div class="NLM_p last">To verify that <b>29</b> interacted with CRAF protein rather than RAS, cellular thermal shift assays were performed. Briefly, A549 cell lysates were divided equally into PCR tubes and co-incubated with <b>26</b> (5 Î¼M), <b>29</b> (5 Î¼M), and DMF at room temperature for 30 min. Thereafter, the complexes were divided equally (20 Î¼L) into PCR tubes and heated at the temperature ranged from 47 to 67 Â°C for 5 min. The lysates obtained after centrifugation were subjected to Western blotting to analyze the stability of RAS and CRAF proteins with the antibodies in material.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.12.  Cell Apoptosis Analysis</h3><div class="NLM_p last">A549 cells (2 Ã 10<sup>6</sup> cells/mL) in the DMEM medium with 10% FBS were seeded in six-well plates and allowed to adhere overnight. After incubation overnight, the tumor cells were treated with different compounds, namely compound <b>26</b> (5 Î¼M), compound <b>29</b> (5 Î¼M), cisplatin (5 Î¼M), and vehicle (DMF) for 24 h. Then, the cells were collected and washed twice with PBS followed by the addition of 1Ã binding buffer (2 Ã 10<sup>6</sup> cells/mL) to resuspend the cells. The cells were treated with 5 Î¼L AnnexinV-FITC (BD, Pharmingen) and 5 Î¼L PI using annexin-V FITC apoptosis kit and incubated at RT in dark for 20 min and centrifuged. The apoptosis value was obtained with system software (Cell Quest; BD Biosciences). As for the cell apoptosis analysis of <b>26</b>, <b>29</b>, and CDDP at IC<sub>50</sub> concentration, the concentration of each compound was changed to 83 nM, 6 nM, and 8.2 Î¼Î and recorded the results after 72 h co-incubation with A549 cells, following the illustration mentioned above.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.13.  Cell Cycle Arrest Analysis</h3><div class="NLM_p last">A549 cells (2 Ã 10<sup>6</sup> cells/mL) in the DMEM medium with 10% FBS were seeded in six-well plates and allowed to adhere overnight. After incubation overnight, the tumor cells were treated with different compounds: compound <b>26</b> (5 Î¼M), compound <b>29</b> (5 Î¼M), CDDP (5 Î¼M), and vehicle (DMF) for 24 h. Then, the cells were collected and washed twice with ice-cold PBS and fixed with ice-cold ethanol at â20 Â°C overnight. After this, the cells were washed twice with cold PBS and treated with RNase A (100 Î¼g/mL) at 37 Â°C for 20 min, centrifuged, and collected. The cells were then stained with PI (1 mg/mL) in dark at 4 Â°C for 30 min, following the instructions of test kit, and analyzed with system software (Cell Quest; BD Biosciences).</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">4.14.  Comet Assay</h3><div class="NLM_p last">Human lung cancer A549 cells (2 Ã 10<sup>6</sup> cells/mL) were incubated in six-well plates and allowed to coherent overnight and then treated with various compound: vehicle (DMF), CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M). After 24 h co-incubation with various compounds mentioned above, Molten LM Agarose (Trevigen) at a ratio of 1/10 (v/v) was added and transferred onto Comet Slide (Trevigen) and incubated for another 10 min at 4 Â°C in dark. After this, the slides were first immersed in lysis buffer for 30 min at 4 Â°C before incubating in alkaline unwinding solution (1 mM EDTA, 200 mM NaOH) for 20 min at room temperature. Finally, the slides were washed with water and 70% ethanol, dried, and used for laser confocal microscope analysis.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">4.15.  ROS Active Oxygen Analysis</h3><div class="NLM_p last">Human lung cancer A549 cells (2 Ã 10<sup>6</sup> cells/mL) were incubated in six-well plates and allowed to coherent overnight and then treated with various compound: vehicle (DMF), CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M). After 24 h treatment, the cells were collected at 2000 rpm and washed twice with ice PBS. Subsequently, the tumor cells were incubated with DCFH-DA (Molecular Probe, Beyotime, Haimen, China) in dark at 37 Â°C for 30 min, following the instructions of kit. Finally, cellular fluorescence was observed and recorded with a fluorescence microscope. The colocation analyses of ROS and mitochondria were conducted as illustrated above, while using DCFH-DA and Mitochondrion Red (KEYGEN BIOTECH, KGMP0071) as probes.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">4.16.  MMP Analysis Induced by <b>26</b> and <b>29</b></h3><div class="NLM_p last">Human lung cancer A549 cells (2 Ã 10<sup>6</sup> cells/mL) were incubated in six-well plates and allowed to coherent overnight and then treated with various compound: vehicle (DMF), CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M). After 24 h treatment, the medium was replaced followed by staining with a JC-1 fluorescent probe prepared previously according to the instructions of test kit. After 30 min treatment in dark at 37 Â°C, cells were collected at 2500 rpm and washed twice with new ice PBS, and then the effects of various compounds on MMP of tumor cells were analyzed with a flow cytometer using 530, 590, and 488 nm as emission fluorescence and excitation wavelength.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">4.17.  Cell Morphology of Apoptosis Induced by <b>26</b> and <b>29</b> (AO and EB Co-Staining)</h3><div class="NLM_p last">A549 cells (2 Ã 10<sup>6</sup> cells/mL) in the DMEM medium with 10% FBS were seeded in six-well plates and allowed to adhere overnight. After incubation overnight, the tumor cells were treated with different compounds: compound <b>26</b> (5 Î¼M), compound <b>29</b> (5 Î¼M), CDDP (5 Î¼M), and vehicle (DMF) for 24 h. After this, the cells were washed twice with cold PBS and treated with RNase A (100 Î¼g/mL) at 37 Â°C for 20 min. The cells were resuspended with treatment of trypsin (20 Î¼L) and then transferred to glass substrates and co-stained with AO (6 Î¼g/mL) and EB (6 Î¼g/mL), following the instructions of test kit. Finally, the morphology of the cells treated with different compounds was observed and recorded with a fluorescence microscope.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">4.18.  Regulated Proteins Analyzed by Western Blotting</h3><div class="NLM_p last">Human lung cancer A549 cells (2 Ã 10<sup>6</sup> cells/mL) were incubated in six-well plates and allowed to coherent overnight and then treated with various compounds: vehicle (DMF), CDDP (5 Î¼M), <b>26</b> (2, 5 Î¼M), and <b>29</b> (2, 5 Î¼M). After 48 h treatment, cells were collected, centrifuged, and washed twice with cold PBS. Then the, cell pellet harvested was lysed with a lysis buffer on ice for 30 min, centrifuged at 15â000 rpm for 15 min at 4 Â°C, and collected. Protein amount of the cell lysates was measured with BCA protein assay reagents (Imgenex, USA) under the instructions of manufacture. Equal amounts of cellular protein lysed were separated on SDS-PAGE on 12% gels and transferred to PVDF Hybond-P membrane (GE Healthcare). Then, the membrane was blocked with 5% nonfat milk in Tris-buffered saline with Tween 20 (TBST) buffer and co-incubated with primary antibodies (anti-Bcl-2, anti-Bax, anti-Cyt <i>c</i>, anti-pro-caspase-9, anti-caspase-9, anti-pro-caspase-3, anti-caspase-3, anti-total-PARP, anti-cleaved PARP, anti-Î²-actin, anti-GAPDH, anti-MEK, anti-p-MEK, anti-ERK, anti-p-ERK, anti-Î³H2AX, anti-p53, anti-BRAF and anti-Pin 1) at 4 Â°C overnight. Subsequently, the membrane was incubated with second antibodies conjugated with peroxidase for 2 h, washed three times with TBST buffer for 15 min, and visualized with chemiluminescence reagent (Thermo Fischer Scientifics Ltd.).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">4.19.  UVâvis and Fluorescence Emission Detection</h3><div class="NLM_p last">Compound <b>26</b> or <b>29</b> (1.0 mg) was dissolved in acetonitrile (200 Î¼L) and diluted to 5 Î¼Î with PBS (pH 7.4) or DMEM (10% in PBS 7.4) solution. Also the CDDP was dissolved in water or DMEM (10% in PBS 7.4) to a final solution (5 Î¼Î). Then, the UV absorption of the samples was recorded on a Shimadzu UV2600 instrument with wavelength ranging from 190 to 450 nm. The fluorescence emission was recorded with a Shimadzu RF-6000 instrument with the excitation wavelength of 315 nm (wavelength of maximum absorption), 494 nm (wavelength of excitation wavelength), and 535 nm (wavelength of PI-DNA complexes).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">4.20.  In Vivo Antitumor Activity Assay</h3><div class="NLM_p">The mice used in in vivo experiments were purchased from Shanghai Slac Laboratory Animal Co., Ltd. (China), housed in the facility at the Laboratory Animal Center, Academy of Simcere, according to the guidelines approved for laboratory animals. All surgical interventions and postoperative animal care procedures were approved by the Experimental Animal Ethics Committee of Southeast University (Nanjing, China).</div><div class="NLM_p">To investigate the antitumor activity of compound <b>29</b>, A549 in vivo xenograft tumor models were utilized following the method described previously.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32â34)</a> Briefly, 3 Ã 10<sup>6</sup> A549 cells in 100 Î¼L of sterile PBS were injected subcutaneously in the flank of female BALB/c athymic nude mice of 5â6 weeks of age, which were purchased from Shanghai Slac Laboratory Animal Co., Ltd. (China). After allowing the tumors reached to 150â250 mm<sup>3</sup>, animals were assigned to four groups (three animals per group) randomly for efficacy studies and treated via injecting intravenously through tail vein with compound 29 (6 Î¼mol/kg, on days 0, 2 and 4), Rigosertib (6 Î¼mol/kg, on days 0, 2 and 4), CDDP (6 Î¼mol/kg, on days 0, 2 and 4), and vehicle (equivalent volume of normal saline injection, on days 0, 2 and 4), respectively. Compound <b>29</b> was dissolved in a mixture of 0.1% Tween-80 and 2.5% DMF and diluted in saline for desired concentration. Tumor volumes and body weights were measured 2â3 times a week. Tumor volumes were obtained by measuring the perpendicular diameter of tumor in length and width and calculated according to the formula:</div><div class="NLM_p last">Tumor volume (mm<sup>3</sup>) = 1/2 Ã length Ã width<sup>2</sup>. Curves of tumor growth and body weights were plotted using the average data at the same group by origin 9.0.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01223" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01223?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01223</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Table of IC<sub>50</sub> values in vitro of tested compounds against multidrug-resistant cancer lines, expression of P-glycoprotein (P-gp) in CDDP/DOX-resistant cancer cell lines, charts of stability of compound <b>29</b> and the release of CDDP and compound <b>26</b> under reduction of ascorbic acid and under acidic condition, figure and data of standard curve of <b>26</b>, HPLC analysis on the release of <b>26</b> in A549 cells, MST assays and CETSAs of <b>26</b> and <b>29</b>, western blotting analysis of the effect on BRAF and BRAF/CRAF complexes induced by <b>29</b>, table of IC<sub>50</sub> values of <b>26</b>, <b>29</b>, and CDDP at 24 h. A549 apoptosis induced by <b>29</b> by IC<sub>50</sub> concentration in 72 h, DNA damage assays and ROS assays induced by <b>29</b>, UV and fluorescence spectra of <b>26</b> and <b>29</b>, western blotting analysis of Pin 1 protein induced by <b>29</b>, table of antitumor activity of compound <b>29</b> on A549 xenograft models, and figures of HR-MS, <sup>1</sup>H, <sup>13</sup>C NMR spectra, and HPLC chromatograms (<b>18â23</b>, <b>27â29</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf">jm9b01223_si_001.pdf (4.01 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_002.csv">jm9b01223_si_002.csv (2.31 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01223" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Fang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bad6dfd394dcdbd4ddfac9dfcf94dfdecf94d9d4"><span class="__cf_email__" data-cfemail="2b474e42054d4a454c6b584e5e054e4f5e054845">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaohua Gou</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#becdd9d1cbfecddbcb90dbdacb90ddd0"><span class="__cf_email__" data-cfemail="4d3e2a22380d3e283863282938632e23">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhikun Liu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meng Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical
Sciences of Guangxi Normal University, Guilin 541004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengshan Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical
Sciences of Guangxi Normal University, Guilin 541004, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6474-8323" title="Orcid link">http://orcid.org/0000-0001-6474-8323</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Z.L. and M.W. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the National Natural Science Foundation of China (grant nos. 21571033; 81760626) and Priority Academic Program Development of Jiangsu Higher Education Institutions for the construction of fundamental facilities (project 1107047002) for financial support of this study. We also show gratitude to KeyGen Biotech Company for co-immunoprecipitation assays. Dr. Fang is thankful to the support of the State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University) (CMEMR2017-B05), âQing-Lanâ project in Colleges and Universities of Jiangsu Province, the National Science and Technology Major Foundation of China, and the Priority Academic Program Development of Jiangsu Higher Education Institutions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">RAS.GDP</td><td class="NLM_def"><p class="first last">GDP-bound state of RAS</p></td></tr><tr><td class="NLM_term">RAS.GTP</td><td class="NLM_def"><p class="first last">GTP-bound state of RAS</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">CDDP</td><td class="NLM_def"><p class="first last">cisplatin</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>â²,<i>N</i>â²-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">the half maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">A549</td><td class="NLM_def"><p class="first last">non-small cell lung cancer cell line</p></td></tr><tr><td class="NLM_term">MGC-803</td><td class="NLM_def"><p class="first last">gastric cancer cell line</p></td></tr><tr><td class="NLM_term">SKOV-3</td><td class="NLM_def"><p class="first last">ovarian cancer cell line</p></td></tr><tr><td class="NLM_term">NCI-H460</td><td class="NLM_def"><p class="first last">large cell lung cancer cell line</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP binding cassette</p></td></tr><tr><td class="NLM_term">A549/CDDP</td><td class="NLM_def"><p class="first last">CDDP resistant A549 cells</p></td></tr><tr><td class="NLM_term">A549/DOX</td><td class="NLM_def"><p class="first last">doxorubicin resistant A549 cells</p></td></tr><tr><td class="NLM_term">SKOV3/CDDP</td><td class="NLM_def"><p class="first last">CDDP resistant SKOV3 cells</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">RF</td><td class="NLM_def"><p class="first last">resistant factor</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">ICPâMS</td><td class="NLM_def"><p class="first last">inductively coupled plasmaâmass spectrometry</p></td></tr><tr><td class="NLM_term">MST</td><td class="NLM_def"><p class="first last">microscale thermophoresis</p></td></tr><tr><td class="NLM_term">CETSA</td><td class="NLM_def"><p class="first last">cellular protein thermal shift assay</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>d</sub></td><td class="NLM_def"><p class="first last">affinity constant</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">double-strand break</p></td></tr><tr><td class="NLM_term">Î³H2AX</td><td class="NLM_def"><p class="first last">phosphorylation of H2AX</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">DCHF-DA</td><td class="NLM_def"><p class="first last">2,7-dichlorodi-hydrofluorescein diacetate</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">mitochondrial membrane potential</p></td></tr><tr><td class="NLM_term">AO/EB</td><td class="NLM_def"><p class="first last">acridine orange/ethidium bromide</p></td></tr><tr><td class="NLM_term">Cyt <i>c</i></td><td class="NLM_def"><p class="first last">cytochrome <i>C</i></p></td></tr><tr><td class="NLM_term">Bcl-2</td><td class="NLM_def"><p class="first last">B-cell lymphoma-2 protein</p></td></tr><tr><td class="NLM_term">Bax</td><td class="NLM_def"><p class="first last">Bcl-2 associated X protein</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP-ribose polymerase</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">Pin 1</td><td class="NLM_def"><p class="first last">prolyl-isomerase 1</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">inhibition ration</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">tetramethylsilane</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">HR-MS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbeccoâs modified Eagle medium</p></td></tr><tr><td class="NLM_term">FACS</td><td class="NLM_def"><p class="first last">fluorescence-activated cell sorting</p></td></tr><tr><td class="NLM_term">SDS-PAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0lgc9IMngruZYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, M.</span></span> <span> </span><span class="NLM_article-title">A âtug of warâ maintains a dynamic proteinâmembrane complex: molecular dynamics simulations of C-Raf RBD-CRD bound to K-Ras4B at an anionic membrane</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.7b00593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1egu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=298-305&author=Z.-L.+Liauthor=P.+Prakashauthor=M.+Buck&title=A+%E2%80%9Ctug+of+war%E2%80%9D+maintains+a+dynamic+protein%E2%80%93membrane+complex%3A+molecular+dynamics+simulations+of+C-Raf+RBD-CRD+bound+to+K-Ras4B+at+an+anionic+membrane&doi=10.1021%2Facscentsci.7b00593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A "Tug of War" Maintains a Dynamic Protein-Membrane Complex: Molecular Dynamics Simulations of C-Raf RBD-CRD Bound to K-Ras4B at an Anionic Membrane</span></div><div class="casAuthors">Li, Zhen-Lu; Prakash, Priyanka; Buck, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Assocn. of Raf kinase with activated Ras triggers downstream signaling cascades, towards regulating transcription in the cells' nucleus.  Dysregulation of Ras: Raf signaling stimulates cancers.  We investigate the C-Raf RBD and CRD regions when bound to oncogenic K-Ras4B at the membrane.  All-atom mol. dynamics simulations suggest that the membrane plays an integral role in regulating the configurational ensemble of the complex.  Remarkably, the complex samples a few states dynamically, reflecting a competition between C-Raf CRD and K-Ras4B- membrane interactions.  This competition arises because the interaction between the RBD and K-Ras is strong and the linker between the RBD and CRD is short.  This study reveals a mechanism that maintains a modest binding for the overall complex at the membrane to facilitate fast signaling processes.  It is likely a common mechanism for other multi-protein, if not multidomain proteins at membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBrkdc42HYCrVg90H21EOLACvtfcHk0lgc9IMngruZYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1egu7o%253D&md5=42197b5574f7fc277876ed67312ade83</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00593%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.-L.%26aulast%3DPrakash%26aufirst%3DP.%26aulast%3DBuck%26aufirst%3DM.%26atitle%3DA%2520%25E2%2580%259Ctug%2520of%2520war%25E2%2580%259D%2520maintains%2520a%2520dynamic%2520protein%25E2%2580%2593membrane%2520complex%253A%2520molecular%2520dynamics%2520simulations%2520of%2520C-Raf%2520RBD-CRD%2520bound%2520to%2520K-Ras4B%2520at%2520an%2520anionic%2520membrane%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2018%26volume%3D4%26spage%3D298%26epage%3D305%26doi%3D10.1021%2Facscentsci.7b00593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25155755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+complex+reveals+a+kinase+activity+independent+role+for+BRAF+in+MAPK+signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span></div><div class="casAuthors">Haling, Jacob R.; Sudhamsu, Jawahar; Yen, Ivana; Sideris, Steve; Sandoval, Wendy; Phung, Wilson; Bravo, Brandon J.; Giannetti, Anthony M.; Peck, Ariana; Masselot, Alexandre; Morales, Tony; Smith, Darin; Brandhuber, Barbara J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-413</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Numerous oncogenic mutations occur within the BRAF kinase domain (BRAFKD).  Here we show that stable BRAF-MEK1 complexes are enriched in BRAFWT and KRAS mutant (MT) cells but not in BRAFMT cells.  The crystal structure of the BRAFKD in a complex with MEK1 reveals a face-to-face dimer sensitive to MEK1 phosphorylation but insensitive to BRAF dimerization.  Structure-guided studies reveal that oncogenic BRAF mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the interaction with MEK1.  Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant BRAF-MEK1 complex resulting in pathway inhibition.  Taken together, these findings reveal a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXE20AD1ZxrLVg90H21EOLACvtfcHk0ljMB8tdo38vAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ&md5=a4a931aa158afbac09b972fc2a0142b8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520complex%2520reveals%2520a%2520kinase%2520activity%2520independent%2520role%2520for%2520BRAF%2520in%2520MAPK%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1537</span>â <span class="NLM_lpage">1548</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-17-2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F0008-5472.can-17-2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29343524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1537-1548&author=W.+Shaoauthor=Y.+M.+Mishinaauthor=Y.+Fengauthor=G.+Caponigroauthor=V.+G.+Cookeauthor=S.+Riveraauthor=Y.+Wangauthor=F.+Shenauthor=J.+M.+Kornauthor=L.+A.+Mathews+Grinerauthor=G.+Nishiguchiauthor=A.+Ricoauthor=J.+Tellewauthor=J.+R.+Halingauthor=R.+Aversaauthor=V.+Polyakovauthor=R.+Zangauthor=M.+Hekmat-Nejadauthor=P.+Amiriauthor=M.+Singhauthor=N.+Keenauthor=M.+P.+Dillonauthor=E.+Leesauthor=S.+Ramurthyauthor=W.+R.+Sellersauthor=D.+D.+Stuart&title=Antitumor+properties+of+RAF709%2C+a+highly+selective+and+potent+inhibitor+of+RAF+kinase+dimers%2C+in+tumors+driven+by+mutant+RAS+or+BRAF&doi=10.1158%2F0008-5472.can-17-2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF</span></div><div class="casAuthors">Shao, Wenlin; Mishina, Yuji M.; Feng, Yun; Caponigro, Giordano; Cooke, Vesselina G.; Rivera, Stacy; Wang, Yingyun; Shen, Fang; Korn, Joshua M.; Mathews Griner, Lesley A.; Nishiguchi, Gisele; Rico, Alice; Tellew, John; Haling, Jacob R.; Aversa, Robert; Polyakov, Valery; Zang, Richard; Hekmat-Nejad, Mohammad; Amiri, Payman; Singh, Mallika; Keen, Nicholas; Dillon, Michael P.; Lees, Emma; Ramurthy, Savithri; Sellers, William R.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1537-1548</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene.  Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kinases.  RAF709 exhibited a mode of RAF inhibition distinct from RAF monomer inhibitors such as vemurafenib, showing equal activity against both RAF monomers and dimers.  As a result, RAF709 inhibited MAPK signaling activity in tumor models harboring either BRAFV600 alterations or mutant N- and KRAS-driven signaling, with minimal paradoxical activation of wild-type RAF.  In cell lines and murine xenograft models, RAF709 demonstrated selective antitumor activity in tumor cells harboring BRAF or RAS mutations compared with cells with wild-type BRAF and RAS genes.  RAF709 demonstrated a direct pharmacokinetic/pharmacodynamic relationship in in vivo tumor models harboring KRAS mutation.  Furthermore, RAF709 elicited regression of primary human tumor-derived xenograft models with BRAF, NRAS, or KRAS mutations with excellent tolerability.  Our results support further development of inhibitors like RAF709, which represents a next-generation RAF inhibitor with unique biochem. and cellular properties that enables antitumor activities in RAS-mutant tumors.  Significance: In an effort to develop RAF inhibitors with the appropriate pharmacol. properties to treat RAS mutant tumors, RAF709, a compd. with potency, selectivity, and in vivo properties, was developed that will allow preclin. therapeutic hypothesis testing, but also provide an excellent probe to further unravel the complexities of RAF kinase signaling.  Cancer Res; 78(6); 1537-48. Â©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOvhVkNT32bVg90H21EOLACvtfcHk0ljMB8tdo38vAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D&md5=607b45deb150d83b01394d43f776c097</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-17-2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-17-2033%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW.%26aulast%3DMishina%26aufirst%3DY.%2BM.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DRivera%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DKorn%26aufirst%3DJ.%2BM.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DAversa%26aufirst%3DR.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DAntitumor%2520properties%2520of%2520RAF709%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RAF%2520kinase%2520dimers%252C%2520in%2520tumors%2520driven%2520by%2520mutant%2520RAS%2520or%2520BRAF%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D1537%26epage%3D1548%26doi%3D10.1158%2F0008-5472.can-17-2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactive Ras in developmental disorders and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">295</span>â <span class="NLM_lpage">308</span>, <span class="refDoi">Â DOI: 10.1038/nrc2109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc2109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17384584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=295-308&author=S.+Schubbertauthor=K.+Shannonauthor=G.+Bollag&title=Hyperactive+Ras+in+developmental+disorders+and+cancer&doi=10.1038%2Fnrc2109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactive Ras in developmental disorders and cancer</span></div><div class="casAuthors">Schubbert, Suzanne; Shannon, Kevin; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ras genes are the most common targets for somatic gain-of-function mutations in human cancer.  Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Nonan, Costello and cardio-facio-cutaneous syndromes.  Many of these mutant alleles encode proteins with aberrant biochem. and functional properties.  Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRvjqrp1ho7Vg90H21EOLACvtfcHk0lhspHPC-uf7pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D&md5=25fcaa959dae5e8512b959936bcbb347</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2109%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DHyperactive%2520Ras%2520in%2520developmental%2520disorders%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D295%26epage%3D308%26doi%3D10.1038%2Fnrc2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2467</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F0008-5472.can-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.can-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0lhspHPC-uf7pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.can-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matallanas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, P.</span></span> <span> </span><span class="NLM_article-title">New druggable targets in the Ras pathway?</span>. <i>Curr. Opin. Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">674</span>â <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21154159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVelu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=674-683&author=D.+Matallanasauthor=P.+Crespo&title=New+druggable+targets+in+the+Ras+pathway%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New druggable targets in the Ras pathway?</span></div><div class="casAuthors">Matallanas, David; Crespo, Piero</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">674-683</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ras proteins are key elements in the regulation of cellular proliferation, differentiation and survival.  Mutational activation of Ras or of components of its effector pathways are detected in one-third of human cancers and are essential for the genesis and maintenance of the tumoral phenotype.  Research efforts have been dedicated to the development of therapeutic agents that inhibit aberrant Ras signals and, subsequently, tumor progression.  However, many of these initiatives have proven less successful than expected.  This review summarizes the current status of developments in Ras research, the challenges that have arisen during preclin. and clin. stages, and how novel approaches to targeting Ras pathways have introduced new strategies toward the development of antitumoral agents that are alternative or complementary to those currently in use.  These new approaches would be aimed at disrupting key protein-protein interactions that are essential for the conveyance of Ras aberrant signals or would be directed against new proteins recently demonstrated to be crit. participants in Ras-regulated pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra7ew0StgcBrVg90H21EOLACvtfcHk0lhspHPC-uf7pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVelu7s%253D&md5=3788fab9a1650a1d5b33726e3f281165</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatallanas%26aufirst%3DD.%26aulast%3DCrespo%26aufirst%3DP.%26atitle%3DNew%2520druggable%2520targets%2520in%2520the%2520Ras%2520pathway%253F%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D674%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+V.+R.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0lhspHPC-uf7pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slupsky, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalmes, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span> <span> </span><span class="NLM_article-title">Active Ras induces heterodimerization of cRaf and BRaf</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3595</span>â <span class="NLM_lpage">3598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=11325826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFCgtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3595-3598&author=C.+K.+Weberauthor=J.+R.+Slupskyauthor=H.+A.+Kalmesauthor=U.+R.+Rapp&title=Active+Ras+induces+heterodimerization+of+cRaf+and+BRaf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Active Ras induces heterodimerization of cRaf and BRaf</span></div><div class="casAuthors">Weber, Christoph K.; Slupsky, Joseph R.; Kalmes, H. Andreas; Rapp, Ulf R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3598</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Growth factor-induced signaling leads to activation of members of the Ras family and subsequent stimulation of different Raf isoforms.  Within the mechanism of Raf activation, two isoforms of Raf, cRaf and BRaf, may cooperate.  The authors investigated the relation between cRaf and BRaf and found that active Ras induced heterodimerization of cRaf and BRaf, an effect that was dependent on the serine residue at position 621 of cRaf.  Moreover, the authors also found that cRaf COOH-terminus constitutively assocd. with BRaf, whereas the NH2 terminus did not, even in the presence of active Ras.  These data suggest that Ras induces the cRaf-BRaf complex formation through the exposure of 14-3-3 binding sites in the COOH-terminus of cRaf.  Thus, Ras-induced cRaf-Braf heterodimerization may explain the obsd. cooperativity of cRaf and BRaf in cells responding to growth factor signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZNOGMIko_7Vg90H21EOLACvtfcHk0linAhr5rz5pxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFCgtLk%253D&md5=13f7c23245dee7b7ea80b74fba6482b7</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DC.%2BK.%26aulast%3DSlupsky%26aufirst%3DJ.%2BR.%26aulast%3DKalmes%26aufirst%3DH.%2BA.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DActive%2520Ras%2520induces%2520heterodimerization%2520of%2520cRaf%2520and%2520BRaf%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3595%26epage%3D3598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specht, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">806</span>â <span class="NLM_lpage">819</span>, <span class="refDoi">Â DOI: 10.1128/mcb.00569-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.00569-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19933846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslarsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=806-819&author=D.+A.+Rittauthor=D.+M.+Monsonauthor=S.+I.+Spechtauthor=D.+K.+Morrison&title=Impact+of+feedback+phosphorylation+and+Raf+heterodimerization+on+normal+and+mutant+B-Raf+signaling&doi=10.1128%2Fmcb.00569-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling</span></div><div class="casAuthors">Ritt, Daniel A.; Monson, Daniel M.; Specht, Suzanne I.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">806-819</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The B-Raf kinase is a Ras pathway effector activated by mutation in numerous human cancers and certain developmental disorders.  Here we report that normal and oncogenic B-Raf proteins are subject to a regulatory cycle of extracellular signal-regulated kinase (ERK)-dependent feedback phosphorylation, followed by PP2A- and Pin1-dependent dephosphorylation/recycling.  We identify four S/TP sites of B-Raf phosphorylated by activated ERK and find that feedback phosphorylation of B-Raf inhibits binding to activated Ras and disrupts heterodimerization with C-Raf, which is dependent on the B-Raf pS729/14-3-3 binding site.  Moreover, we find that events influencing Raf heterodimerization can alter the transforming potential of oncogenic B-Raf proteins possessing intermediate or impaired kinase activity but have no significant effect on proteins with high kinase activity, such as V600E B-Raf.  Mutation of the feedback sites or overexpression of the Pin1 prolylisomerase, which facilitates B-Raf dephosphorylation/recycling, resulted in increased transformation, whereas mutation of the S729/14-3-3 binding site or expression of dominant neg. Pin1 reduced transformation.  Mutation of each feedback site caused increased transformation and correlated with enhanced heterodimerization and activation of C-Raf.  Finally, we find that B-Raf and C-Raf proteins contg. mutations identified in certain developmental disorders constitutively heterodimerize and that their signaling activity can also be modulated by feedback phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorJLukfx2EmLVg90H21EOLACvtfcHk0linAhr5rz5pxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslarsL0%253D&md5=146b72cc196bf1e5904803176845b7a8</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1128%2Fmcb.00569-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.00569-09%26sid%3Dliteratum%253Aachs%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMonson%26aufirst%3DD.%2BM.%26aulast%3DSpecht%26aufirst%3DS.%2BI.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DImpact%2520of%2520feedback%2520phosphorylation%2520and%2520Raf%2520heterodimerization%2520on%2520normal%2520and%2520mutant%2520B-Raf%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D806%26epage%3D819%26doi%3D10.1128%2Fmcb.00569-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">Regulation and role of Raf-1/B-Raf heterodimerization</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2262</span>â <span class="NLM_lpage">2272</span>, <span class="refDoi">Â DOI: 10.1128/mcb.26.6.2262-2272.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.26.6.2262-2272.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16508002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2262-2272&author=L.+K.+Rushworthauthor=A.+D.+Hindleyauthor=E.+O%E2%80%99Neillauthor=W.+Kolch&title=Regulation+and+role+of+Raf-1%2FB-Raf+heterodimerization&doi=10.1128%2Fmcb.26.6.2262-2272.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8dR"><div class="casContent"><span class="casTitleNuber">8d</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of Raf-1/B-Raf heterodimerization</span></div><div class="casAuthors">Rushworth, Linda K.; Hindley, Alison D.; O'Neill, Eric; Kolch, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2262-2272</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway participates in the control of many fundamental cellular processes including proliferation, survival, and differentiation.  The pathway is deregulated in up to 30% of human cancers, often due to mutations in Ras and the B-Raf isoform.  Raf-1 and B-Raf can form heterodimers, and this may be important for cellular transformation.  Here, we have analyzed the biochem. and biol. properties of Raf-1/B-Raf heterodimers.  Isolated Raf-1/B-Raf heterodimers possessed a highly increased kinase activity compared to the resp. homodimers or monomers.  Heterodimers between wild-type Raf-1 and B-Raf mutants with low or no kinase activity still displayed elevated kinase activity, as did heterodimers between wild-type B-Raf and kinase-neg. Raf-1.  In contrast, heterodimers contg. both kinase-neg. Raf-1 and kinase-neg. B-Raf were completely inactive, suggesting that the kinase activity of the heterodimer specifically originates from Raf and that either kinase-competent Raf isoform is sufficient to confer high catalytic activity to the heterodimer.  In cell lines, Raf-1/B-Raf heterodimers were found at low levels.  Heterodimerization was enhanced by 14-3-3 proteins and by mitogens independently of ERK.  However, ERK-induced phosphorylation of B-Raf on T753 promoted the disassembly of Raf heterodimers, and the mutation of T753 prolonged growth factor-induced heterodimerization.  The B-Raf T753A mutant enhanced differentiation of PC12 cells, which was previously shown to be dependent on sustained ERK signaling.  Fine mapping of the interaction sites by peptide arrays suggested a complex mode of interaction involving multiple contact sites with a main Raf-1 binding site in B-Raf encompassing T753.  In summary, our data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiol. activation process and that the heterodimer has distinct biochem. properties that may be important for the regulation of some biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4CMv4bNtn7Vg90H21EOLACvtfcHk0linAhr5rz5pxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D&md5=2826875a4a2509255bb203ec154be080</span></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1128%2Fmcb.26.6.2262-2272.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.26.6.2262-2272.2006%26sid%3Dliteratum%253Aachs%26aulast%3DRushworth%26aufirst%3DL.%2BK.%26aulast%3DHindley%26aufirst%3DA.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DRegulation%2520and%2520role%2520of%2520Raf-1%252FB-Raf%2520heterodimerization%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D2262%26epage%3D2272%26doi%3D10.1128%2Fmcb.26.6.2262-2272.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagba, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naji, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Hoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorfe, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of high-affinity noncovalent allosteric KRAS Inhibitors that disrupt effector binding</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2921</span>â <span class="NLM_lpage">2930</span>, <span class="refDoi">Â DOI: 10.1021/acsomega.8b03308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b03308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1Wqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=2921-2930&author=M.+J.+McCarthyauthor=C.+V.+Pagbaauthor=P.+Prakashauthor=A.+K.+Najiauthor=D.+van+der%0AHoevenauthor=H.+Liangauthor=A.+K.+Guptaauthor=Y.+Zhouauthor=K.-J.+Choauthor=J.+F.+Hancockauthor=A.+A.+Gorfe&title=Discovery+of+high-affinity+noncovalent+allosteric+KRAS+Inhibitors+that+disrupt+effector+binding&doi=10.1021%2Facsomega.8b03308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding</span></div><div class="casAuthors">McCarthy, Michael J.; Pagba, Cynthia V.; Prakash, Priyanka; Naji, Ali K.; van der Hoeven, Dharini; Liang, Hong; Gupta, Amit K.; Zhou, Yong; Cho, Kwang-Jin; Hancock, John F.; Gorfe, Alemayehu A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2921-2930</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 15% of all human tumors harbor mutant KRAS, a membrane-assocd. small GTPase and notorious oncogene.  Mutations that render KRAS constitutively active will lead to uncontrolled cell growth and cancer.  However, despite aggressive efforts in recent years, there are no drugs on the market that directly target KRAS and inhibit its aberrant functions.  In the current work, the authors combined structure-based design with a battery of cell and biophys. assays to discover a novel, pyrazolopyrimidine-based allosteric KRAS inhibitor that binds to activated KRAS with sub-micromolar affinity and disrupt effector binding, thereby inhibiting KRAS signaling and cancer cell growth.  These results show that pyrazolopyrimidine-based compds. represent the first-in-class allosteric noncovalent inhibitors of KRAS.  Moreover, by studying two of its analogs, the authors identified key chem. features of the compd. predicted to interact with a set of specific residues at the switch regions of KRAS as crit. for its high affinity binding and unique mode of action, thus providing a blueprint for future optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIVRBvSpzsULVg90H21EOLACvtfcHk0li9SSc6C0RoyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1Wqtr0%253D&md5=b6178c3ed69407ccbdecc03bfd63c0bf</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b03308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b03308%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BJ.%26aulast%3DPagba%26aufirst%3DC.%2BV.%26aulast%3DPrakash%26aufirst%3DP.%26aulast%3DNaji%26aufirst%3DA.%2BK.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DK.-J.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DGorfe%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520high-affinity%2520noncovalent%2520allosteric%2520KRAS%2520Inhibitors%2520that%2520disrupt%2520effector%2520binding%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D2921%26epage%3D2930%26doi%3D10.1021%2Facsomega.8b03308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertz, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>472</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">369</span>, <span class="refDoi">Â DOI: 10.1038/nature09860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnature09860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21441910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=472&publication_year=2011&pages=366-369&author=D.+F.+Brennanauthor=A.+C.+Darauthor=N.+T.+Hertzauthor=W.+C.+H.+Chaoauthor=A.+L.+Burlingameauthor=K.+M.+Shokatauthor=D.+Barford&title=A+Raf-induced+allosteric+transition+of+KSR+stimulates+phosphorylation+of+MEK&doi=10.1038%2Fnature09860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK</span></div><div class="casAuthors">Brennan, Damian F.; Dar, Arvin C.; Hertz, Nicholas T.; Chao, William C. H.; Burlingame, Alma L.; Shokat, Kevan M.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">472</span>
        (<span class="NLM_cas:issue">7343</span>),
    <span class="NLM_cas:pages">366-369</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In metazoans, the Ras-Raf-MEK (mitogen-activated protein-kinase kinase)-ERK (extracellular signal-regulated kinase) signaling pathway relays extracellular stimuli to elicit changes in cellular function and gene expression.  Aberrant activation of this pathway through oncogenic mutations is responsible for a large proportion of human cancer.  Kinase suppressor of Ras (KSR) functions as an essential scaffolding protein to coordinate the assembly of Raf-MEK-ERK complexes.  Here we integrate structural and biochem. studies to understand how KSR promotes stimulatory Raf phosphorylation of MEK.  We show, from the crystal structure of the kinase domain of human KSR2 (KSR2(KD)) in complex with rabbit MEK1, that interactions between KSR2(KD) and MEK1 are mediated by their resp. activation segments and C-lobe Î±G helixes.  KSR2 self-assocs. through a side-to-side interface involving Arg 718, a residue identified in a genetic screen as a suppressor of Ras signaling.  ATP is bound to the KSR2(KD) catalytic site, and we demonstrate KSR2 kinase activity towards MEK1 by in vitro assays and chem. genetics.  In the KSR2(KD)-MEK1 complex, the activation segments of both kinases are mutually constrained, and KSR2 adopts an inactive conformation.  BRAF allosterically stimulates the kinase activity of KSR2, which is dependent on formation of a side-to-side KSR2-BRAF heterodimer.  Furthermore, KSR2-BRAF heterodimerization results in an increase of BRAF-induced MEK phosphorylation via the KSR2-mediated relay of a signal from BRAF to release the activation segment of MEK for phosphorylation.  We propose that KSR interacts with a regulatory Raf mol. in cis to induce a conformational switch of MEK, facilitating MEK's phosphorylation by a sep. catalytic Raf mol. in trans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjx1SOihPKPrVg90H21EOLACvtfcHk0li9SSc6C0RoyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb4%253D&md5=05d164517bd5c1625903200d99c699af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature09860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09860%26sid%3Dliteratum%253Aachs%26aulast%3DBrennan%26aufirst%3DD.%2BF.%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DHertz%26aufirst%3DN.%2BT.%26aulast%3DChao%26aufirst%3DW.%2BC.%2BH.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DA%2520Raf-induced%2520allosteric%2520transition%2520of%2520KSR%2520stimulates%2520phosphorylation%2520of%2520MEK%26jtitle%3DNature%26date%3D2011%26volume%3D472%26spage%3D366%26epage%3D369%26doi%3D10.1038%2Fnature09860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">828</span>â <span class="NLM_lpage">851</span>, <span class="refDoi">Â DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0li9SSc6C0RoyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francoz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SantamarÃ­a, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CaÃ±amero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21514245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGls7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=652-663&author=R.+B.+Blascoauthor=S.+Francozauthor=D.+Santamar%C3%ADaauthor=M.+Ca%C3%B1ameroauthor=P.+Dubusauthor=J.+Charronauthor=M.+Baccariniauthor=M.+Barbacid&title=c-Raf%2C+but+Not+B-Raf%2C+Is+Essential+for+Development+of+K-Ras+Oncogene-Driven+Non-Small+Cell+Lung+Carcinoma&doi=10.1016%2Fj.ccr.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma</span></div><div class="casAuthors">Blasco, Rafael B.; Francoz, Sarah; Santamaria, David; Canamero, Marta; Dubus, Pierre; Charron, Jean; Baccarini, Manuela; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-663</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma (NSCLC).  Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells had no significant effect due to compensatory activities.  Yet, elimination of both Erk kinases completely blocked tumor development.  Similar results were obtained with Mek kinases.  Ablation of B-Raf had no significant effect on tumor development.  However, c-Raf expression was absolutely essential for the onset of NSCLC.  Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no deleterious consequences for normal homeostasis.  These results indicate that c-Raf plays a unique role in mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCWweCotG3S7Vg90H21EOLACvtfcHk0lgcMHhMbCtE1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGls7c%253D&md5=11e9470b124d1c3ba6afe7e930f8438f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlasco%26aufirst%3DR.%2BB.%26aulast%3DFrancoz%26aufirst%3DS.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DCa%25C3%25B1amero%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DCharron%26aufirst%3DJ.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3Dc-Raf%252C%2520but%2520Not%2520B-Raf%252C%2520Is%2520Essential%2520for%2520Development%2520of%2520K-Ras%2520Oncogene-Driven%2520Non-Small%2520Cell%2520Lung%2520Carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D652%26epage%3D663%26doi%3D10.1016%2Fj.ccr.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">14903</span>â <span class="NLM_lpage">14908</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1008990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner&doi=10.1073%2Fpnas.1008990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0lgcMHhMbCtE1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908%26doi%3D10.1073%2Fpnas.1008990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caunt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S. J.</span></span> <span> </span><span class="NLM_article-title">MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1038/nrc4000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc4000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=26399658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=577-592&author=C.+J.+Cauntauthor=M.+J.+Saleauthor=P.+D.+Smithauthor=S.+J.+Cook&title=MEK1+and+MEK2+inhibitors+and+cancer+therapy%3A+the+long+and+winding+road&doi=10.1038%2Fnrc4000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road</span></div><div class="casAuthors">Caunt, Christopher J.; Sale, Matthew J.; Smith, Paul D.; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">577-592</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The role of the ERK signaling pathway in cancer is thought to be most prominent in tumors in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival.  New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clin. evaluation.  In this Review, the authors consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity.  The authors discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 vs. BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2.  The authors also consider how some of the systems-level properties (intrapathway regulatory loops and wider signaling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clin. progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnTcSz8CvRcLVg90H21EOLACvtfcHk0lgcMHhMbCtE1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsb%252FO&md5=b1fd44051024a59608dd61310a437c65</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc4000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc4000%26sid%3Dliteratum%253Aachs%26aulast%3DCaunt%26aufirst%3DC.%2BJ.%26aulast%3DSale%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DMEK1%2520and%2520MEK2%2520inhibitors%2520and%2520cancer%2520therapy%253A%2520the%2520long%2520and%2520winding%2520road%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D577%26epage%3D592%26doi%3D10.1038%2Fnrc4000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rebocho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">New Insight Puts CRAF in Sight as a Therapeutic Target: Figure 1</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-11-0118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F2159-8290.cd-11-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22318779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=98-99&author=A.+P.+Rebochoauthor=R.+Marais&title=New+Insight+Puts+CRAF+in+Sight+as+a+Therapeutic+Target%3A+Figure+1&doi=10.1158%2F2159-8290.cd-11-0118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight Puts CRAF in Sight as a Therapeutic Target</span></div><div class="casAuthors">Rebocho, Ana Paula; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-99</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">A review.  By selectively depleting components of the RAF-MEK-ERK pathway in transgenic mice, it is now shown in 2 studies that CRAF is crit. for signaling to MEK downstream of oncogenic Kras and that BRAF is not required.  Cancer Discovery; 1(2); 98-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGown_LK1MCqvbVg90H21EOLACvtfcHk0lgqmJOA_JQQPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D&md5=fc2cd219ee60d00cb7d32a3a83a05e86</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-11-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-11-0118%26sid%3Dliteratum%253Aachs%26aulast%3DRebocho%26aufirst%3DA.%2BP.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DNew%2520Insight%2520Puts%2520CRAF%2520in%2520Sight%2520as%2520a%2520Therapeutic%2520Target%253A%2520Figure%25201%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D98%26epage%3D99%26doi%3D10.1158%2F2159-8290.cd-11-0118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">c-Raf in KRas Mutant Cancers: A Moving Target</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">158</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2018.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccell.2018.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29438690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=158-159&author=F.+McCormick&title=c-Raf+in+KRas+Mutant+Cancers%3A+A+Moving+Target&doi=10.1016%2Fj.ccell.2018.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">c-Raf in KRas Mutant Cancers: A Moving Target</span></div><div class="casAuthors">McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-159</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The research of Sanclemente et al. (Cancer Cell: 33, 217-228) is reviewed with commentary and refs.  Therapies for KRas cancers remain a major clin. need.  C-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZnd5oVueKn7Vg90H21EOLACvtfcHk0lgqmJOA_JQQPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgtrs%253D&md5=f4e5d02e22585051c4fedcff76f81723</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3Dc-Raf%2520in%2520KRas%2520Mutant%2520Cancers%253A%2520A%2520Moving%2520Target%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D158%26epage%3D159%26doi%3D10.1016%2Fj.ccell.2018.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatapuram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a clinical stage multi kinase inhibitor sodium (E)-2-{2-Methoxy-5-[(2â², 4â², 6â²-trimethoxystyrylsulfonyl)methyl] phenylamino- acetate (ON 01910.Na): synthesis, structure activity relationship and biological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6254</span>â <span class="NLM_lpage">6276</span>, <span class="refDoi">Â DOI: 10.1021/jm200570p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200570p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6254-6276&author=M.+V.+R.+Reddyauthor=P.+Venkatapuramauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=S.+C.+Cosenzaauthor=K.+A.+Robellauthor=B.+Akulaauthor=B.+S.+Hoffmanauthor=E.+P.+Reddy&title=Discovery+of+a+clinical+stage+multi+kinase+inhibitor+sodium+%28E%29-2-%7B2-Methoxy-5-%5B%282%E2%80%B2%2C+4%E2%80%B2%2C+6%E2%80%B2-trimethoxystyrylsulfonyl%29methyl%5D+phenylamino-+acetate+%28ON+01910.Na%29%3A+synthesis%2C+structure+activity+relationship+and+biological+activity&doi=10.1021%2Fjm200570p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity</span></div><div class="casAuthors">Reddy, M. V. Ramana; Venkatapuram, Padmavathi; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Cosenza, Stephen C.; Robell, Kimberly A.; Akula, Balaiah; Hoffman, Benjamin S.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6254-6276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer.  Accordingly, there is an increasing awareness of this novel nonenzymic target for cancer therapeutics.  We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells.  The development of styrylbenzylsulfone derivs. followed logically from a tumor cell cytotoxicity screen performed in our lab. that did not have an a priori target profile.  Modifications of some of the precursor mols. led to lead optimization with regard to tumor cell cytotoxicity.  In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (I) (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) assocd. with aberrant expression of cyclin D proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyWp-VIWe7rVg90H21EOLACvtfcHk0lgqmJOA_JQQPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP&md5=216de055e27dc53794018fc1416bc62f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200570p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200570p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DB.%2BS.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520clinical%2520stage%2520multi%2520kinase%2520inhibitor%2520sodium%2520%2528E%2529-2-%257B2-Methoxy-5-%255B%25282%25E2%2580%25B2%252C%25204%25E2%2580%25B2%252C%25206%25E2%2580%25B2-trimethoxystyrylsulfonyl%2529methyl%255D%2520phenylamino-%2520acetate%2520%2528ON%252001910.Na%2529%253A%2520synthesis%252C%2520structure%2520activity%2520relationship%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6254%26epage%3D6276%26doi%3D10.1021%2Fjm200570p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gumireddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papathi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2005.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2005.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=15766665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFCqu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=275-286&author=K.+Gumireddyauthor=M.+V.+R.+Reddyauthor=S.+C.+Cosenzaauthor=R.+B.+Nathanauthor=S.+J.+Bakerauthor=N.+Papathiauthor=J.+Jiangauthor=J.+Hollandauthor=E.+P.+Reddy&title=ON01910%2C+a+non-ATP-competitive+small+molecule+inhibitor+of+Plk1%2C+is+a+potent+anticancer+agent&doi=10.1016%2Fj.ccr.2005.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent</span></div><div class="casAuthors">Gumireddy, Kiranmai; Reddy, M. V. Ramana; Cosenza, Stephen C.; Nathan, R. Boomi; Baker, Stacey J.; Papathi, Nabisa; Jiang, Jiandong; Holland, James; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Elevated expression of polo-like kinase-1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis.  Here we describe the profile of ON01910, a small mol. inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis.  This compd. was not ATP-competitive, but competed for the substrate binding site of the enzyme.  In vivo, this compd. did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.  ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSUR7gRV8hAbVg90H21EOLACvtfcHk0lj_z5mRcYdCJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFCqu70%253D&md5=d93f0f896b0471550b9c163c175402b8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DNathan%26aufirst%3DR.%2BB.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DPapathi%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DON01910%252C%2520a%2520non-ATP-competitive%2520small%2520molecule%2520inhibitor%2520of%2520Plk1%252C%2520is%2520a%2520potent%2520anticancer%2520agent%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D275%26epage%3D286%26doi%3D10.1016%2Fj.ccr.2005.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndagi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlongo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, M.</span></span> <span> </span><span class="NLM_article-title">Metal complexes in cancer therapy â an update from drug design perspective</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.2147/dddt.s119488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.2147%2Fdddt.s119488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28424538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=599-616&author=U.+Ndagiauthor=N.+Mhlongoauthor=M.+Soliman&title=Metal+complexes+in+cancer+therapy+%E2%80%93+an+update+from+drug+design+perspective&doi=10.2147%2Fdddt.s119488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Metal complexes in cancer therapy - an update from drug design perspective</span></div><div class="casAuthors">Ndagi, Umar; Mhlongo, Ndumiso; Soliman, Mahmoud E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">599-616</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In the past, metal-based compds. were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge.  With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compds. used in the treatment of cancers was witnessed.  This forms the foundation for the modern era of the metal-based anticancer drugs.  Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, are the mainstay of the metal-based compds. in the treatment of cancer, but the delay in the therapeutic accomplishment of other metal-based compds. hampered the progress of research in this field.  Recently, however, there has been an upsurge of activities relying on the structural information, aimed at improving and developing other forms of metal-based compds. and nonclassical platinum complexes whose mechanism of action is distinct from known drugs such as cisplatin.  In line with this, many more metal-based compds. have been synthesized by redesigning the existing chem. structure through ligand substitution or building the entire new compd. with enhanced safety and cytotoxic profile.  However, because of increased emphasis on the clin. relevance of metal-based complexes, a few of these drugs are currently on clin. trial and many more are awaiting ethical approval to join the trial.  In this review, we seek to give an overview of previous reviews on the cytotoxic effect of metal-based complexes while focusing more on newly designed metal-based complexes and their cytotoxic effect on the cancer cell lines, as well as on new approach to metal-based drug design and mol. target in cancer therapy.  We are optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrltxUp021QdrVg90H21EOLACvtfcHk0lj_z5mRcYdCJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7bI&md5=3ef5ff6ea1338c3c47fb10901a18c4c8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2147%2Fdddt.s119488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fdddt.s119488%26sid%3Dliteratum%253Aachs%26aulast%3DNdagi%26aufirst%3DU.%26aulast%3DMhlongo%26aufirst%3DN.%26aulast%3DSoliman%26aufirst%3DM.%26atitle%3DMetal%2520complexes%2520in%2520cancer%2520therapy%2520%25E2%2580%2593%2520an%2520update%2520from%2520drug%2520design%2520perspective%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D599%26epage%3D616%26doi%3D10.2147%2Fdddt.s119488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span> <span> </span><span class="NLM_article-title">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kB</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>396</i></span>,  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.canlet.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28323031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=396&publication_year=2017&pages=76-84&author=T.-S.+Kangauthor=W.+Wangauthor=H.-J.+Zhongauthor=Z.-Z.+Dongauthor=Q.+Huangauthor=S.+W.+F.+Mokauthor=C.-H.+Leungauthor=V.+K.+W.+Wongauthor=D.-L.+Ma&title=An+anti-prostate+cancer+benzofuran-conjugated+iridium%28III%29+complex+as+a+dual+inhibitor+of+STAT3+and+NF-kB&doi=10.1016%2Fj.canlet.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span></div><div class="casAuthors">Kang, Tian-Shu; Wang, Wanhe; Zhong, Hai-Jing; Dong, Zhen-Zhen; Huang, Qi; Mok, Simon Wing Fai; Leung, Chung-Hang; Wong, Vincent Kam Wai; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">396</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells.  All complexes show the high stability and soly. in the biol. system.  In this study, an iridium(III) complex engages STAT3 and NF-ÎºB to inhibit their translocation and transcriptional activities.  Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects.  Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGS7qZTHhEVrVg90H21EOLACvtfcHk0lj_z5mRcYdCJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D&md5=d410face71ded9bdd70b16ad00eb8b11</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.-S.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DDong%26aufirst%3DZ.-Z.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DLeung%26aufirst%3DC.-H.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.-L.%26atitle%3DAn%2520anti-prostate%2520cancer%2520benzofuran-conjugated%2520iridium%2528III%2529%2520complex%2520as%2520a%2520dual%2520inhibitor%2520of%2520STAT3%2520and%2520NF-kB%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D396%26spage%3D76%26epage%3D84%26doi%3D10.1016%2Fj.canlet.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4756</span>â <span class="NLM_lpage">4763</span>, <span class="refDoi">Â DOI: 10.1039/c7sc00311k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc7sc00311k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28959398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=4756-4763&author=L.-J.+Liuauthor=W.+Wangauthor=S.-Y.+Huangauthor=Y.+Hongauthor=G.+Liauthor=S.+Linauthor=J.+Tianauthor=Z.+Caiauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Inhibition+of+the+Ras%2FRaf+interaction+and+repression+of+renal+cancer+xenografts+in+vivo+by+an+enantiomeric+iridium%28III%29+metal-based+compound&doi=10.1039%2Fc7sc00311k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span></div><div class="casAuthors">Liu, Li-Juan; Wang, Wanhe; Huang, Shi-Ying; Hong, Yanjun; Li, Guodong; Lin, Sheng; Tian, Jinglin; Cai, Zongwei; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4756-4763</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Targeting protein-protein interactions (PPIs) offers tantalizing opportunities for therapeutic intervention for the treatment of human diseases.  Modulating PPI interfaces with org. small mols. has been found to be exceptionally challenging, and few candidates have been successfully developed into clin. drugs.  Meanwhile, the striking array of distinctive properties exhibited by metal compds. renders them attractive scaffolds for the development of bioactive leads.  Here, we report the identification of iridium(III) compds. as inhibitors of the H-Ras/Raf-1 PPI.  The lead iridium(III) compd. 1 exhibited potent inhibitory activity against the H-Ras/Raf-1 interaction and its signaling pathway in vitro and in vivo, and also directly engaged both H-Ras and Raf-1-RBD in cell lysates.  Moreover, 1 repressed tumor growth in a mouse renal xenograft tumor model.  Intriguingly, the Î-enantiomer of 1 showed superior potency in the biol. assays compared to Î-1 or racemic 1.  These compds. could potentially be used as starting scaffolds for the development of more potent Ras/Raf PPI inhibitors for the treatment of kidney cancer or other proliferative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr81r1n5s7wkrVg90H21EOLACvtfcHk0liAEUMr0Ly9rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D&md5=b1c8c88211bab7eca780eb33b35dc772</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc7sc00311k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc7sc00311k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-Y.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DInhibition%2520of%2520the%2520Ras%252FRaf%2520interaction%2520and%2520repression%2520of%2520renal%2520cancer%2520xenografts%2520in%2520vivo%2520by%2520an%2520enantiomeric%2520iridium%2528III%2529%2520metal-based%2520compound%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D4756%26epage%3D4763%26doi%3D10.1039%2Fc7sc00311k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Chirality in metal-based anticancer agents</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4017</span>â <span class="NLM_lpage">4026</span>, <span class="refDoi">Â DOI: 10.1039/c8dt00089a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc8dt00089a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29479608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=4017-4026&author=Y.+Wangauthor=H.+Huangauthor=Q.+Zhangauthor=P.+Zhang&title=Chirality+in+metal-based+anticancer+agents&doi=10.1039%2Fc8dt00089a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Chirality in metal-based anticancer agents</span></div><div class="casAuthors">Wang, Yi; Huang, Huaiyi; Zhang, Qianling; Zhang, Pingyu</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4017-4026</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Chiral natural biol. mols., such as nucleic acids and proteins, guide the research of chiral compds.  Chiral metal-based drugs are currently an interesting and rapidly growing field in anticancer research.  This perspective focuses on chiral metal compds. with application in cancer chemotherapy.  The different chiral metal-based anticancer agents and the extent to which the chiral resoln. affects their biol. properties are discussed.  This perspective will aid the design of new potent and efficient chiral metal-based anticancer drugs that exploit their unique properties combined with their potential selectivity toward targeted chiral biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDzj4YMeZDbVg90H21EOLACvtfcHk0liAEUMr0Ly9rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeltbw%253D&md5=1ff36b7b4aa03ae760a0a2da549f67cb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc8dt00089a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc8dt00089a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DChirality%2520in%2520metal-based%2520anticancer%2520agents%26jtitle%3DDalton%2520Trans.%26date%3D2018%26volume%3D47%26spage%3D4017%26epage%3D4026%26doi%3D10.1039%2Fc8dt00089a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>â <span class="NLM_lpage">8127</span>, <span class="refDoi">Â DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0liAEUMr0Ly9rw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florea, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¼sselberg, D.</span></span> <span> </span><span class="NLM_article-title">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1351</span>â <span class="NLM_lpage">1371</span>, <span class="refDoi">Â DOI: 10.3390/cancers3011351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.3390%2Fcancers3011351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=24212665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1351-1371&author=A.-M.+Floreaauthor=D.+B%C3%BCsselberg&title=Cisplatin+as+an+anti-tumor+drug%3A+cellular+mechanisms+of+activity%2C+drug+resistance+and+induced+side+effects&doi=10.3390%2Fcancers3011351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span></div><div class="casAuthors">Florea, Ana-Maria; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1351-1371</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Platinum complexes are clin. used as adjuvant therapy of cancers aiming to induce tumor cell death.  Depending on cell type and concn., cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms.  Addnl., cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways.  Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression.  Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochem. mechanism of action.  While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant.  Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair.  To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers.  Thus, understanding of the biochem. mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7eCBHQ5T5rVg90H21EOLACvtfcHk0ljGu3TWbrePiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D&md5=368b8ef25e06a41747ec0940872966b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fcancers3011351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3011351%26sid%3Dliteratum%253Aachs%26aulast%3DFlorea%26aufirst%3DA.-M.%26aulast%3DB%25C3%25BCsselberg%26aufirst%3DD.%26atitle%3DCisplatin%2520as%2520an%2520anti-tumor%2520drug%253A%2520cellular%2520mechanisms%2520of%2520activity%252C%2520drug%2520resistance%2520and%2520induced%2520side%2520effects%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26spage%3D1351%26epage%3D1371%26doi%3D10.3390%2Fcancers3011351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabik, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance and toxicity associated with platinating agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.ctrv.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ctrv.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17084534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=9-23&author=C.+A.+Rabikauthor=M.+E.+Dolan&title=Molecular+mechanisms+of+resistance+and+toxicity+associated+with+platinating+agents&doi=10.1016%2Fj.ctrv.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance and toxicity associated with platinating agents</span></div><div class="casAuthors">Rabik, Cara A.; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Platinating agents, including cisplatin, carboplatin, and oxaliplatin, have been used clin. for nearly 30 years as part of the treatment of many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma.  The cytotoxic lesion of platinating agents is thought to be the platinum intrastrand crosslink that forms on DNA, although treatment activates a no. of signal transduction pathways.  Treatment with these agents is characterized by resistance, both acquired and intrinsic.  This resistance can be caused by a no. of cellular adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and increased levels of DNA repair or DNA tolerance.  Here we investigate the pathways that treatment with platinating agents activate, the mechanisms of resistance, potential candidate genes involved in the development of resistance, and assocd. clin. toxicities.  Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclin. data that has clin. relevance generated over the past five years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxn13FCg9DbVg90H21EOLACvtfcHk0ljGu3TWbrePiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D&md5=9d5cc75e635b074a03a11c2f67c7914b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRabik%26aufirst%3DC.%2BA.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520and%2520toxicity%2520associated%2520with%2520platinating%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D9%26epage%3D23%26doi%3D10.1016%2Fj.ctrv.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanellato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fregonese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative activity of a series of cisplatinbased Pt(IV)-acetylamido/carboxylato prodrugs</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5300</span>â <span class="NLM_lpage">5309</span>, <span class="refDoi">Â DOI: 10.1039/c5dt04905a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc5dt04905a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=26903367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1agur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=5300-5309&author=M.+Raveraauthor=E.+Gabanoauthor=I.+Zanellatoauthor=F.+Fregoneseauthor=G.+Pelosiauthor=J.+A.+Plattsauthor=D.+Osella&title=Antiproliferative+activity+of+a+series+of+cisplatinbased+Pt%28IV%29-acetylamido%2Fcarboxylato+prodrugs&doi=10.1039%2Fc5dt04905a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs</span></div><div class="casAuthors">Ravera, Mauro; Gabano, Elisabetta; Zanellato, Ilaria; Fregonese, Federico; Pelosi, Giorgio; Platts, James A.; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5300-5309</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The authors report studies of a novel series of Pt(IV) complexes exhibiting an asym. combination of acetylamido and carboxylato ligands in the axial positions.  The authors demonstrate efficient synthesis of a series of analogs, differing in the alkyl chain length and hence lipophilicity, from a stable acetylamido/hydroxido complex formed by reaction of cisplatin with peroxyacetimidic acid (PAIA).  NMR spectroscopy and x-ray crystallog. confirm the identity of the resulting complexes, and highlight subtle differences in the structure and stability of acetylamido complexes compared to the equiv. acetato complexes.  Redn. of acetylamido complexes, whether achieved chem. or electro-chem., is significantly more difficult than that of acetate complexes, resulting in lower antiproliferative activity for shorter-chain complexes.  For those with longer chains and hence greater cell uptake, this difference is negated and acetylamido complexes are as active as acetato analogs, both exhibiting antiproliferative potency (1/IC50) against A2780 ovarian cancer cells similar to that of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeDevbWiPRS7Vg90H21EOLACvtfcHk0ljGu3TWbrePiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1agur4%253D&md5=f19910d04a38e1701fedfdb48a71b7d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1039%2Fc5dt04905a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5dt04905a%26sid%3Dliteratum%253Aachs%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DZanellato%26aufirst%3DI.%26aulast%3DFregonese%26aufirst%3DF.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3DPlatts%26aufirst%3DJ.%2BA.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DAntiproliferative%2520activity%2520of%2520a%2520series%2520of%2520cisplatinbased%2520Pt%2528IV%2529-acetylamido%252Fcarboxylato%2520prodrugs%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D5300%26epage%3D5309%26doi%3D10.1039%2Fc5dt04905a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>â <span class="NLM_lpage">1883</span>, <span class="refDoi">Â DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0ljGu3TWbrePiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Chalcoplatin, a dual-targeting and p53 activator-containing anticancer Pt(IV) prodrug with unique mode of action</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6301</span>â <span class="NLM_lpage">6304</span>, <span class="refDoi">Â DOI: 10.1039/c4cc10409a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc4cc10409a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25644651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslelsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6301-6304&author=L.+Maauthor=R.+Maauthor=Y.+Wangauthor=X.+Zhuauthor=J.+Zhangauthor=H.+C.+Chanauthor=X.+Chenauthor=W.+Zhangauthor=S.-K.+Chiuauthor=G.+Zhu&title=Chalcoplatin%2C+a+dual-targeting+and+p53+activator-containing+anticancer+Pt%28IV%29+prodrug+with+unique+mode+of+action&doi=10.1039%2Fc4cc10409a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action</span></div><div class="casAuthors">Ma, Lili; Ma, Rong; Wang, Yiping; Zhu, Xiaoyue; Zhang, Junliang; Chan, Hoi Ching; Chen, Xianfeng; Zhang, Wenjun; Chiu, Sung-Kay; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6301-6304</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells.  Mechanistic investigation was carried out on this dual-targeting Pt(IV) prodrug, chalcoplatin.  The prodrug effectively entered cancer cells and arrested the cell cycle at the S and G2/M phases, distinctive of that from cisplatin.  Chalcoplatin significantly induced p53 activation as well as the subsequent apoptosis pathways.  This unique mode of action renders chalcoplatin remarkably cytotoxic and makes this compd. among the first examples of a Pt(IV) prodrug that directly interacts with the downstream pathway after the formation of Pt-DNA lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5te1PhnZbxLVg90H21EOLACvtfcHk0liXj9TJ2gxV4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslelsr8%253D&md5=19b60de49f0552793f3e87ca8f2efa16</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc4cc10409a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cc10409a%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DChiu%26aufirst%3DS.-K.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DChalcoplatin%252C%2520a%2520dual-targeting%2520and%2520p53%2520activator-containing%2520anticancer%2520Pt%2528IV%2529%2520prodrug%2520with%2520unique%2520mode%2520of%2520action%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D6301%26epage%3D6304%26doi%3D10.1039%2Fc4cc10409a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, R. T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2546</span>â <span class="NLM_lpage">2554</span>, <span class="refDoi">Â DOI: 10.1021/ja411811w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja411811w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslarsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=2546-2554&author=Y.+Yuanauthor=R.+T.+K.+Kwokauthor=B.+Z.+Tangauthor=B.+Liu&title=Targeted+theranostic+platinum%28IV%29+prodrug+with+a+built-in+aggregation-induced+emission+light-up+apoptosis+sensor+for+noninvasive+early+evaluation+of+its+therapeutic+responses+in+situ&doi=10.1021%2Fja411811w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Theranostic Platinum(IV) Prodrug with a Built-In Aggregation-Induced Emission Light-Up Apoptosis Sensor for Noninvasive Early Evaluation of Its Therapeutic Responses in Situ</span></div><div class="casAuthors">Yuan, Youyong; Kwok, Ryan T. K.; Tang, Ben Zhong; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2546-2554</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted drug delivery to tumor cells with minimized side effects and real-time in situ monitoring of drug efficacy is highly desirable for personalized medicine.  In this work, we report the synthesis and biol. evaluation of a chemotherapeutic Pt(IV) prodrug whose two axial positions are functionalized with a cyclic arginine-glycine-aspartic acid (cRGD) tripeptide for targeting integrin Î±vÎ²3 overexpressed cancer cells and an apoptosis sensor which is composed of tetraphenylsilole (TPS) fluorophore with aggregation-induced emission (AIE) characteristics and a caspase-3 enzyme specific Asp-Glu-Val-Asp (DEVD) peptide.  The targeted Pt(IV) prodrug can selectively bind to Î±vÎ²3 integrin overexpressed cancer cells to facilitate cellular uptake.  In addn., the Pt(IV) prodrug can be reduced to active Pt(II) drug in cells and release the apoptosis sensor TPS-DEVD simultaneously.  The reduced Pt(II) drug can induce the cell apoptosis and activate caspase-3 enzyme to cleave the DEVD peptide sequence.  Due to free rotation of the phenylene rings, TPS-DEVD is nonemissive in aq. media.  The specific cleavage of DEVD by caspase-3 generates the hydrophobic TPS residue, which tends to aggregate, resulting in restriction of intramol. rotations of the Ph rings and ultimately leading to fluorescence enhancement.  Such noninvasive and real-time imaging of drug-induced apoptosis in situ can be used as an indicator for early evaluation of the therapeutic responses of a specific anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcarQMtyRDprVg90H21EOLACvtfcHk0liXj9TJ2gxV4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslarsQ%253D%253D&md5=722226adf51710b50744cdbb6ea35565</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja411811w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja411811w%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DKwok%26aufirst%3DR.%2BT.%2BK.%26aulast%3DTang%26aufirst%3DB.%2BZ.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DTargeted%2520theranostic%2520platinum%2528IV%2529%2520prodrug%2520with%2520a%2520built-in%2520aggregation-induced%2520emission%2520light-up%2520apoptosis%2520sensor%2520for%2520noninvasive%2520early%2520evaluation%2520of%2520its%2520therapeutic%2520responses%2520in%2520situ%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D2546%26epage%3D2554%26doi%3D10.1021%2Fja411811w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ammar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benita, S.</span></span> <span> </span><span class="NLM_article-title">A lipophilic Pt(IV) oxaliplatin derivative enhances antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9035</span>â <span class="NLM_lpage">9046</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00955</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00955" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9035-9046&author=A.+A.+Ammarauthor=R.+Raveendranauthor=D.+Gibsonauthor=T.+Nassarauthor=S.+Benita&title=A+lipophilic+Pt%28IV%29+oxaliplatin+derivative+enhances+antitumor+activity&doi=10.1021%2Facs.jmedchem.6b00955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00955%26sid%3Dliteratum%253Aachs%26aulast%3DAmmar%26aufirst%3DA.%2BA.%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DNassar%26aufirst%3DT.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DA%2520lipophilic%2520Pt%2528IV%2529%2520oxaliplatin%2520derivative%2520enhances%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9035%26epage%3D9046%26doi%3D10.1021%2Facs.jmedchem.6b00955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29031068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=211-220&author=Z.+Xuauthor=W.+Huauthor=Z.+Wangauthor=S.+Gou&title=Platinum%28IV%29+prodrugs+multiply+targeting+genomic+DNA%2C+histone+deacetylases+and+PARP-1&doi=10.1016%2Fj.ejmech.2017.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1</span></div><div class="casAuthors">Xu, Zichen; Hu, Weiwei; Wang, Zhimei; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Several Pt(IV) prodrugs contg. SAA, a histone deacetylases inhibitor, were designed and prepd. for multiply targeting genomic DNA, histone deacetylases and PARP-1.  The resulting Pt(IV) prodrug had significantly strong antiproliferative activity against the tested cancer cell lines, esp. SAA1, derived from the conjugation of cisplatin and SAA, had potent ability to overcome cisplatin resistance.  Under the combined action of DNA platination and inhibition of HDACs and PARP-1 activity, the cytotoxic activity of SAA1 was 174-fold higher than cisplatin against cisplatin-resistant SGC7901/CDDP cancer cells.  The mechanism of action of SAA1 was preliminarily investigated, in which cellular uptake, cell apoptosis and cell cycle arrest as well as western blot anal. were made by treating SAA1 with SGC7901/CDDP cells.  Besides, HDACs inhibition activity and PARP-1 enzyme inhibition of SAA1 were also studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpassqM0HVpH7Vg90H21EOLACvtfcHk0liTC0D9obZNRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrnJ&md5=87982d0f22d37dc9d13628a44d0e2703</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DPlatinum%2528IV%2529%2520prodrugs%2520multiply%2520targeting%2520genomic%2520DNA%252C%2520histone%2520deacetylases%2520and%2520PARP-1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D211%26epage%3D220%26doi%3D10.1016%2Fj.ejmech.2017.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BarnÃ©s, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1021/bc070031k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc070031k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=39-49&author=S.+Mukhopadhyayauthor=C.+M.+Barn%C3%A9sauthor=A.+Haskelauthor=S.+M.+Shortauthor=K.+R.+Barnesauthor=S.+J.+Lippard&title=Conjugated+platinum%28IV%29-peptide+complexes+for+targeting+angiogenic+tumor+vasculature&doi=10.1021%2Fbc070031k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span></div><div class="casAuthors">Mukhopadhyay, Sumitra; Barnes, Carmen M.; Haskel, Ariel; Short, Sarah M.; Barnes, Katie R.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The integrins Î±vÎ²3 and Î±vÎ²5 and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed in tumor-induced angiogenesis, making them attractive targets for therapeutic intervention.  Both integrins and APN recognize a broad range of peptides contg. RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) motifs, resp.  Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, contg. RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a "tumor-homing device" to target tumor endothelial cells selectively over healthy cells. Platinum(IV)-peptide complexes with nonspecific amino acids or peptide moieties were prepd. as controls.  Concn.-response curves of these compds. were evaluated against primary proliferating endothelial cells and tumor cell lines and compared to those of cisplatin, a well-described platinum-based chemotherapeutic agent.  The Pt(IV)-RGD conjugates were highly and specifically cytotoxic to cell lines contg. Î±vÎ²3 and Î±vÎ²5, approaching the activity of cisplatin.  The Pt(IV)-NGR complexes were less active than Pt(IV)-RGD-contg. compds. but more active than nonspecific Pt-peptide controls.  Integrin Î±vÎ²3 mediated, at least in part, the anti-proliferative effect of a Pt(IV)-RGD conjugate, as demonstrated by a decreased inhibitory response when endothelial cells were either (1) incubated with an excess of Î±vÎ²3/Î±vÎ²5-specific RGD pentapeptides or (2) transfected with RNAi for Î²3, but not Î²1, integrins.  These results suggest a rational approach to improved chemotherapy with Pt(IV)-peptide conjugates by selective drug delivery to the tumor compartment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl92LLNxja-rVg90H21EOLACvtfcHk0liTC0D9obZNRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ&md5=d12897f15d2582321ee037868e81c87c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fbc070031k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc070031k%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DBarn%25C3%25A9s%26aufirst%3DC.%2BM.%26aulast%3DHaskel%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DBarnes%26aufirst%3DK.%2BR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugated%2520platinum%2528IV%2529-peptide%2520complexes%2520for%2520targeting%2520angiogenic%2520tumor%2520vasculature%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D39%26epage%3D49%26doi%3D10.1021%2Fbc070031k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Construction of dual stimuli-responsive platinum(IV) hybrids with NQO1 targeting ability and overcoming cisplatin resistance</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2191</span>â <span class="NLM_lpage">2200</span>, <span class="refDoi">Â DOI: 10.1021/acs.inorgchem.8b03386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.8b03386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12qs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2191-2200&author=L.+Fangauthor=X.+Qinauthor=J.+Zhaoauthor=S.+Gou&title=Construction+of+dual+stimuli-responsive+platinum%28IV%29+hybrids+with+NQO1+targeting+ability+and+overcoming+cisplatin+resistance&doi=10.1021%2Facs.inorgchem.8b03386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance</span></div><div class="casAuthors">Fang, Lei; Qin, Xiaodong; Zhao, Jian; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2191-2200</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quinone oxidoreductase isoenzyme I (NQO1) is a cytoprotective two-electron-specific reductase that highly expresses in various cancer cells.  Taking NQO1 as the target, we herein report three hybrid compds. from Pt(IV) complexes and a quinone propionic acid unit.  The mechanism studies showed that the hybrids could be activated by both NQO1 and ascorbic acid to release the cytotoxic Pt(II) unit, exhibiting a dual stimuli-responsive character.  In the pharmacol. studies, complexes 2 and 3 presented higher antitumor activity than cisplatin.  More importantly, the hybrid could also overcome cisplatin resistance due to the NQO1 targeting ability, improved cellular uptake, and/or different action mechanism.  Significantly, complex 3 contg. a coumarin moiety could be effectively activated in NQO1-overexpressed cancer cells to "turn on" fluorescence, showing a promising visual effect in cancer cells.  In vivo study revealed that both 2 and 3 exhibited higher antitumor efficacy than cisplatin in the A549 xenograft mouse model at an equimolar dose to cisplatin.  In all, the hybrids may serve as promising NQO1-targeting anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmTZGLtzJprVg90H21EOLACvtfcHk0liTC0D9obZNRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12qs7s%253D&md5=a85adfa507e6e09031d51218ef6e7326</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.8b03386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.8b03386%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DConstruction%2520of%2520dual%2520stimuli-responsive%2520platinum%2528IV%2529%2520hybrids%2520with%2520NQO1%2520targeting%2520ability%2520and%2520overcoming%2520cisplatin%2520resistance%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D2191%26epage%3D2200%26doi%3D10.1021%2Facs.inorgchem.8b03386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Conjugation of Pt(IV) complexes with chlorambucil to overcome cisplatin resistance via a â³joint actionâ³ mode toward DNA</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28586717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=167-175&author=X.+Qinauthor=L.+Fangauthor=F.+Chenauthor=S.+Gou&title=Conjugation+of+Pt%28IV%29+complexes+with+chlorambucil+to+overcome+cisplatin+resistance+via+a+%E2%80%B3joint+action%E2%80%B3+mode+toward+DNA&doi=10.1016%2Fj.ejmech.2017.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA</span></div><div class="casAuthors">Qin, Xiaodong; Fang, Lei; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two platinum(IV) complexes were designed and prepd. by conjugation of cisplatin and oxaliplatin units with a DNA-damaging agent, chlorambucil, resp.  By taking a joint action to enhance the damage of DNA, the conjugates displayed potent antitumor activity against all the tested cancer cell lines comparable to cisplatin and oxaliplatin, and notably could overcome cisplatin resistance at certain degree.  Complex [Pt(NH3)2Cl2(OCO(CH2)3-p-C6H4-N(CH2CH2Cl)2)] (I), a hybrid of cisplatin and chlorambucil, arrested the cell cycle at the S and G2 phases, distinctive from those of cisplatin and oxaliplatin.  Apoptosis studies revealed that complex 4 could induce cell apoptosis significantly in both SGC7901 and SGC7901/CDDP cells.  Moreover, further investigation indicated that complex I suppressed the drug resistance by the improvement of the platinum uptake and the inhibition of PARP-1 protein.  These results show that the "joint action" on DNA is an effective strategy to overcome cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovGAma6fthdLVg90H21EOLACvtfcHk0liy8njcob0Xww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73P&md5=c1bfa5b72c30b2df08d4124b8bd34f44</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DConjugation%2520of%2520Pt%2528IV%2529%2520complexes%2520with%2520chlorambucil%2520to%2520overcome%2520cisplatin%2520resistance%2520via%2520a%2520%25E2%2580%25B3joint%2520action%25E2%2580%25B3%2520mode%2520toward%2520DNA%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D137%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.ejmech.2017.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>â <span class="NLM_lpage">2148</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+a+dual-targeting+and+tubulin+inhibitor+containing+antitumor+Pt%28IV%29+moiety+with+a+unique+mode+of+action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0liy8njcob0Xww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520a%2520dual-targeting%2520and%2520tubulin%2520inhibitor%2520containing%2520antitumor%2520Pt%2528IV%2529%2520moiety%2520with%2520a%2520unique%2520mode%2520of%2520action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-F.</span></span> <span> </span><span class="NLM_article-title">Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">385</span>â <span class="NLM_lpage">395</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2012.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.bcp.2012.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=23142712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnu7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=385-395&author=C.-C.+Hsuauthor=J.-C.+Lienauthor=C.-W.+Changauthor=C.-H.+Changauthor=S.-C.+Kuoauthor=T.-F.+Huang&title=Yuwen02f1+suppresses+LPS-induced+endotoxemia+and+adjuvant-induced+arthritis+primarily+through+blockade+of+ROS+formation%2C+NFkB+and+MAPK+activation&doi=10.1016%2Fj.bcp.2012.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation</span></div><div class="casAuthors">Hsu, Chun-Chieh; Lien, Jin-Cherng; Chang, Chia-Wen; Chang, Chien-Hsin; Kuo, Sheng-Chu; Huang, Tur-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phagocytes release inflammatory mediators to defense harmful stimuli upon bacterial invasion, however, excessive inflammatory reaction leads to tissue damage and manifestation of pathol. states.  Therefore, targeting on uncontrolled inflammation seems feasible to control numerous inflammation-assocd. diseases.  Under the drug screening process of synthetic diphenylpyrazole derivs., we discovered compd. yuwen02f1 possesses anti-inflammatory effects in decreasing the release of pro-inflammatory cytokines including TNFÎ± and IL-6, nitric oxide, reactive oxygen species (ROS) as well as inhibiting migration of LPS-stimulated phagocytes.  In addn., we obsd. that the mol. mechanism of yuwen02f1-mediated anti-inflammation is assocd. with decreasing phosphorylation of MAPK mols. including ERK1/2, JNK and p38, and attenuating translocation of p47phox and p67phox to the cell membrane.  Yuwen02f1 also reverses IÎºBÎ± degrdn. and attenuates the expression of NFÎºB-related downstream inducible enzymes like iNOS and COX-2.  Furthermore, we found that yuwen02f1 attenuates some pathol. syndromes of LPS-induced sepsis and adjuvant-induced arthritis in mice, as evidenced by decreasing the cytokine prodn., reversing thrombocytopenic syndrome, protecting the mice from tissue injury in septic mice, and attenuating paw edema in arthritic mice as well.  These results suggest that yuwen02f1 is a potential anti-inflammatory agent for alleviating syndromes of acute and chronic inflammatory diseases as evidenced by attenuating the generation of cytokines and down-regulating the expression of iNOS and COX-2 through the blockade of ROS generation and NADPH oxidase, NFÎºB and MAPK activation pathways in LPS-stimulated phagocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0PHxiILK5XrVg90H21EOLACvtfcHk0liy8njcob0Xww"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnu7jK&md5=ed0d620f43912d7c37ec04cf5279cb72</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.-C.%26aulast%3DLien%26aufirst%3DJ.-C.%26aulast%3DChang%26aufirst%3DC.-W.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DKuo%26aufirst%3DS.-C.%26aulast%3DHuang%26aufirst%3DT.-F.%26atitle%3DYuwen02f1%2520suppresses%2520LPS-induced%2520endotoxemia%2520and%2520adjuvant-induced%2520arthritis%2520primarily%2520through%2520blockade%2520of%2520ROS%2520formation%252C%2520NFkB%2520and%2520MAPK%2520activation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D385%26epage%3D395%26doi%3D10.1016%2Fj.bcp.2012.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1021</span>â <span class="NLM_lpage">1027</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.11.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.11.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1021-1027&author=K.-J.+Wuauthor=H.-J.+Zhongauthor=G.+Liauthor=C.+Liuauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Structure-based+identification+of+a+NEDD8-activating+enzyme+inhibitor+via+drug+repurposing&doi=10.1016%2Fj.ejmech.2017.11.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34cR"><div class="casContent"><span class="casTitleNuber">34c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span></div><div class="casAuthors">Wu, Ke-Jia; Zhong, Hai-Jing; Li, Guodong; Liu, Chenfu; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1021-1027</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">NEDD8-activating enzyme (NAE) is an essential player of the NEDD8 conjugation pathway that regulates protein degrdn.  Meanwhile, drug repurposing is a cost-efficient strategy to identify new therapeutic uses for existing scaffolds.  In this report, mitoxantrone (1) was repurposed as an inhibitor of NAE by virtual screening of an FDA-approved drug database.  Compd. 1 inhibited NAE activity in cell-free and cell-based systems with high selectivity and was competitive with ATP.  Furthermore, compd. 1 induced apoptosis of colorectal adenocarcinoma cancer cells through inhibiting the degrdn. of the neddylation substrate p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAq1axDoEP7Vg90H21EOLACvtfcHk0liCpM-o0MLyCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I&md5=c9d129e8a7887bcdc3e77cdc27e4fdbf</span></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.101%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DStructure-based%2520identification%2520of%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%2520via%2520drug%2520repurposing%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2Fj.ejmech.2017.11.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span> <span> </span><span class="NLM_article-title">Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">999</span>â <span class="NLM_lpage">1014</span>, <span class="refDoi">Â DOI: 10.1080/15548627.2016.1166318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1080%2F15548627.2016.1166318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=27124102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVWgsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=999-1014&author=Q.+Huangauthor=L.+Zhanauthor=H.+Caoauthor=J.+Liauthor=Y.+Lyuauthor=X.+Guoauthor=J.+Zhangauthor=L.+Jiauthor=T.+Renauthor=J.+Anauthor=B.+Liuauthor=Y.+Nieauthor=J.+Xing&title=Increased+mitochondrial+fission+promotes+autophagy+and+hepatocellular+carcinoma+cell+survival+through+the+ROS-modulated+coordinated+regulation+of+the+NFKB+and+TP53+pathways&doi=10.1080%2F15548627.2016.1166318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34dR"><div class="casContent"><span class="casTitleNuber">34d</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways</span></div><div class="casAuthors">Huang, Qichao; Zhan, Lei; Cao, Haiyan; Li, Jibin; Lyu, Yinghua; Guo, Xu; Zhang, Jing; Ji, Lele; Ren, Tingting; An, Jiaze; Liu, Bingrong; Nie, Yongzhan; Xing, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial morphol. is dynamically remodeled by fusion and fission in cells, and dysregulation of this process is closely implicated in tumorigenesis.  However, the mechanism by which mitochondrial dynamics influence cancer cell survival is considerably less clear, esp. in hepatocellular carcinoma (HCC).  In this study, we systematically investigated the alteration of mitochondrial dynamics and its functional role in the regulation of autophagy and HCC cell survival.  Furthermore, the underlying mol. mechanisms and therapeutic application were explored in depth.  Mitochondrial fission was frequently upregulated in HCC tissues mainly due to an elevated expression ratio of DNM1L to MFN1, which significantly contributed to poor prognosis of HCC patients.  Increased mitochondrial fission by forced expression of DNM1L or knockdown of MFN1 promoted the survival of HCC cells both in vitro and in vivo mainly by facilitating autophagy and inhibiting mitochondria-dependent apoptosis.  We further demonstrated that the survival-promoting role of increased mitochondrial fission was mediated via elevated ROS prodn. and subsequent activation of AKT, which facilitated MDM2-mediated TP53 degrdn., and NFKBIA- and IKK-mediated transcriptional activity of NFKB in HCC cells.  Also, a crosstalk between TP53 and NFKB pathways was involved in the regulation of mitochondrial fission-mediated cell survival.  Moreover, treatment with mitochondrial division inhibitor-1 significantly suppressed tumor growth in an in vivo xenograft nude mice model.  Our findings demonstrate that increased mitochondrial fission plays a crit. role in regulation of HCC cell survival, which provides a strong evidence for this process as drug target in HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfIjpHitJclbVg90H21EOLACvtfcHk0liCpM-o0MLyCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVWgsbc%253D&md5=944ea7dc2bf6d7b43ffe54a44656bf42</span></div><a href="/servlet/linkout?suffix=cit34d&amp;dbid=16384&amp;doi=10.1080%2F15548627.2016.1166318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2016.1166318%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLyu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DNie%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DJ.%26atitle%3DIncreased%2520mitochondrial%2520fission%2520promotes%2520autophagy%2520and%2520hepatocellular%2520carcinoma%2520cell%2520survival%2520through%2520the%2520ROS-modulated%2520coordinated%2520regulation%2520of%2520the%2520NFKB%2520and%2520TP53%2520pathways%26jtitle%3DAutophagy%26date%3D2016%26volume%3D12%26spage%3D999%26epage%3D1014%26doi%3D10.1080%2F15548627.2016.1166318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nishanth, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jyotsna, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlager, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddanna, P.</span></span> <span> </span><span class="NLM_article-title">Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFÎºB signaling pathway</span>. <i>Nanotoxicology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>â <span class="NLM_lpage">516</span>, <span class="refDoi">Â DOI: 10.3109/17435390.2010.541604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.3109%2F17435390.2010.541604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21417802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1egurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=502-516&author=R.+P.+Nishanthauthor=R.+G.+Jyotsnaauthor=J.+J.+Schlagerauthor=S.+M.+Hussainauthor=P.+Reddanna&title=Inflammatory+responses+of+RAW+264.7+macrophages+upon+exposure+to+nanoparticles%3A+role+of+ROS-NF%CE%BAB+signaling+pathway&doi=10.3109%2F17435390.2010.541604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34eR"><div class="casContent"><span class="casTitleNuber">34e</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFÎºB signaling pathway</span></div><div class="casAuthors">Nishanth, Reddy P.; Jyotsna, Radhika G.; Schlager, John J.; Hussain, Saber M.; Reddanna, Pallu</div><div class="citationInfo"><span class="NLM_cas:title">Nanotoxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">502-516</span>CODEN:
                <span class="NLM_cas:coden">NANOGK</span>;
        ISSN:<span class="NLM_cas:issn">1743-5404</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent advances in particle-forming chemistries used for developing nanotechnol. has not only widened novel applications for nanoscale materials but also has provided significant concern regarding their biol. effects.  The present study investigates the inflammatory responses of RAW 264.7 mouse macrophages exposed to nanoparticles (NPs, 5 Î¼g/mL) of varied sizes including silver (Ag), aluminum (Al), carbon black (CB), carbon coated silver (CAg) and gold (Au).  A significant increase in IL-6, reactive oxygen species (ROS) generation, nuclear translocation of nuclear factor-kappa B (NF-ÎºB), induction of cyclooxygenase-2 (COX-2), and tumor necrosis factor-alpha (TNF-Î±) expression was obsd. in macrophages with max. response found in cells exposed to Ag NPs followed by Al, CB and CAg.  These pro-inflammatory effects of NPs were dependent on size and duration of exposure and comparable to those induced by lipopolysaccharide (LPS), a known inflammatory mediator.  Au NPs, on the other hand, induced small but significant inflammatory responses in macrophages upon prolonged exposure.  These studies reveal that Ag NPs exhibit higher propensity in inducing inflammation, mediated by ROS and NF-ÎºB signaling pathways and leading to the induction of COX-2, TNF-Î± and IL-6.  However, no such prominent pro-inflammatory responses were obsd. with Au NPs, suggesting their bio-compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBXe19-iFdMLVg90H21EOLACvtfcHk0liCpM-o0MLyCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1egurY%253D&md5=fa78ce9bbf060611afdc45b7a92611b9</span></div><a href="/servlet/linkout?suffix=cit34e&amp;dbid=16384&amp;doi=10.3109%2F17435390.2010.541604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17435390.2010.541604%26sid%3Dliteratum%253Aachs%26aulast%3DNishanth%26aufirst%3DR.%2BP.%26aulast%3DJyotsna%26aufirst%3DR.%2BG.%26aulast%3DSchlager%26aufirst%3DJ.%2BJ.%26aulast%3DHussain%26aufirst%3DS.%2BM.%26aulast%3DReddanna%26aufirst%3DP.%26atitle%3DInflammatory%2520responses%2520of%2520RAW%2520264.7%2520macrophages%2520upon%2520exposure%2520to%2520nanoparticles%253A%2520role%2520of%2520ROS-NF%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DNanotoxicology%26date%3D2011%26volume%3D5%26spage%3D502%26epage%3D516%26doi%3D10.3109%2F17435390.2010.541604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">751</span>â <span class="NLM_lpage">758</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=23352452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+Raf+dimerization+and+its+inhibition+on+normal+and+disease-associated+Raf+signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span></div><div class="casAuthors">Freeman, Alyson K.; Ritt, Daniel A.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Raf kinases are essential for normal Ras-Raf-MEK-ERK pathway signaling, and activating mutations in components of this pathway are assocd. with a variety of human cancers, as well as the related developmental disorders Noonan, LEOPARD, and cardiofaciocutaneous syndromes.  Although the Raf kinases are known to dimerize during normal and disease-assocd. Raf signaling, the functional significance of Raf dimerization has not been fully elucidated.  Here, using mutational anal. and a peptide inhibitor, we show that dimerization is required for normal Ras-dependent Raf activation and for the biol. function of disease-assocd. Raf mutants with moderate, low, or impaired kinase activity.  However, dimerization is not needed for the function of B-Raf mutants with high catalytic activity, such as V600E-B-Raf.  Importantly, we find that a dimer interface peptide can effectively block Raf dimerization and inhibit Raf signaling when dimerization is required for Raf function, thus identifying the Raf dimer interface as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_CXtQf2fRqbVg90H21EOLACvtfcHk0ljAomedglsKoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D&md5=7c8dfaa1a8c01cd4d87cbd8ef364df8d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520Raf%2520dimerization%2520and%2520its%2520inhibition%2520on%2520normal%2520and%2520disease-associated%2520Raf%2520signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wildtype and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16364920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wildtype+and+mutant+B-RAF+activate+C-RAF+through+distinct+mechanisms+involving+heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span></div><div class="casAuthors">Garnett, Mathew J.; Rana, Sareena; Paterson, Hugh; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-969</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The protein kinase B-Raf is mutated in approx. 7% of human cancers.  Most mutations are activating, but, surprisingly, a small no. have reduced kinase activity.  However, the latter can still stimulate cellular signaling through the MEK-ERK pathway because they activate the related family member C-Raf.  We examd. the mechanism underlying C-Raf activation by B-Raf.  We show that C-Raf is activated in the cytosol in a Ras-independent manner that requires activation segment phosphorylation and binding of 14-3-3 to C-Raf.  We show that wild-type B-Raf forms a complex with C-Raf in a Ras-dependent manner, whereas the mutants bind independently of Ras.  Importantly, we show that wild-type B-Raf can also activate C-Raf.  Our data suggest that B-Raf activates C-Raf through a mechanism involving 14-3-3 mediated heterooligomerization and C-Raf transphosphorylation.  Thus, we have identified a B-Raf-C-Raf-MEK-ERK cascade that signals not only in cancer but also in normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcr3ut9vW0NrVg90H21EOLACvtfcHk0ljAomedglsKoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D&md5=5db9fcc0a36f7670fcd3e92b399ed0de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWildtype%2520and%2520mutant%2520B-RAF%2520activate%2520C-RAF%2520through%2520distinct%2520mechanisms%2520involving%2520heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">Regulationand role of Raf-1/B-Raf heterodimerization</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2262</span>â <span class="NLM_lpage">2272</span>, <span class="refDoi">Â DOI: 10.1128/mcb.26.6.2262-2272.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.26.6.2262-2272.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16508002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2262-2272&author=L.+K.+Rushworthauthor=A.+D.+Hindleyauthor=E.+O%E2%80%99Neillauthor=W.+Kolch&title=Regulationand+role+of+Raf-1%2FB-Raf+heterodimerization&doi=10.1128%2Fmcb.26.6.2262-2272.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of Raf-1/B-Raf heterodimerization</span></div><div class="casAuthors">Rushworth, Linda K.; Hindley, Alison D.; O'Neill, Eric; Kolch, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2262-2272</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway participates in the control of many fundamental cellular processes including proliferation, survival, and differentiation.  The pathway is deregulated in up to 30% of human cancers, often due to mutations in Ras and the B-Raf isoform.  Raf-1 and B-Raf can form heterodimers, and this may be important for cellular transformation.  Here, we have analyzed the biochem. and biol. properties of Raf-1/B-Raf heterodimers.  Isolated Raf-1/B-Raf heterodimers possessed a highly increased kinase activity compared to the resp. homodimers or monomers.  Heterodimers between wild-type Raf-1 and B-Raf mutants with low or no kinase activity still displayed elevated kinase activity, as did heterodimers between wild-type B-Raf and kinase-neg. Raf-1.  In contrast, heterodimers contg. both kinase-neg. Raf-1 and kinase-neg. B-Raf were completely inactive, suggesting that the kinase activity of the heterodimer specifically originates from Raf and that either kinase-competent Raf isoform is sufficient to confer high catalytic activity to the heterodimer.  In cell lines, Raf-1/B-Raf heterodimers were found at low levels.  Heterodimerization was enhanced by 14-3-3 proteins and by mitogens independently of ERK.  However, ERK-induced phosphorylation of B-Raf on T753 promoted the disassembly of Raf heterodimers, and the mutation of T753 prolonged growth factor-induced heterodimerization.  The B-Raf T753A mutant enhanced differentiation of PC12 cells, which was previously shown to be dependent on sustained ERK signaling.  Fine mapping of the interaction sites by peptide arrays suggested a complex mode of interaction involving multiple contact sites with a main Raf-1 binding site in B-Raf encompassing T753.  In summary, our data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiol. activation process and that the heterodimer has distinct biochem. properties that may be important for the regulation of some biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4CMv4bNtn7Vg90H21EOLACvtfcHk0ljAomedglsKoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D&md5=2826875a4a2509255bb203ec154be080</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2Fmcb.26.6.2262-2272.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.26.6.2262-2272.2006%26sid%3Dliteratum%253Aachs%26aulast%3DRushworth%26aufirst%3DL.%2BK.%26aulast%3DHindley%26aufirst%3DA.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DRegulationand%2520role%2520of%2520Raf-1%252FB-Raf%2520heterodimerization%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D2262%26epage%3D2272%26doi%3D10.1128%2Fmcb.26.6.2262-2272.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khamisy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span> <span> </span><span class="NLM_article-title">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/s0092-8674(04)00206-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2FS0092-8674%2804%2900206-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=15066279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=17-28&author=J.+I.+Loizouauthor=S.+F.+El-Khamisyauthor=A.+Zlatanouauthor=D.+J.+Mooreauthor=D.+W.+Chanauthor=J.+Qinauthor=S.+Sarnoauthor=F.+Meggioauthor=L.+A.+Pinnaauthor=K.+W.+Caldecott&title=The+protein+kinase+CK2+facilitates+repair+of+chromosomal+DNA+single-strand+breaks&doi=10.1016%2Fs0092-8674%2804%2900206-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span></div><div class="casAuthors">Loizou, Joanna I.; El-Khamisy, Sherif F.; Zlatanou, Anastasia; Moore, David J.; Chan, Douglas W.; Qin, Jun; Sarno, Stefania; Meggio, Flavio; Pinna, Lorenzo A.; Caldecott, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CK2 was the first protein kinase identified and is required for the proliferation and survival of mammalian cells.  Here, we have identified an unanticipated role for CK2.  We show that this essential protein kinase phosphorylates the scaffold protein XRCC1 and thereby enables the assembly and activity of DNA single-strand break repair protein complexes in vitro and at sites of chromosomal breakage.  Moreover, we show that inhibiting XRCC1 phosphorylation by mutation of the CK2 phosphorylation sites or preventing CK2 activity using a highly specific inhibitor ablates the rapid repair of cellular DNA single-strand breaks by XRCC1.  These data identify a direct role for CK2 in the repair of chromosomal DNA strand breaks and in maintaining genetic integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqiQqOcdOwurVg90H21EOLACvtfcHk0ljAomedglsKoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D&md5=494c5eb7c11f74d080dc07ebc17eda77</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900206-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900206-5%26sid%3Dliteratum%253Aachs%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DEl-Khamisy%26aufirst%3DS.%2BF.%26aulast%3DZlatanou%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DThe%2520protein%2520kinase%2520CK2%2520facilitates%2520repair%2520of%2520chromosomal%2520DNA%2520single-strand%2520breaks%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fs0092-8674%2804%2900206-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabik, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance and toxicity associated with platinating agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.ctrv.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ctrv.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17084534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=9-23&author=C.+A.+Rabikauthor=M.+E.+Dolan&title=Molecular+mechanisms+of+resistance+and+toxicity+associated+with+platinating+agents&doi=10.1016%2Fj.ctrv.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance and toxicity associated with platinating agents</span></div><div class="casAuthors">Rabik, Cara A.; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Platinating agents, including cisplatin, carboplatin, and oxaliplatin, have been used clin. for nearly 30 years as part of the treatment of many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma.  The cytotoxic lesion of platinating agents is thought to be the platinum intrastrand crosslink that forms on DNA, although treatment activates a no. of signal transduction pathways.  Treatment with these agents is characterized by resistance, both acquired and intrinsic.  This resistance can be caused by a no. of cellular adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and increased levels of DNA repair or DNA tolerance.  Here we investigate the pathways that treatment with platinating agents activate, the mechanisms of resistance, potential candidate genes involved in the development of resistance, and assocd. clin. toxicities.  Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclin. data that has clin. relevance generated over the past five years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxn13FCg9DbVg90H21EOLACvtfcHk0lioibjAk94eYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D&md5=9d5cc75e635b074a03a11c2f67c7914b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRabik%26aufirst%3DC.%2BA.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520and%2520toxicity%2520associated%2520with%2520platinating%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D9%26epage%3D23%26doi%3D10.1016%2Fj.ctrv.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saris, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vaart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rietbroek, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloramaert, F.</span></span> <span> </span><span class="NLM_article-title">In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2763</span>â <span class="NLM_lpage">2769</span>, <span class="refDoi">Â DOI: 10.1093/carcin/17.12.2763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1093%2Fcarcin%2F17.12.2763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=9006117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADyaK2sXos1Sltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=2763-2769&author=C.+P.+Sarisauthor=P.+M.+van+de+Vaartauthor=R.+C.+Rietbroekauthor=F.+Bloramaert&title=In+vitro+formation+of+DNA+adducts+by+cisplatin%2C+lobaplatin+and+oxaliplatin+in+calf+thymus+DNA+in+solution+and+in+cultured+human+cells&doi=10.1093%2Fcarcin%2F17.12.2763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells</span></div><div class="casAuthors">Saris, C. P.; van de Vaart, P. J. M.; Rietbroek, R. C.; Blommaert, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2763-2769</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Two interesting representatives of a new generation of platinum-based cytostatic drugs that are currently being tested in clin. trials are lobaplatin [1,2-diaminomethylcyclobutane platinum(II) lactate] and oxaliplatin [1,2-diaminocyclohexane platinum (II) oxalate].  Since little is known about the DNA adduct formation of these compds., the authors studied their formation in DNA in vitro in calf thymus DNA and in cells.  The major adducts formed in vitro were the Pt-GG and Pt-Ag intrastrand crosslinks.  The latter adducts could be detected using a recently developed 32P-postlabeling method.  Using both this assay and at. absorption spectroscopy, it was shown that there is a substantially higher rate of the in vitro adduct formation by cisplatin, compared with lobaplatin and oxaliplatin.  Platinum concns. required to obtain 90% cell kill during a 2 h incubation of A2780 cells were 15 Î¼M for cisplatin and oxaliplatin and 22 Î¼M for lobaplatin.  Using an antiserum originally raised against cisplatin-treated DNA, the authors were also able to detect platinum-DNA adducts induced by lobaplatin and oxaliplatin.  Maximal nuclear staining for all three compds. was obsd. after a 4 h post-incubation period.  The nuclear staining level induced by cisplatin was about 10-fold higher than after lobaplatin and oxaliplatin treatment.  GG and AG adducts, measured by 32P-postlabeling, also showed max. levels at about 4 h after cisplatin, lobaplatin and oxaliplatin, resp.  The ratios of GG over AG intrastrand crosslinks in the A2780 cells were not significantly different for the various compds.  In conclusion, the 32P-postlabeling technique has been shown to be appropriate for adduct anal., not only for the classical Pt compds. cisplatin and carboplatin but also for novel platinum compds. like lobaplatin and oxaliplatin.  Results indicated large differences in reactivity of the latter compds. to DNA in vitro, compared with cisplatin.  This difference was smaller in cells, suggesting enhancement of adduct formation by certain cellular mechanisms and/or compds.  From these studies, no conclusions can be drawn with resp. to the cytotoxicity of the different Pt-GG and Pt-Ag intrastrand crosslinks formed by these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqR-jeAv0gIrVg90H21EOLACvtfcHk0lioibjAk94eYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXos1Sltg%253D%253D&md5=c1b398e21c11c9fa5da5a79e39298270</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F17.12.2763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F17.12.2763%26sid%3Dliteratum%253Aachs%26aulast%3DSaris%26aufirst%3DC.%2BP.%26aulast%3Dvan%2Bde%2BVaart%26aufirst%3DP.%2BM.%26aulast%3DRietbroek%26aufirst%3DR.%2BC.%26aulast%3DBloramaert%26aufirst%3DF.%26atitle%3DIn%2520vitro%2520formation%2520of%2520DNA%2520adducts%2520by%2520cisplatin%252C%2520lobaplatin%2520and%2520oxaliplatin%2520in%2520calf%2520thymus%2520DNA%2520in%2520solution%2520and%2520in%2520cultured%2520human%2520cells%26jtitle%3DCarcinogenesis%26date%3D1996%26volume%3D17%26spage%3D2763%26epage%3D2769%26doi%3D10.1093%2Fcarcin%2F17.12.2763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stennett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibellini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-GalÃ¡n, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span> <span> </span><span class="NLM_article-title">ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1979</span>â <span class="NLM_lpage">1991</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-11-2113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F1078-0432.ccr-11-2113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22351695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOlsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1979-1991&author=C.+M.+Chapmanauthor=X.+Sunauthor=M.+Roschewskiauthor=G.+Aueauthor=M.+Farooquiauthor=L.+Stennettauthor=F.+Gibelliniauthor=D.+Arthurauthor=P.+P%C3%A9rez-Gal%C3%A1nauthor=A.+Wiestner&title=ON+01910.Na+is+selectively+cytotoxic+for+chronic+lymphocytic+leukemia+cells+through+a+dual+mechanism+of+action+involving+PI3K%2FAKT+inhibition+and+induction+of+oxidative+stress&doi=10.1158%2F1078-0432.ccr-11-2113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress</span></div><div class="casAuthors">Chapman, Colby M.; Sun, Xiameng; Roschewski, Mark; Aue, Georg; Farooqui, Mohamed; Stennett, Lawrence; Gibellini, Federica; Arthur, Diane; Perez-Galan, Patricia; Wiestner, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1979-1991</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Chronic lymphocytic leukemia (CLL), a malignancy of mature B cells, is incurable with chemotherapy.  Signals from the microenvironment support leukemic cell survival and proliferation and may confer chemotherapy resistance.  ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.  Our aim was to analyze the efficacy of ON 01910.Na against CLL cells in vitro and investigate the mol. effects of this drug on tumor biol.  Exptl. Design: Cytotoxicity of ON 01910.Na against CLL cells from 34 patients was detd. in vitro with flow cytometry of cells stained with Annexin V and CD19.  Global gene expression profiling on Affymetrix microarrays, flow cytometry, Western blotting, and cocultures with stroma cells were used to delineate ON 01910.Na mechanism of action.  RESULTS: ON 01910.Na induced apoptosis in CLL B cells without significant toxicity against T cells or normal B cells.  ON 01910.Na was equally active against leukemic cells assocd. with a more aggressive disease course [Ig heavy-chain variable region unmutated, adverse cytogenetics] than against cells without these features.  Gene expression profiling revealed two main mechanisms of action: PI3K/AKT inhibition and induction of ROS that resulted in an oxidative stress response through activating protein 1 (AP-1), c-jun-NH2-terminal kinase, and ATF3 culminating in the upregulation of NOXA.  ROS scavengers and shRNA mediated knockdown of ATF3- and NOXA-protected cells from drug-induced apoptosis.  ON 01910.Na also abrogated the prosurvival effect of follicular dendritic cells on CLL cells and reduced SDF-1-induced migration of leukemic cells.  CONCLUSIONS: These data support the clin. development of ON 01910.Na in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHq7SJ_-_G0LVg90H21EOLACvtfcHk0lioibjAk94eYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOlsr8%253D&md5=befc3ea20445bc4c39da0f19074d4b34</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-2113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-2113%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DC.%2BM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DAue%26aufirst%3DG.%26aulast%3DFarooqui%26aufirst%3DM.%26aulast%3DStennett%26aufirst%3DL.%26aulast%3DGibellini%26aufirst%3DF.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DP%25C3%25A9rez-Gal%25C3%25A1n%26aufirst%3DP.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DON%252001910.Na%2520is%2520selectively%2520cytotoxic%2520for%2520chronic%2520lymphocytic%2520leukemia%2520cells%2520through%2520a%2520dual%2520mechanism%2520of%2520action%2520involving%2520PI3K%252FAKT%2520inhibition%2520and%2520induction%2520of%2520oxidative%2520stress%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1979%26epage%3D1991%26doi%3D10.1158%2F1078-0432.ccr-11-2113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations</span>. <i>J. Formosan Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">611</span>, <span class="refDoi">Â DOI: 10.1016/s0929-6646(09)60380-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fs0929-6646%2809%2960380-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19666347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKmsLjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=599-611&author=C.-Y.+Liuauthor=C.-F.+Leeauthor=Y.-H.+Wei&title=Role+of+reactive+oxygen+species-elicited+apoptosis+in+the+pathophysiology+of+mitochondrial+and+neurodegenerative+diseases+associated+with+mitochondrial+DNA+mutations&doi=10.1016%2Fs0929-6646%2809%2960380-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations</span></div><div class="casAuthors">Liu, Chun-Yi; Lee, Cheng-Feng; Wei, Yau-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Formosan Medical Association</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">599-611</span>CODEN:
                <span class="NLM_cas:coden">JFASEO</span>;
        ISSN:<span class="NLM_cas:issn">0929-6646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier (Singapore) Pte Ltd.</span>)
        </div><div class="casAbstract">A review.  A wide spectrum of pathogenic mutations of mitochondrial DNA (mtDNA) has been demonstrated to cause mitochondrial dysfunction and overprodn. of reactive oxygen species (ROS), in relation to mitochondrial and neurodegenerative diseases.  Our previous studies have shown that large-scale deletions of mtDNA not only serve as an indicator of oxidative damage, but also result in greater susceptibility of human cells to apoptosis triggered by UV irradn. and other apoptotic stimuli.  In this review, we focus on the involvement of mtDNA-mutation-assocd. oxidative stress and susceptibility to apoptosis in the pathophysiol. of mitochondrial and neurodegenerative diseases.  Different lines of research have provided concordant data to suggest that the mtDNA-mutation-elicited energy insufficiency and enhanced oxidative stress and damage lead to cell dysfunction, and increase the susceptibility of affected cells to apoptosis in patients with these diseases.  Moreover, accumulating exptl. evidence has shown that antioxidant therapy is a good strategy for decreasing intracellular ROS and alleviating oxidative-stress-induced apoptosis in cells of patients that harbor pathogenic mtDNA mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfnZBRyvsj67Vg90H21EOLACvtfcHk0ljehBTOTE8c4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKmsLjP&md5=1a4ccf4fec0113ee06e8251158f8e0f5</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1016%2Fs0929-6646%2809%2960380-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0929-6646%252809%252960380-6%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.-Y.%26aulast%3DLee%26aufirst%3DC.-F.%26aulast%3DWei%26aufirst%3DY.-H.%26atitle%3DRole%2520of%2520reactive%2520oxygen%2520species-elicited%2520apoptosis%2520in%2520the%2520pathophysiology%2520of%2520mitochondrial%2520and%2520neurodegenerative%2520diseases%2520associated%2520with%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DJ.%2520Formosan%2520Med.%2520Assoc.%26date%3D2009%26volume%3D108%26spage%3D599%26epage%3D611%26doi%3D10.1016%2Fs0929-6646%2809%2960380-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of mitochondria targeted Flavoneânaphthalimideâpolyamine conjugates with antimetastatic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2071</span>â <span class="NLM_lpage">2083</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2071-2083&author=F.+Daiauthor=Q.+Liauthor=Y.+Wangauthor=C.+Geauthor=C.+Fengauthor=S.+Xieauthor=H.+Heauthor=X.+Xuauthor=C.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+mitochondria+targeted+Flavone%E2%80%93naphthalimide%E2%80%93polyamine+conjugates+with+antimetastatic+activity&doi=10.1021%2Facs.jmedchem.6b01846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity</span></div><div class="casAuthors">Dai, Fujun; Li, Qian; Wang, Yuxia; Ge, Chaochao; Feng, Chenyang; Xie, Songqiang; He, Haoying; Xu, Xiaojuan; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2071-2083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 90% of cancer-assocd. deaths result from disseminated tumors, indicating the ineffectiveness of current therapies and the imperative need of antimetastatic drugs.  A novel pharmacophore with flavonoid and naphthalimide moieties was constructed by using a fragment-based drug design and a series of eight flavone-naphthalimide-polyamine conjugates were synthesized.  In vitro evaluation revealed that compd. I with a homospermidine motif displayed better cell selectivity between cancerous and normal liver cells than amonafide did.  The in vivo assays on two hepatocellular carcinoma (HCC) models verified that I potently suppressed pulmonary metastasis with improved organ indexes compared to amonafide.  Various expts. showed that I as a potential fluorescent chem. probe could target the mitochondria.  Preliminary investigation into the mechanism of action of I indicated that it might harness a polyamine transporter for cell entrance, localize in the mitochondria, selectively cause reactive oxygen species (ROS) overprodn. in hepatoma cells instead of normal liver cells, and finally lead to HCC cell apoptosis and migration inhibition via multiple ROS-mediated signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnOVDRABi27Vg90H21EOLACvtfcHk0ljehBTOTE8c4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D&md5=de5add465c72748224b38fd9a153f131</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01846%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520mitochondria%2520targeted%2520Flavone%25E2%2580%2593naphthalimide%25E2%2580%2593polyamine%2520conjugates%2520with%2520antimetastatic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2071%26epage%3D2083%26doi%3D10.1021%2Facs.jmedchem.6b01846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span> <span> </span><span class="NLM_article-title">Cancer cell killing via ROS: To increase or decrease, that is the question</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1875</span>â <span class="NLM_lpage">1884</span>, <span class="refDoi">Â DOI: 10.4161/cbt.7.12.7067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.4161%2Fcbt.7.12.7067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=18981733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Glt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1875-1884&author=J.+Wangauthor=J.+Yi&title=Cancer+cell+killing+via+ROS%3A+To+increase+or+decrease%2C+that+is+the+question&doi=10.4161%2Fcbt.7.12.7067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell killing via ROS: to increase or decrease, that is the question</span></div><div class="casAuthors">Wang, Jie; Yi, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1875-1884</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Reactive oxygen species (ROS) act as a second messenger in cell signaling and are essential for various biol. processes in normal cells.  Any aberrance in redox balance may relate to human pathogenesis including cancers.  Since ROS are usually increased in cancer cells due to oncogene activation, relative lack of blood supply or other variances and ROS do involve in initiation, progression and metastasis of cancers, ROS are considered oncogenic.  Ironically, ROS prodn. is a mechanism shared by all non-surgical therapeutic approaches for cancers, including chemotherapy, radiotherapy and photodynamic therapy, due to their implication in triggering cell death, therefore ROS are also used to kill cancer cells.  Because of the double-edged sword property of ROS in detg. cell fate, both pro- or anti-oxidant therapies have been proposed for treatments of cancers.  Based on either side, a no. of drugs, agents and approaches are developed or in the progress of development, some of which have shown clin. promise.  This review summarizes the current understanding on ROS-manipulation strategies in cancer treatment and underlying mechanisms.  ROS-producing or -eliminating agents and the potential drugs in this aspect are categorized.  An effort is made in particular to discuss the paradox in the rationales of two opposite ROS-manipulation strategies and the concerns for their use.  Selectivity between tumor and non-tumor cells may depend on difference of their redox environments.  A combinational set of cellular parameters including redox status, antioxidant enzymes expression, cell signaling and transcription factor activation profiles, namely "redox signaling signature", is waiting for being developed in order to choose ROS-elevating or ROS-depleting therapy specific to certain type of cancer cells.  In clin. setting individualized choice of an optimal ROS-manipulation therapy may require accurate and convenient measurements for ROS as well as "redox signaling signature" for prediction of efficacy and systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-R3JAlagNIbVg90H21EOLACvtfcHk0ljehBTOTE8c4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Glt7g%253D&md5=61838888fcbc11271f6474919d572cde</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4161%2Fcbt.7.12.7067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.7.12.7067%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.%26atitle%3DCancer%2520cell%2520killing%2520via%2520ROS%253A%2520To%2520increase%2520or%2520decrease%252C%2520that%2520is%2520the%2520question%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1875%26epage%3D1884%26doi%3D10.4161%2Fcbt.7.12.7067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clerkin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, T. G.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of ROS modulated cell survival during carcinogenesis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2008.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.canlet.2008.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=18372105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2008&pages=30-36&author=J.+S.+Clerkinauthor=R.+Naughtonauthor=C.+Quineyauthor=T.+G.+Cotter&title=Mechanisms+of+ROS+modulated+cell+survival+during+carcinogenesis&doi=10.1016%2Fj.canlet.2008.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ROS modulated cell survival during carcinogenesis</span></div><div class="casAuthors">Clerkin, J. S.; Naughton, R.; Quiney, C.; Cotter, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  There is increasing evidence within the literature that the decreased susceptibility of tumor cells to stimuli that induce apoptosis can be linked to their inherently increased redox potential.  The review primarily focuses on the PI3-kinase/Akt pathway, and the multiple points along this signalling pathway that may be redox regulated.  The PI3-kinase/Akt pathway can influence a cells' sensitivity to death inducing signals, through direct manipulation of apoptosis regulating mols. or by regulating the activity of key transcription factors.  Proteins involved in the control of apoptosis that are directly regulated by the PI3-kinase/Akt pathway include caspase-9, Bad and the transcription factor GSK-3Î².  Lately, it is becoming increasingly obvious that phosphatases are a major counter balance to the PI3-kinase/Akt pathway.  Phosphatases such as PP2A and PP1Î± can dephosphorylate signalling mols. within the PI3-kinase/Akt pathway, blocking their activity.  It is the balance between the kinase activity and the phosphatase activity that dets. the presence and strength of the PI3-kinase/Akt signal.  This is why any protein modifications that hinder dephosphorylation can increase the tumors survival advantage.  One such modification is the oxidn. of the sulphydryl group in key cysteine residues present within the active site of the phosphatases.  This highlights the link between the increased redox stress in tumors with the PI3-kinase/Akt pathway.  This review will discuss the various sources of reactive oxygen species within a tumor and the effect of these radicals on the PI3-kinase/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfmcBwEYdkbbVg90H21EOLACvtfcHk0lgELeILSGzQrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKlu7c%253D&md5=b5dd40feb838ad74d7a22bdba45a52fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DClerkin%26aufirst%3DJ.%2BS.%26aulast%3DNaughton%26aufirst%3DR.%26aulast%3DQuiney%26aufirst%3DC.%26aulast%3DCotter%26aufirst%3DT.%2BG.%26atitle%3DMechanisms%2520of%2520ROS%2520modulated%2520cell%2520survival%2520during%2520carcinogenesis%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D266%26spage%3D30%26epage%3D36%26doi%3D10.1016%2Fj.canlet.2008.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusatis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheelhouse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulesza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">618</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fonc.2008.424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19029951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=610-618&author=A.+Jimenoauthor=A.+Chanauthor=G.+Cusatisauthor=X.+Zhangauthor=J.+Wheelhouseauthor=A.+Solomonauthor=F.+Chanauthor=M.+Zhaoauthor=S.+C.+Cosenzaauthor=M.+R.+Reddyauthor=M.+A.+Rudekauthor=P.+Kuleszaauthor=R.+C.+Donehowerauthor=E.+P.+Reddyauthor=M.+Hidalgo&title=Evaluation+of+the+novel+mitotic+modulator+ON+01910.Na+in+pancreatic+cancer+and+preclinical+development+of+an+ex+vivo+predictive+assay&doi=10.1038%2Fonc.2008.424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay</span></div><div class="casAuthors">Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">610-618</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy.  Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xenografts.  ON 01910.Na showed equiv. activity to gemcitabine against pancreatic cancer cell lines in vitro.  The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1.  These markers were optimized for a fine-needle aspirate ex vivo rapid assay.  Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility.  Next, nine patient-derived tumors from the PancXenoBank were profiled using the assay developed in cell lines and treated with ON 01910.Na for 28 days.  Two cases were cataloged as potential responders and seven as resistant.  There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response.  Of the seven tumors of predictive resistant, only one was sensitive to ON 01910.Na.  In addn., there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment.  The novel mitotic inhibitor, ON 01910.Na, showed activity in preclin. model of pancreatic cancer.  A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeiRhg4c6sqLVg90H21EOLACvtfcHk0lgELeILSGzQrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7zM&md5=ad45c01db1c55597ea204767e63cd262</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.424%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DCusatis%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWheelhouse%26aufirst%3DJ.%26aulast%3DSolomon%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DKulesza%26aufirst%3DP.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520novel%2520mitotic%2520modulator%2520ON%252001910.Na%2520in%2520pancreatic%2520cancer%2520and%2520preclinical%2520development%2520of%2520an%2520ex%2520vivo%2520predictive%2520assay%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D610%26epage%3D618%26doi%3D10.1038%2Fonc.2008.424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohrens, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzinger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang-Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKoy, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozols, R. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of a cis-diamrninedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">414</span>â <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=3539322" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1987&pages=414-418&author=B.+C.+Bohrensauthor=T.+C.+Hamiltonauthor=H.+Masudaauthor=K.+R.+Grotzingerauthor=J.+Whang-Pengauthor=K.+G.+Louieauthor=T.+Knutsenauthor=W.+M.+McKoyauthor=R.+C.+Youngauthor=R.+F.+Ozols&title=Characterization+of+a+cis-diamrninedichloroplatinum%28II%29-resistant+human+ovarian+cancer+cell+line+and+its+use+in+evaluation+of+platinum+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBohrens%26aufirst%3DB.%2BC.%26aulast%3DHamilton%26aufirst%3DT.%2BC.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DGrotzinger%26aufirst%3DK.%2BR.%26aulast%3DWhang-Peng%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DK.%2BG.%26aulast%3DKnutsen%26aufirst%3DT.%26aulast%3DMcKoy%26aufirst%3DW.%2BM.%26aulast%3DYoung%26aufirst%3DR.%2BC.%26aulast%3DOzols%26aufirst%3DR.%2BF.%26atitle%3DCharacterization%2520of%2520a%2520cis-diamrninedichloroplatinum%2528II%2529-resistant%2520human%2520ovarian%2520cancer%2520cell%2520line%2520and%2520its%2520use%2520in%2520evaluation%2520of%2520platinum%2520analogues%26jtitle%3DCancer%2520Res.%26date%3D1987%26volume%3D47%26spage%3D414%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amos, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twentyman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1316</span>â <span class="NLM_lpage">1323</span>, <span class="refDoi">Â DOI: 10.1038/bjc.1993.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fbjc.1993.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=8099807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGht7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=1316-1323&author=H.+Coleyauthor=W.+Amosauthor=P.+Twentymanauthor=P.+Workman&title=Examination+by+laser+scanning+confocal+fluorescence+imaging+microscopy+of+the+subcellular+localisation+of+anthracyclines+in+parent+and+multidrug+resistant+cell+lines&doi=10.1038%2Fbjc.1993.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localization of anthracyclines in parent and multidrug resistant cell lines</span></div><div class="casAuthors">Coley, H. M.; Amos, W. B.; Twentyman, P. R.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1316-23</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">This study highlights the usefulness of laser scanning confocal microscopy in the examn. of subcellular disposition of anthracyclines in tumor cell lines.  The distribution of anthracycline compds. has been studied in two pairs of parental and multidrug resistant (MDR) cell lines.  For the parental EMT6 mouse mammary tumor cell line EMT6/P treated with doxorubicin (DOX) the anthracycline fluorescence was shown to be predominantly nuclear but with some particulate cytoplasmic fluorescence and very low levels of plasma membrane staining.  In the same expts. much fainter fluorescence was seen for the EMT5/AR 1.0 MDR subline which hyperexpresses P-glycoprotein.  The loss of nuclear fluorescence was comparatively greater than loss of cytoplasmic fluorescence.  For the human large cell lung cancer line COR-L23/P cellular DOX disposition was markedly nuclear with nuclear membrane staining and diffuse cytoplasmic fluorescence.  For the MDR line COR-L23/R, which lacks P-glycoprotein expression, DOX fluorescence was reduced in the nucleus compared with the parental line, but an intense area of perinuclear staining was seen consistent with localization to the Golgi app.  The morpholinyl-substituted analog MR-DOX achieved very similar subcellular distribution in both parental and MDR lines, consistent with its retention of activity in the latter.  The presence of verapamil during anthracycline exposure increased the intensity of fluorescence in the MDR lines, particularly in the nucleus.  Relatively little effect was seen in the parental lines.  Confocal microscopy provides high resoln. images of the subcellular distribution of anthracyclines in parent and MDR cell lines.  Differences in drug disposition in various cell lines may provide insights into the mechanism of multidrug resistance and suggest strategies for its therapeutic circumvention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6AjVNm_Dl_LVg90H21EOLACvtfcHk0lgELeILSGzQrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGht7k%253D&md5=5b836e6e7a5a747139831af60f18d2c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1993.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1993.244%26sid%3Dliteratum%253Aachs%26aulast%3DColey%26aufirst%3DH.%26aulast%3DAmos%26aufirst%3DW.%26aulast%3DTwentyman%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DExamination%2520by%2520laser%2520scanning%2520confocal%2520fluorescence%2520imaging%2520microscopy%2520of%2520the%2520subcellular%2520localisation%2520of%2520anthracyclines%2520in%2520parent%2520and%2520multidrug%2520resistant%2520cell%2520lines%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1993%26volume%3D67%26spage%3D1316%26epage%3D1323%26doi%3D10.1038%2Fbjc.1993.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b','cit34c','cit34d','cit34e'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41a','cit41b'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jiye Wang, Zengrui Wu, Yayuan Peng, Weihua Li, Guixia Liu, <span class="NLM_string-name hlFld-ContribAuthor">Yun Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Pathway-Based Drug Repurposing with DPNetinfer: A Method to Predict DrugâPathway Associations via Network-Based Approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (5)
                                     , 2475-2485. <a href="https://doi.org/10.1021/acs.jcim.1c00009" title="DOI URL">https://doi.org/10.1021/acs.jcim.1c00009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.1c00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.1c00009%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPathway-Based%252BDrug%252BRepurposing%252Bwith%252BDPNetinfer%25253A%252BA%252BMethod%252Bto%252BPredict%252BDrug%2525E2%252580%252593Pathway%252BAssociations%252Bvia%252BNetwork-Based%252BApproaches%26aulast%3DWang%26aufirst%3DJiye%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05012021%26date%3D26042021%26volume%3D61%26issue%3D5%26spage%3D2475%26epage%3D2485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nafees Muhammad, Cai-Ping Tan, Uroosa Nawaz, Jie Wang, Fang-Xin Wang, Sadia Nasreen, Liang-Nian Ji, <span class="NLM_string-name hlFld-ContribAuthor">Zong-Wan Mao</span>. </span><span class="cited-content_cbyCitation_article-title">Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2020,</strong> <em>59 </em>
                                    (17)
                                     , 12632-12642. <a href="https://doi.org/10.1021/acs.inorgchem.0c01736" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.0c01736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.0c01736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.0c01736%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DMultiaction%252BPlatinum%252528IV%252529%252BProdrug%252BContaining%252BThymidylate%252BSynthase%252BInhibitor%252Band%252BMetabolic%252BModifier%252Bagainst%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DMuhammad%26aufirst%3DNafees%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12062020%26date%3D24082020%26volume%3D59%26issue%3D17%26spage%3D12632%26epage%3D12642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Chun-Peng  Jia</span>, <span class="hlFld-ContribAuthor ">An-Na  Mo</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Chemodynamic therapy agents Cu(II) complexes of quinoline derivatives induced ER stress and mitochondria-mediated apoptosis in SK-OV-3Â cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113636. <a href="https://doi.org/10.1016/j.ejmech.2021.113636" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113636%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChemodynamic%252Btherapy%252Bagents%252BCu%252528II%252529%252Bcomplexes%252Bof%252Bquinoline%252Bderivatives%252Binduced%252BER%252Bstress%252Band%252Bmitochondria-mediated%252Bapoptosis%252Bin%252BSK-OV-3%2525C2%2525A0cells%26aulast%3DShen%26aufirst%3DWen-Ying%26date%3D2021%26volume%3D223%26spage%3D113636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinguang  Cao</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>, <span class="hlFld-ContribAuthor ">Huihua  Xiong</span>, <span class="hlFld-ContribAuthor ">Jinfang  Su</span>, <span class="hlFld-ContribAuthor ">Changqing  Guo</span>, <span class="hlFld-ContribAuthor ">Tianqi  An</span>, <span class="hlFld-ContribAuthor ">Hong  Zong</span>, <span class="hlFld-ContribAuthor ">Ruihua  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113520. <a href="https://doi.org/10.1016/j.ejmech.2021.113520" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113520%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BPt%252528IV%252529%252Bcomplexes%252Bto%252Bovercome%252Bmultidrug%252Bresistance%252Bin%252Bgastric%252Bcancer%252Bby%252Btargeting%252BP-glycoprotein%26aulast%3DCao%26aufirst%3DXinguang%26date%3D2021%26volume%3D221%26spage%3D113520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-Qin  Qin</span>, <span class="hlFld-ContribAuthor ">Zu-Zhuang  Wei</span>, <span class="hlFld-ContribAuthor ">Lin  Yang</span>, <span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Jia-Jing  Zeng</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Strong in vitro and in vivo cytotoxic effects of two platinum(II) complexes with cryptolepine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (7)
                                     , 1419-1426. <a href="https://doi.org/10.1007/s00044-021-02739-0" title="DOI URL">https://doi.org/10.1007/s00044-021-02739-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02739-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02739-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DStrong%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bcytotoxic%252Beffects%252Bof%252Btwo%252Bplatinum%252528II%252529%252Bcomplexes%252Bwith%252Bcryptolepine%252Bderivatives%26aulast%3DQin%26aufirst%3DLi-Qin%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D7%26spage%3D1419%26epage%3D1426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisabetta  Gabano</span>, <span class="hlFld-ContribAuthor ">Beatrice  Rangone</span>, <span class="hlFld-ContribAuthor ">Elena  Perin</span>, <span class="hlFld-ContribAuthor ">Giulia  Caron</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Ermondi</span>, <span class="hlFld-ContribAuthor ">Maura  Vallaro</span>, <span class="hlFld-ContribAuthor ">Valentina  Gandin</span>, <span class="hlFld-ContribAuthor ">Cristina  Marzano</span>, <span class="hlFld-ContribAuthor ">Alessandra  Barbanente</span>, <span class="hlFld-ContribAuthor ">Nicola  Margiotta</span>, <span class="hlFld-ContribAuthor ">Mauro  Ravera</span>. </span><span class="cited-content_cbyCitation_article-title">Pt(
              iv
              ) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2021,</strong> <em>50 </em>
                                    (13)
                                     , 4663-4672. <a href="https://doi.org/10.1039/D0DT04135A" title="DOI URL">https://doi.org/10.1039/D0DT04135A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT04135A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT04135A%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DPt%252528%252Biv%252B%252529%252Bcomplexes%252Bbased%252Bon%252Bcyclohexanediamines%252Band%252Bthe%252Bhistone%252Bdeacetylase%252Binhibitor%252B2-%2525282-propynyl%252529octanoic%252Bacid%25253A%252Bsynthesis%25252C%252Bcharacterization%25252C%252Bcell%252Bpenetration%252Bproperties%252Band%252Bantitumor%252Bactivity%26aulast%3DGabano%26aufirst%3DElisabetta%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D13%26spage%3D4663%26epage%3D4672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shengjin  Xia</span>, <span class="hlFld-ContribAuthor ">Qingqing  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113300. <a href="https://doi.org/10.1016/j.ejmech.2021.113300" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113300%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfamoylphenyl-quinazoline%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FCAIX%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DBin%26date%3D2021%26volume%3D216%26spage%3D113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eslam M.H.  Ali</span>, <span class="hlFld-ContribAuthor ">Mohammed S.  Abdel-Maksoud</span>, <span class="hlFld-ContribAuthor ">Usama M.  Ammar</span>, <span class="hlFld-ContribAuthor ">Karim I.  Mersal</span>, <span class="hlFld-ContribAuthor ">Kyung  Ho Yoo</span>, <span class="hlFld-ContribAuthor ">Park  Jooryeong</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>106 </em>, 104508. <a href="https://doi.org/10.1016/j.bioorg.2020.104508" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104508%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bimidazole%252Bderivatives%252Bpossessing%252Bterminal%252Bsulphonamides%252Bas%252Bpotential%252BBRAFV600Einhibitors%26aulast%3DAli%26aufirst%3DEslam%2BM.H.%26date%3D2021%26volume%3D106%26spage%3D104508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochao  Huang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Xiulian  Yin</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Lumei  Dai</span>, <span class="hlFld-ContribAuthor ">Hengshan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104430. <a href="https://doi.org/10.1016/j.bioorg.2020.104430" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104430</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104430%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPlatinum%252528IV%252529%252Bcomplexes%252Bconjugated%252Bwith%252Bchalcone%252Banalogs%252Bas%252Bdual%252Btargeting%252Banticancer%252Bagents%25253A%252BIn%252Bvitro%252Band%252Bin%252Bvivo%252Bstudies%26aulast%3DHuang%26aufirst%3DXiaochao%26date%3D2020%26volume%3D105%26spage%3D104430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tai-Ming  Shao</span>, <span class="hlFld-ContribAuthor ">Zu-Zhuang  Wei</span>, <span class="hlFld-ContribAuthor ">Xiao-Ling  Luo</span>, <span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Jia-Jing  Zeng</span>, <span class="hlFld-ContribAuthor ">Chun-Jie  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">High cytotoxic and apoptotic effects of platinum(
              ii
              ) complexes bearing the 4-acridinol ligand. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (45)
                                     , 19885-19890. <a href="https://doi.org/10.1039/D0NJ04753H" title="DOI URL">https://doi.org/10.1039/D0NJ04753H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ04753H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ04753H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DHigh%252Bcytotoxic%252Band%252Bapoptotic%252Beffects%252Bof%252Bplatinum%252528%252Bii%252B%252529%252Bcomplexes%252Bbearing%252Bthe%252B4-acridinol%252Bligand%26aulast%3DShao%26aufirst%3DTai-Ming%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D45%26spage%3D19885%26epage%3D19890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of Rigosertib and current Pt(II) drugs approved for worldwide use.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural modification strategy and the drug design idea of the target compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Pt(IV)Â Complexes <b>18â23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) NaBH<sub>4</sub>, MeOH; (c) PBr<sub>3</sub>, DCM; (d) mercapto acetic acid, NaOH, MeOH; (e) H<sub>2</sub>O<sub>2</sub>, AcOH; (f) piperidine, benzoic acid, toluene; (g) Fe, NH<sub>4</sub>Cl, EtOH, H<sub>2</sub>O; (h) oxalyl chloride, Et<sub>3</sub>N, DCM; (i) LiOHÂ·H<sub>2</sub>O, CH<sub>3</sub>OH, H<sub>2</sub>O; (j) TBTU, Et<sub>3</sub>N, <b>15</b>/<b>16</b>/<b>17</b>, DMF.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Pt(IV) Complexes <b>27â29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, KI, DMF; (b) LiOHÂ·H<sub>2</sub>O, CH<sub>3</sub>OH, H<sub>2</sub>O; (c) <b>15/16/17</b>, TBTU, Et<sub>3</sub>N, DMF.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell uptake of 26 in A549 cells treated with <b>29</b> for 12 h at the concentration of 5 and 10 Î¼M. Platinum content was measured by ICPâMS after digestion with 65% HNO<sub>3</sub>. Data represented the mean Â± SD of at least three different experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>29</b> interfered with the interaction of Ras/Raf and MEK/ERK activation. (A) Cell lysates collected from A549 cells that were pretreated with <b>29</b> (5 Î¼M) and <b>26</b> (5 Î¼M) for 24 h were subjected to immunoprecipitation with anti-Ras antibodies and determined the associated CRAF with Western blot. (B) Statistics of gray intensity were normalized with input. Data were presented as the mean Â± SD of three independent experiments. (C): MST trace lines of <b>29</b> binding to CRAF-RBD protein. (D): MST results of <b>29</b> binding to CRAF protein. Results provided above showed that <b>29</b> binds to the CRAF protein (<i>K</i><sub>d</sub> values was 149 nM). (E) Thermal stability of RAS; (F) statistics of gray intensity were normalized with gray intensity of 47 Â°C. Data were presented as the mean Â± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Phosphorylation and expression of the indicated proteins determined by Western blot in A549 cells after treatment with CDDP or increasing concentrations of <b>29</b> and <b>26</b>. (B) Signals obtained from Western blot and normalized with GAPDH. Data were presented as the mean Â± SD of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Annexin V-FITC and PI staining to evaluate apoptosis in A549 cells treated with various compounds. A549 cells were co-incubated with DMF, cisplatin (5 Î¼M), compound <b>26</b> (5 Î¼M), and compound <b>29</b> (5 Î¼M) and stained with Annexin V-FITC and PI and analyzed with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle arrest was analyzed after 24 h being treated with various compounds. A549 cells were treated with DMF, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), stained with PI, and analyzed with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. After 24 h treatment with vehicle, cisplatin (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were transferred onto the comet slide and treated according to the method reported previously.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Images were analyzed and recorded with a laser confocal microscope. Tail DNA was marked with a white arrow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. After 24 h treatment with vehicle, cisplatin (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were incubated with fluoresce probe DCFH-DA. Images were analyzed and recorded with a fluorescence microscope.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. After 24 h treatment with vehicle, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were stained with a JC-1 probe. MMP (ÎÏ<sub>m</sub>) was analyzed and recorded with flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Morphological changes of A549 cells induce by <b>29</b>. After 24 h treatment with DMF, CDDP (5 Î¼M), <b>26</b> (5 Î¼M), and <b>29</b> (5 Î¼M), A549 cells were stained with AO/EB. Results were analyzed and recorded with a Nikon Te2000 deconvolution microscope (magnification 200Ã).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. After 24 h treatment of A549 cells with <b>26</b> (5 Î¼M) and <b>29</b> (5 Î¼M), (A) Western blot analysis of Cyt <i>c</i>, Bcl-2, Bax, pro-caspase 9, caspase-9, pro-caspase 3, caspase-3, total-PARP, and cleaved PARP were analyzed, using Î²-actin antibody was used as the reference control. (B) Expression levels of (A) shown as percentages.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Antitumor activity of compound <b>29</b> on A549 xenograft models. Nude mice implanted with A549 cells in the flank were dosed via injecting intravenously of <b>29</b> (6 Î¼mol/kg), Rigosertib (6 Î¼mol/kg), CDDP (6 Î¼mol/kg), and vehicle (equivalent volume of normal saline injection) on days 0, 2, and 4. The mice were sacrificed and made mathematical statistics. (A) Tumor pictures obtained after sacrifice of the mice treated with <b>29</b>, Rigosertib, CDDP, and vehicle. (B) The RTV (relative tumor volume) (Â±SEM) is graphed with error bars representing the standard deviation. (c) The average body weights (Â±SEM) were plotted after sacrifice of the mice treated with <b>29</b>, Rigosertib, CDDP, and vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/medium/jm9b01223_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Proposed antitumor action mode of <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b01223/20200106/images/large/jm9b01223_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01223&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57456" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57456" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downward, J.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11</span>â <span class="NLM_lpage">22</span>, <span class="refDoi">Â DOI: 10.1038/nrc969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy&doi=10.1038%2Fnrc969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0liHfz2sCYETVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22%26doi%3D10.1038%2Fnrc969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buck, M.</span></span> <span> </span><span class="NLM_article-title">A âtug of warâ maintains a dynamic proteinâmembrane complex: molecular dynamics simulations of C-Raf RBD-CRD bound to K-Ras4B at an anionic membrane</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">298</span>â <span class="NLM_lpage">305</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.7b00593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1egu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=298-305&author=Z.-L.+Liauthor=P.+Prakashauthor=M.+Buck&title=A+%E2%80%9Ctug+of+war%E2%80%9D+maintains+a+dynamic+protein%E2%80%93membrane+complex%3A+molecular+dynamics+simulations+of+C-Raf+RBD-CRD+bound+to+K-Ras4B+at+an+anionic+membrane&doi=10.1021%2Facscentsci.7b00593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A "Tug of War" Maintains a Dynamic Protein-Membrane Complex: Molecular Dynamics Simulations of C-Raf RBD-CRD Bound to K-Ras4B at an Anionic Membrane</span></div><div class="casAuthors">Li, Zhen-Lu; Prakash, Priyanka; Buck, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-305</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Assocn. of Raf kinase with activated Ras triggers downstream signaling cascades, towards regulating transcription in the cells' nucleus.  Dysregulation of Ras: Raf signaling stimulates cancers.  We investigate the C-Raf RBD and CRD regions when bound to oncogenic K-Ras4B at the membrane.  All-atom mol. dynamics simulations suggest that the membrane plays an integral role in regulating the configurational ensemble of the complex.  Remarkably, the complex samples a few states dynamically, reflecting a competition between C-Raf CRD and K-Ras4B- membrane interactions.  This competition arises because the interaction between the RBD and K-Ras is strong and the linker between the RBD and CRD is short.  This study reveals a mechanism that maintains a modest binding for the overall complex at the membrane to facilitate fast signaling processes.  It is likely a common mechanism for other multi-protein, if not multidomain proteins at membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBrkdc42HYCrVg90H21EOLACvtfcHk0liHfz2sCYETVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1egu7o%253D&md5=42197b5574f7fc277876ed67312ade83</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00593%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.-L.%26aulast%3DPrakash%26aufirst%3DP.%26aulast%3DBuck%26aufirst%3DM.%26atitle%3DA%2520%25E2%2580%259Ctug%2520of%2520war%25E2%2580%259D%2520maintains%2520a%2520dynamic%2520protein%25E2%2580%2593membrane%2520complex%253A%2520molecular%2520dynamics%2520simulations%2520of%2520C-Raf%2520RBD-CRD%2520bound%2520to%2520K-Ras4B%2520at%2520an%2520anionic%2520membrane%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2018%26volume%3D4%26spage%3D298%26epage%3D305%26doi%3D10.1021%2Facscentsci.7b00593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25155755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+complex+reveals+a+kinase+activity+independent+role+for+BRAF+in+MAPK+signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span></div><div class="casAuthors">Haling, Jacob R.; Sudhamsu, Jawahar; Yen, Ivana; Sideris, Steve; Sandoval, Wendy; Phung, Wilson; Bravo, Brandon J.; Giannetti, Anthony M.; Peck, Ariana; Masselot, Alexandre; Morales, Tony; Smith, Darin; Brandhuber, Barbara J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-413</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Numerous oncogenic mutations occur within the BRAF kinase domain (BRAFKD).  Here we show that stable BRAF-MEK1 complexes are enriched in BRAFWT and KRAS mutant (MT) cells but not in BRAFMT cells.  The crystal structure of the BRAFKD in a complex with MEK1 reveals a face-to-face dimer sensitive to MEK1 phosphorylation but insensitive to BRAF dimerization.  Structure-guided studies reveal that oncogenic BRAF mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the interaction with MEK1.  Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant BRAF-MEK1 complex resulting in pathway inhibition.  Taken together, these findings reveal a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXE20AD1ZxrLVg90H21EOLACvtfcHk0lin7Vphm0NLLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ&md5=a4a931aa158afbac09b972fc2a0142b8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520complex%2520reveals%2520a%2520kinase%2520activity%2520independent%2520role%2520for%2520BRAF%2520in%2520MAPK%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1537</span>â <span class="NLM_lpage">1548</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-17-2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F0008-5472.can-17-2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29343524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1537-1548&author=W.+Shaoauthor=Y.+M.+Mishinaauthor=Y.+Fengauthor=G.+Caponigroauthor=V.+G.+Cookeauthor=S.+Riveraauthor=Y.+Wangauthor=F.+Shenauthor=J.+M.+Kornauthor=L.+A.+Mathews+Grinerauthor=G.+Nishiguchiauthor=A.+Ricoauthor=J.+Tellewauthor=J.+R.+Halingauthor=R.+Aversaauthor=V.+Polyakovauthor=R.+Zangauthor=M.+Hekmat-Nejadauthor=P.+Amiriauthor=M.+Singhauthor=N.+Keenauthor=M.+P.+Dillonauthor=E.+Leesauthor=S.+Ramurthyauthor=W.+R.+Sellersauthor=D.+D.+Stuart&title=Antitumor+properties+of+RAF709%2C+a+highly+selective+and+potent+inhibitor+of+RAF+kinase+dimers%2C+in+tumors+driven+by+mutant+RAS+or+BRAF&doi=10.1158%2F0008-5472.can-17-2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF</span></div><div class="casAuthors">Shao, Wenlin; Mishina, Yuji M.; Feng, Yun; Caponigro, Giordano; Cooke, Vesselina G.; Rivera, Stacy; Wang, Yingyun; Shen, Fang; Korn, Joshua M.; Mathews Griner, Lesley A.; Nishiguchi, Gisele; Rico, Alice; Tellew, John; Haling, Jacob R.; Aversa, Robert; Polyakov, Valery; Zang, Richard; Hekmat-Nejad, Mohammad; Amiri, Payman; Singh, Mallika; Keen, Nicholas; Dillon, Michael P.; Lees, Emma; Ramurthy, Savithri; Sellers, William R.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1537-1548</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene.  Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kinases.  RAF709 exhibited a mode of RAF inhibition distinct from RAF monomer inhibitors such as vemurafenib, showing equal activity against both RAF monomers and dimers.  As a result, RAF709 inhibited MAPK signaling activity in tumor models harboring either BRAFV600 alterations or mutant N- and KRAS-driven signaling, with minimal paradoxical activation of wild-type RAF.  In cell lines and murine xenograft models, RAF709 demonstrated selective antitumor activity in tumor cells harboring BRAF or RAS mutations compared with cells with wild-type BRAF and RAS genes.  RAF709 demonstrated a direct pharmacokinetic/pharmacodynamic relationship in in vivo tumor models harboring KRAS mutation.  Furthermore, RAF709 elicited regression of primary human tumor-derived xenograft models with BRAF, NRAS, or KRAS mutations with excellent tolerability.  Our results support further development of inhibitors like RAF709, which represents a next-generation RAF inhibitor with unique biochem. and cellular properties that enables antitumor activities in RAS-mutant tumors.  Significance: In an effort to develop RAF inhibitors with the appropriate pharmacol. properties to treat RAS mutant tumors, RAF709, a compd. with potency, selectivity, and in vivo properties, was developed that will allow preclin. therapeutic hypothesis testing, but also provide an excellent probe to further unravel the complexities of RAF kinase signaling.  Cancer Res; 78(6); 1537-48. Â©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOvhVkNT32bVg90H21EOLACvtfcHk0lin7Vphm0NLLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D&md5=607b45deb150d83b01394d43f776c097</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-17-2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-17-2033%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW.%26aulast%3DMishina%26aufirst%3DY.%2BM.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DRivera%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DKorn%26aufirst%3DJ.%2BM.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DAversa%26aufirst%3DR.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DAntitumor%2520properties%2520of%2520RAF709%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RAF%2520kinase%2520dimers%252C%2520in%2520tumors%2520driven%2520by%2520mutant%2520RAS%2520or%2520BRAF%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D1537%26epage%3D1548%26doi%3D10.1158%2F0008-5472.can-17-2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schubbert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Hyperactive Ras in developmental disorders and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">295</span>â <span class="NLM_lpage">308</span>, <span class="refDoi">Â DOI: 10.1038/nrc2109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc2109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17384584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=295-308&author=S.+Schubbertauthor=K.+Shannonauthor=G.+Bollag&title=Hyperactive+Ras+in+developmental+disorders+and+cancer&doi=10.1038%2Fnrc2109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperactive Ras in developmental disorders and cancer</span></div><div class="casAuthors">Schubbert, Suzanne; Shannon, Kevin; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Ras genes are the most common targets for somatic gain-of-function mutations in human cancer.  Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Nonan, Costello and cardio-facio-cutaneous syndromes.  Many of these mutant alleles encode proteins with aberrant biochem. and functional properties.  Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRvjqrp1ho7Vg90H21EOLACvtfcHk0lhJ0V9nK_Vc8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlyhtLs%253D&md5=25fcaa959dae5e8512b959936bcbb347</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2109%26sid%3Dliteratum%253Aachs%26aulast%3DSchubbert%26aufirst%3DS.%26aulast%3DShannon%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DHyperactive%2520Ras%2520in%2520developmental%2520disorders%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D295%26epage%3D308%26doi%3D10.1038%2Fnrc2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prior, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattos, C.</span></span> <span> </span><span class="NLM_article-title">A comprehensive survey of Ras mutations in cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">2457</span>â <span class="NLM_lpage">2467</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-11-2612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F0008-5472.can-11-2612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22589270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=2457-2467&author=I.+A.+Priorauthor=P.+D.+Lewisauthor=C.+Mattos&title=A+comprehensive+survey+of+Ras+mutations+in+cancer&doi=10.1158%2F0008-5472.can-11-2612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A Comprehensive Survey of Ras Mutations in Cancer</span></div><div class="casAuthors">Prior, Ian A.; Lewis, Paul D.; Mattos, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2457-2467</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  All mammalian cells express 3 closely related Ras proteins, termed H-Ras, K-Ras, and N-Ras, that promote oncogenesis when they are mutationally activated at codon 12, 13, or 61.  Although there is a high degree of similarity among the isoforms, K-Ras mutations are far more frequently obsd. in cancer, and each isoform displays preferential coupling to particular cancer types.  We examd. the mutational spectra of Ras isoforms curated from large-scale tumor profiling and found that each isoform exhibits surprisingly distinctive codon mutation and amino-acid substitution biases.  These findings were unexpected given that these mutations occur in regions that share 100% amino-acid sequence identity among the 3 isoforms.  Of importance, many of these mutational biases were not due to differences in exposure to mutagens, because the patterns were still evident when compared within specific cancer types.  We discuss potential genetic and epigenetic mechanisms, as well as isoform-specific differences in protein structure and signaling, that may promote these distinct mutation patterns and differential coupling to specific cancers.  Cancer Res; 72(10); 2457-67.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2lqiicosOLVg90H21EOLACvtfcHk0lhJ0V9nK_Vc8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvF2ntL4%253D&md5=6d1894847015468f77c8b08b57c6d62a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-11-2612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-11-2612%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DI.%2BA.%26aulast%3DLewis%26aufirst%3DP.%2BD.%26aulast%3DMattos%26aufirst%3DC.%26atitle%3DA%2520comprehensive%2520survey%2520of%2520Ras%2520mutations%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D2457%26epage%3D2467%26doi%3D10.1158%2F0008-5472.can-11-2612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matallanas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, P.</span></span> <span> </span><span class="NLM_article-title">New druggable targets in the Ras pathway?</span>. <i>Curr. Opin. Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">674</span>â <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21154159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVelu7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=674-683&author=D.+Matallanasauthor=P.+Crespo&title=New+druggable+targets+in+the+Ras+pathway%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New druggable targets in the Ras pathway?</span></div><div class="casAuthors">Matallanas, David; Crespo, Piero</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Molecular Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">674-683</span>CODEN:
                <span class="NLM_cas:coden">CUOTFO</span>;
        ISSN:<span class="NLM_cas:issn">2040-3445</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ras proteins are key elements in the regulation of cellular proliferation, differentiation and survival.  Mutational activation of Ras or of components of its effector pathways are detected in one-third of human cancers and are essential for the genesis and maintenance of the tumoral phenotype.  Research efforts have been dedicated to the development of therapeutic agents that inhibit aberrant Ras signals and, subsequently, tumor progression.  However, many of these initiatives have proven less successful than expected.  This review summarizes the current status of developments in Ras research, the challenges that have arisen during preclin. and clin. stages, and how novel approaches to targeting Ras pathways have introduced new strategies toward the development of antitumoral agents that are alternative or complementary to those currently in use.  These new approaches would be aimed at disrupting key protein-protein interactions that are essential for the conveyance of Ras aberrant signals or would be directed against new proteins recently demonstrated to be crit. participants in Ras-regulated pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra7ew0StgcBrVg90H21EOLACvtfcHk0lhJ0V9nK_Vc8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVelu7s%253D&md5=3788fab9a1650a1d5b33726e3f281165</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatallanas%26aufirst%3DD.%26aulast%3DCrespo%26aufirst%3DP.%26atitle%3DNew%2520druggable%2520targets%2520in%2520the%2520Ras%2520pathway%253F%26jtitle%3DCurr.%2520Opin.%2520Mol.%2520Ther.%26date%3D2010%26volume%3D12%26spage%3D674%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>â <span class="NLM_lpage">655</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+V.+R.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0lhbHndLBaGXXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slupsky, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalmes, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span> <span> </span><span class="NLM_article-title">Active Ras induces heterodimerization of cRaf and BRaf</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3595</span>â <span class="NLM_lpage">3598</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=11325826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsFCgtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3595-3598&author=C.+K.+Weberauthor=J.+R.+Slupskyauthor=H.+A.+Kalmesauthor=U.+R.+Rapp&title=Active+Ras+induces+heterodimerization+of+cRaf+and+BRaf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Active Ras induces heterodimerization of cRaf and BRaf</span></div><div class="casAuthors">Weber, Christoph K.; Slupsky, Joseph R.; Kalmes, H. Andreas; Rapp, Ulf R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3598</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Growth factor-induced signaling leads to activation of members of the Ras family and subsequent stimulation of different Raf isoforms.  Within the mechanism of Raf activation, two isoforms of Raf, cRaf and BRaf, may cooperate.  The authors investigated the relation between cRaf and BRaf and found that active Ras induced heterodimerization of cRaf and BRaf, an effect that was dependent on the serine residue at position 621 of cRaf.  Moreover, the authors also found that cRaf COOH-terminus constitutively assocd. with BRaf, whereas the NH2 terminus did not, even in the presence of active Ras.  These data suggest that Ras induces the cRaf-BRaf complex formation through the exposure of 14-3-3 binding sites in the COOH-terminus of cRaf.  Thus, Ras-induced cRaf-Braf heterodimerization may explain the obsd. cooperativity of cRaf and BRaf in cells responding to growth factor signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZNOGMIko_7Vg90H21EOLACvtfcHk0lhbHndLBaGXXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsFCgtLk%253D&md5=13f7c23245dee7b7ea80b74fba6482b7</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DC.%2BK.%26aulast%3DSlupsky%26aufirst%3DJ.%2BR.%26aulast%3DKalmes%26aufirst%3DH.%2BA.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26atitle%3DActive%2520Ras%2520induces%2520heterodimerization%2520of%2520cRaf%2520and%2520BRaf%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3595%26epage%3D3598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specht, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">806</span>â <span class="NLM_lpage">819</span>, <span class="refDoi">Â DOI: 10.1128/mcb.00569-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.00569-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19933846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslarsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=806-819&author=D.+A.+Rittauthor=D.+M.+Monsonauthor=S.+I.+Spechtauthor=D.+K.+Morrison&title=Impact+of+feedback+phosphorylation+and+Raf+heterodimerization+on+normal+and+mutant+B-Raf+signaling&doi=10.1128%2Fmcb.00569-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8cR"><div class="casContent"><span class="casTitleNuber">8c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling</span></div><div class="casAuthors">Ritt, Daniel A.; Monson, Daniel M.; Specht, Suzanne I.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">806-819</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The B-Raf kinase is a Ras pathway effector activated by mutation in numerous human cancers and certain developmental disorders.  Here we report that normal and oncogenic B-Raf proteins are subject to a regulatory cycle of extracellular signal-regulated kinase (ERK)-dependent feedback phosphorylation, followed by PP2A- and Pin1-dependent dephosphorylation/recycling.  We identify four S/TP sites of B-Raf phosphorylated by activated ERK and find that feedback phosphorylation of B-Raf inhibits binding to activated Ras and disrupts heterodimerization with C-Raf, which is dependent on the B-Raf pS729/14-3-3 binding site.  Moreover, we find that events influencing Raf heterodimerization can alter the transforming potential of oncogenic B-Raf proteins possessing intermediate or impaired kinase activity but have no significant effect on proteins with high kinase activity, such as V600E B-Raf.  Mutation of the feedback sites or overexpression of the Pin1 prolylisomerase, which facilitates B-Raf dephosphorylation/recycling, resulted in increased transformation, whereas mutation of the S729/14-3-3 binding site or expression of dominant neg. Pin1 reduced transformation.  Mutation of each feedback site caused increased transformation and correlated with enhanced heterodimerization and activation of C-Raf.  Finally, we find that B-Raf and C-Raf proteins contg. mutations identified in certain developmental disorders constitutively heterodimerize and that their signaling activity can also be modulated by feedback phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorJLukfx2EmLVg90H21EOLACvtfcHk0lhbHndLBaGXXA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslarsL0%253D&md5=146b72cc196bf1e5904803176845b7a8</span></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1128%2Fmcb.00569-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.00569-09%26sid%3Dliteratum%253Aachs%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMonson%26aufirst%3DD.%2BM.%26aulast%3DSpecht%26aufirst%3DS.%2BI.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DImpact%2520of%2520feedback%2520phosphorylation%2520and%2520Raf%2520heterodimerization%2520on%2520normal%2520and%2520mutant%2520B-Raf%2520signaling%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D806%26epage%3D819%26doi%3D10.1128%2Fmcb.00569-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">Regulation and role of Raf-1/B-Raf heterodimerization</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2262</span>â <span class="NLM_lpage">2272</span>, <span class="refDoi">Â DOI: 10.1128/mcb.26.6.2262-2272.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.26.6.2262-2272.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16508002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2262-2272&author=L.+K.+Rushworthauthor=A.+D.+Hindleyauthor=E.+O%E2%80%99Neillauthor=W.+Kolch&title=Regulation+and+role+of+Raf-1%2FB-Raf+heterodimerization&doi=10.1128%2Fmcb.26.6.2262-2272.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8dR"><div class="casContent"><span class="casTitleNuber">8d</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of Raf-1/B-Raf heterodimerization</span></div><div class="casAuthors">Rushworth, Linda K.; Hindley, Alison D.; O'Neill, Eric; Kolch, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2262-2272</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway participates in the control of many fundamental cellular processes including proliferation, survival, and differentiation.  The pathway is deregulated in up to 30% of human cancers, often due to mutations in Ras and the B-Raf isoform.  Raf-1 and B-Raf can form heterodimers, and this may be important for cellular transformation.  Here, we have analyzed the biochem. and biol. properties of Raf-1/B-Raf heterodimers.  Isolated Raf-1/B-Raf heterodimers possessed a highly increased kinase activity compared to the resp. homodimers or monomers.  Heterodimers between wild-type Raf-1 and B-Raf mutants with low or no kinase activity still displayed elevated kinase activity, as did heterodimers between wild-type B-Raf and kinase-neg. Raf-1.  In contrast, heterodimers contg. both kinase-neg. Raf-1 and kinase-neg. B-Raf were completely inactive, suggesting that the kinase activity of the heterodimer specifically originates from Raf and that either kinase-competent Raf isoform is sufficient to confer high catalytic activity to the heterodimer.  In cell lines, Raf-1/B-Raf heterodimers were found at low levels.  Heterodimerization was enhanced by 14-3-3 proteins and by mitogens independently of ERK.  However, ERK-induced phosphorylation of B-Raf on T753 promoted the disassembly of Raf heterodimers, and the mutation of T753 prolonged growth factor-induced heterodimerization.  The B-Raf T753A mutant enhanced differentiation of PC12 cells, which was previously shown to be dependent on sustained ERK signaling.  Fine mapping of the interaction sites by peptide arrays suggested a complex mode of interaction involving multiple contact sites with a main Raf-1 binding site in B-Raf encompassing T753.  In summary, our data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiol. activation process and that the heterodimer has distinct biochem. properties that may be important for the regulation of some biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4CMv4bNtn7Vg90H21EOLACvtfcHk0lhc1EJsEpQSbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D&md5=2826875a4a2509255bb203ec154be080</span></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1128%2Fmcb.26.6.2262-2272.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.26.6.2262-2272.2006%26sid%3Dliteratum%253Aachs%26aulast%3DRushworth%26aufirst%3DL.%2BK.%26aulast%3DHindley%26aufirst%3DA.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DRegulation%2520and%2520role%2520of%2520Raf-1%252FB-Raf%2520heterodimerization%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D2262%26epage%3D2272%26doi%3D10.1128%2Fmcb.26.6.2262-2272.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagba, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naji, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Hoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorfe, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of high-affinity noncovalent allosteric KRAS Inhibitors that disrupt effector binding</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2921</span>â <span class="NLM_lpage">2930</span>, <span class="refDoi">Â DOI: 10.1021/acsomega.8b03308</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b03308" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1Wqtr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=2921-2930&author=M.+J.+McCarthyauthor=C.+V.+Pagbaauthor=P.+Prakashauthor=A.+K.+Najiauthor=D.+van+der%0AHoevenauthor=H.+Liangauthor=A.+K.+Guptaauthor=Y.+Zhouauthor=K.-J.+Choauthor=J.+F.+Hancockauthor=A.+A.+Gorfe&title=Discovery+of+high-affinity+noncovalent+allosteric+KRAS+Inhibitors+that+disrupt+effector+binding&doi=10.1021%2Facsomega.8b03308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding</span></div><div class="casAuthors">McCarthy, Michael J.; Pagba, Cynthia V.; Prakash, Priyanka; Naji, Ali K.; van der Hoeven, Dharini; Liang, Hong; Gupta, Amit K.; Zhou, Yong; Cho, Kwang-Jin; Hancock, John F.; Gorfe, Alemayehu A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2921-2930</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 15% of all human tumors harbor mutant KRAS, a membrane-assocd. small GTPase and notorious oncogene.  Mutations that render KRAS constitutively active will lead to uncontrolled cell growth and cancer.  However, despite aggressive efforts in recent years, there are no drugs on the market that directly target KRAS and inhibit its aberrant functions.  In the current work, the authors combined structure-based design with a battery of cell and biophys. assays to discover a novel, pyrazolopyrimidine-based allosteric KRAS inhibitor that binds to activated KRAS with sub-micromolar affinity and disrupt effector binding, thereby inhibiting KRAS signaling and cancer cell growth.  These results show that pyrazolopyrimidine-based compds. represent the first-in-class allosteric noncovalent inhibitors of KRAS.  Moreover, by studying two of its analogs, the authors identified key chem. features of the compd. predicted to interact with a set of specific residues at the switch regions of KRAS as crit. for its high affinity binding and unique mode of action, thus providing a blueprint for future optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIVRBvSpzsULVg90H21EOLACvtfcHk0lhc1EJsEpQSbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1Wqtr0%253D&md5=b6178c3ed69407ccbdecc03bfd63c0bf</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b03308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b03308%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BJ.%26aulast%3DPagba%26aufirst%3DC.%2BV.%26aulast%3DPrakash%26aufirst%3DP.%26aulast%3DNaji%26aufirst%3DA.%2BK.%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DD.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DA.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DK.-J.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DGorfe%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520high-affinity%2520noncovalent%2520allosteric%2520KRAS%2520Inhibitors%2520that%2520disrupt%2520effector%2520binding%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D2921%26epage%3D2930%26doi%3D10.1021%2Facsomega.8b03308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertz, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, W. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span> <span> </span><span class="NLM_article-title">A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>472</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">369</span>, <span class="refDoi">Â DOI: 10.1038/nature09860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnature09860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21441910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=472&publication_year=2011&pages=366-369&author=D.+F.+Brennanauthor=A.+C.+Darauthor=N.+T.+Hertzauthor=W.+C.+H.+Chaoauthor=A.+L.+Burlingameauthor=K.+M.+Shokatauthor=D.+Barford&title=A+Raf-induced+allosteric+transition+of+KSR+stimulates+phosphorylation+of+MEK&doi=10.1038%2Fnature09860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK</span></div><div class="casAuthors">Brennan, Damian F.; Dar, Arvin C.; Hertz, Nicholas T.; Chao, William C. H.; Burlingame, Alma L.; Shokat, Kevan M.; Barford, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">472</span>
        (<span class="NLM_cas:issue">7343</span>),
    <span class="NLM_cas:pages">366-369</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In metazoans, the Ras-Raf-MEK (mitogen-activated protein-kinase kinase)-ERK (extracellular signal-regulated kinase) signaling pathway relays extracellular stimuli to elicit changes in cellular function and gene expression.  Aberrant activation of this pathway through oncogenic mutations is responsible for a large proportion of human cancer.  Kinase suppressor of Ras (KSR) functions as an essential scaffolding protein to coordinate the assembly of Raf-MEK-ERK complexes.  Here we integrate structural and biochem. studies to understand how KSR promotes stimulatory Raf phosphorylation of MEK.  We show, from the crystal structure of the kinase domain of human KSR2 (KSR2(KD)) in complex with rabbit MEK1, that interactions between KSR2(KD) and MEK1 are mediated by their resp. activation segments and C-lobe Î±G helixes.  KSR2 self-assocs. through a side-to-side interface involving Arg 718, a residue identified in a genetic screen as a suppressor of Ras signaling.  ATP is bound to the KSR2(KD) catalytic site, and we demonstrate KSR2 kinase activity towards MEK1 by in vitro assays and chem. genetics.  In the KSR2(KD)-MEK1 complex, the activation segments of both kinases are mutually constrained, and KSR2 adopts an inactive conformation.  BRAF allosterically stimulates the kinase activity of KSR2, which is dependent on formation of a side-to-side KSR2-BRAF heterodimer.  Furthermore, KSR2-BRAF heterodimerization results in an increase of BRAF-induced MEK phosphorylation via the KSR2-mediated relay of a signal from BRAF to release the activation segment of MEK for phosphorylation.  We propose that KSR interacts with a regulatory Raf mol. in cis to induce a conformational switch of MEK, facilitating MEK's phosphorylation by a sep. catalytic Raf mol. in trans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjx1SOihPKPrVg90H21EOLACvtfcHk0lhc1EJsEpQSbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVOisb4%253D&md5=05d164517bd5c1625903200d99c699af</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature09860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09860%26sid%3Dliteratum%253Aachs%26aulast%3DBrennan%26aufirst%3DD.%2BF.%26aulast%3DDar%26aufirst%3DA.%2BC.%26aulast%3DHertz%26aufirst%3DN.%2BT.%26aulast%3DChao%26aufirst%3DW.%2BC.%2BH.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBarford%26aufirst%3DD.%26atitle%3DA%2520Raf-induced%2520allosteric%2520transition%2520of%2520KSR%2520stimulates%2520phosphorylation%2520of%2520MEK%26jtitle%3DNature%26date%3D2011%26volume%3D472%26spage%3D366%26epage%3D369%26doi%3D10.1038%2Fnature09860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimmelman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span> <span> </span><span class="NLM_article-title">Drugging the undruggable RAS: mission possible?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">828</span>â <span class="NLM_lpage">851</span>, <span class="refDoi">Â DOI: 10.1038/nrd4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrd4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25323927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=828-851&author=A.+D.+Coxauthor=S.+W.+Fesikauthor=A.+C.+Kimmelmanauthor=J.+Luoauthor=C.+J.+Der&title=Drugging+the+undruggable+RAS%3A+mission+possible%3F&doi=10.1038%2Fnrd4389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the undruggable RAS: Mission Possible?</span></div><div class="casAuthors">Cox, Adrienne D.; Fesik, Stephen W.; Kimmelman, Alec C.; Luo, Ji; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">828-851</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite more than three decades of intensive effort, no effective pharmacol. inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'.  However, recent data from the lab. and the clinic have renewed our hope for the development of RAS-inhibitory mols.  In this Review, we summarize the progress and the promise of five key approaches.  Firstly, we focus on the prospects of using direct inhibitors of RAS.  Secondly, we address the issue of whether blocking RAS membrane assocn. is a viable approach.  Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favorable current approach.  Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise.  Finally, RAS-mediated changes in cell metab. have recently been described and we discuss whether these changes could be exploited for new therapeutic directions.  We conclude with perspectives on how addnl. complexities, which are not yet fully understood, may affect each of these approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvWzW1JqxN4LVg90H21EOLACvtfcHk0liLsoxLGccC_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKmu7zE&md5=6c8645293b079023de7d31011ae1a192</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4389%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DKimmelman%26aufirst%3DA.%2BC.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DDrugging%2520the%2520undruggable%2520RAS%253A%2520mission%2520possible%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D828%26epage%3D851%26doi%3D10.1038%2Fnrd4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francoz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SantamarÃ­a, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">CaÃ±amero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">652</span>â <span class="NLM_lpage">663</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21514245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGls7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=652-663&author=R.+B.+Blascoauthor=S.+Francozauthor=D.+Santamar%C3%ADaauthor=M.+Ca%C3%B1ameroauthor=P.+Dubusauthor=J.+Charronauthor=M.+Baccariniauthor=M.+Barbacid&title=c-Raf%2C+but+Not+B-Raf%2C+Is+Essential+for+Development+of+K-Ras+Oncogene-Driven+Non-Small+Cell+Lung+Carcinoma&doi=10.1016%2Fj.ccr.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma</span></div><div class="casAuthors">Blasco, Rafael B.; Francoz, Sarah; Santamaria, David; Canamero, Marta; Dubus, Pierre; Charron, Jean; Baccarini, Manuela; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-663</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma (NSCLC).  Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells had no significant effect due to compensatory activities.  Yet, elimination of both Erk kinases completely blocked tumor development.  Similar results were obtained with Mek kinases.  Ablation of B-Raf had no significant effect on tumor development.  However, c-Raf expression was absolutely essential for the onset of NSCLC.  Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no deleterious consequences for normal homeostasis.  These results indicate that c-Raf plays a unique role in mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCWweCotG3S7Vg90H21EOLACvtfcHk0liLsoxLGccC_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGls7c%253D&md5=11e9470b124d1c3ba6afe7e930f8438f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DBlasco%26aufirst%3DR.%2BB.%26aulast%3DFrancoz%26aufirst%3DS.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DCa%25C3%25B1amero%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DCharron%26aufirst%3DJ.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3Dc-Raf%252C%2520but%2520Not%2520B-Raf%252C%2520Is%2520Essential%2520for%2520Development%2520of%2520K-Ras%2520Oncogene-Driven%2520Non-Small%2520Cell%2520Lung%2520Carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D652%26epage%3D663%26doi%3D10.1016%2Fj.ccr.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratilas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halilovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">14903</span>â <span class="NLM_lpage">14908</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1008990107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1073%2Fpnas.1008990107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=20668238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=14903-14908&author=E.+W.+Josephauthor=C.+A.+Pratilasauthor=P.+I.+Poulikakosauthor=M.+Tadiauthor=W.+Wangauthor=B.+S.+Taylorauthor=E.+Halilovicauthor=Y.+Persaudauthor=F.+Xingauthor=A.+Vialeauthor=J.+Tsaiauthor=P.+B.+Chapmanauthor=G.+Bollagauthor=D.+B.+Solitauthor=N.+Rosen&title=The+RAF+inhibitor+PLX4032+inhibits+ERK+signaling+and+tumor+cell+proliferation+in+a+V600E+BRAF-selective+manner&doi=10.1073%2Fpnas.1008990107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</span></div><div class="casAuthors">Joseph, Eric W.; Pratilas, Christine A.; Poulikakos, Poulikos I.; Tadi, Madhavi; Wang, Weiqing; Taylor, Barry S.; Halilovic, Ensar; Persaud, Yogindra; Xing, Feng; Viale, Agnes; Tsai, James; Chapman, Paul B.; Bollag, Gideon; Solit, David B.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">14903-14908, S14903/1-S14903/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK) inhibitors.  In contrast, tumor cells with human EGF receptor (HER) kinase activation proliferate in a MEK-independent manner.  These findings have led to the development of RAF and MEK inhibitors as anticancer agents.  Like MEK inhibitors, the RAF inhibitor PLX4032 inhibits the proliferation of BRAFV600E tumor cells but not that of HER kinase-dependent tumors.  However, tumors with RAS mutation that are sensitive to MEK inhibition are insensitive to PLX4032.  MEK inhibitors inhibit ERK phosphorylation in all normal and tumor cells, whereas PLX4032 inhibits ERK signaling only in tumor cells expressing BRAFV600E.  In contrast, the drug activates MEK and ERK phosphorylation in cells with wild-type BRAF.  In BRAFV600E tumor cells, MEK and RAF inhibitors affect the expression of a common set of genes.  PLX4032 inhibits ERK signaling output in mutant BRAF cells, whereas it transiently activates the expression of these genes in tumor cells with wild-type RAF.  Thus, PLX4032 inhibits ERK signaling output in a mutant BRAF-selective manner.  These data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells.  This selectivity may lead to a broader therapeutic index and help explain the greater antitumor activity obsd. with this drug than with MEK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6Gff4DQiprVg90H21EOLACvtfcHk0liLsoxLGccC_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOjsLrP&md5=c5c99b7faca898bd8e4b1d4ae82a5f84</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1008990107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1008990107%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DE.%2BW.%26aulast%3DPratilas%26aufirst%3DC.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DHalilovic%26aufirst%3DE.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DF.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DThe%2520RAF%2520inhibitor%2520PLX4032%2520inhibits%2520ERK%2520signaling%2520and%2520tumor%2520cell%2520proliferation%2520in%2520a%2520V600E%2520BRAF-selective%2520manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D14903%26epage%3D14908%26doi%3D10.1073%2Fpnas.1008990107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caunt, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, S. J.</span></span> <span> </span><span class="NLM_article-title">MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">592</span>, <span class="refDoi">Â DOI: 10.1038/nrc4000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fnrc4000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=26399658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=577-592&author=C.+J.+Cauntauthor=M.+J.+Saleauthor=P.+D.+Smithauthor=S.+J.+Cook&title=MEK1+and+MEK2+inhibitors+and+cancer+therapy%3A+the+long+and+winding+road&doi=10.1038%2Fnrc4000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road</span></div><div class="casAuthors">Caunt, Christopher J.; Sale, Matthew J.; Smith, Paul D.; Cook, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">577-592</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The role of the ERK signaling pathway in cancer is thought to be most prominent in tumors in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival.  New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clin. evaluation.  In this Review, the authors consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity.  The authors discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 vs. BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2.  The authors also consider how some of the systems-level properties (intrapathway regulatory loops and wider signaling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clin. progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnTcSz8CvRcLVg90H21EOLACvtfcHk0li2Ft-cv4m_nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsb%252FO&md5=b1fd44051024a59608dd61310a437c65</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc4000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc4000%26sid%3Dliteratum%253Aachs%26aulast%3DCaunt%26aufirst%3DC.%2BJ.%26aulast%3DSale%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DCook%26aufirst%3DS.%2BJ.%26atitle%3DMEK1%2520and%2520MEK2%2520inhibitors%2520and%2520cancer%2520therapy%253A%2520the%2520long%2520and%2520winding%2520road%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D577%26epage%3D592%26doi%3D10.1038%2Fnrc4000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rebocho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">New Insight Puts CRAF in Sight as a Therapeutic Target: Figure 1</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">98</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1158/2159-8290.cd-11-0118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F2159-8290.cd-11-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22318779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=98-99&author=A.+P.+Rebochoauthor=R.+Marais&title=New+Insight+Puts+CRAF+in+Sight+as+a+Therapeutic+Target%3A+Figure+1&doi=10.1158%2F2159-8290.cd-11-0118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight Puts CRAF in Sight as a Therapeutic Target</span></div><div class="casAuthors">Rebocho, Ana Paula; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-99</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">A review.  By selectively depleting components of the RAF-MEK-ERK pathway in transgenic mice, it is now shown in 2 studies that CRAF is crit. for signaling to MEK downstream of oncogenic Kras and that BRAF is not required.  Cancer Discovery; 1(2); 98-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGown_LK1MCqvbVg90H21EOLACvtfcHk0li2Ft-cv4m_nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D&md5=fc2cd219ee60d00cb7d32a3a83a05e86</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-11-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-11-0118%26sid%3Dliteratum%253Aachs%26aulast%3DRebocho%26aufirst%3DA.%2BP.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DNew%2520Insight%2520Puts%2520CRAF%2520in%2520Sight%2520as%2520a%2520Therapeutic%2520Target%253A%2520Figure%25201%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D98%26epage%3D99%26doi%3D10.1158%2F2159-8290.cd-11-0118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, F.</span></span> <span> </span><span class="NLM_article-title">c-Raf in KRas Mutant Cancers: A Moving Target</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">158</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1016/j.ccell.2018.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccell.2018.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29438690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgtrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=158-159&author=F.+McCormick&title=c-Raf+in+KRas+Mutant+Cancers%3A+A+Moving+Target&doi=10.1016%2Fj.ccell.2018.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">c-Raf in KRas Mutant Cancers: A Moving Target</span></div><div class="casAuthors">McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">158-159</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The research of Sanclemente et al. (Cancer Cell: 33, 217-228) is reviewed with commentary and refs.  Therapies for KRas cancers remain a major clin. need.  C-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZnd5oVueKn7Vg90H21EOLACvtfcHk0li2Ft-cv4m_nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgtrs%253D&md5=f4e5d02e22585051c4fedcff76f81723</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3Dc-Raf%2520in%2520KRas%2520Mutant%2520Cancers%253A%2520A%2520Moving%2520Target%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D158%26epage%3D159%26doi%3D10.1016%2Fj.ccell.2018.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatapuram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a clinical stage multi kinase inhibitor sodium (E)-2-{2-Methoxy-5-[(2â², 4â², 6â²-trimethoxystyrylsulfonyl)methyl] phenylamino- acetate (ON 01910.Na): synthesis, structure activity relationship and biological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6254</span>â <span class="NLM_lpage">6276</span>, <span class="refDoi">Â DOI: 10.1021/jm200570p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200570p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6254-6276&author=M.+V.+R.+Reddyauthor=P.+Venkatapuramauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=S.+C.+Cosenzaauthor=K.+A.+Robellauthor=B.+Akulaauthor=B.+S.+Hoffmanauthor=E.+P.+Reddy&title=Discovery+of+a+clinical+stage+multi+kinase+inhibitor+sodium+%28E%29-2-%7B2-Methoxy-5-%5B%282%E2%80%B2%2C+4%E2%80%B2%2C+6%E2%80%B2-trimethoxystyrylsulfonyl%29methyl%5D+phenylamino-+acetate+%28ON+01910.Na%29%3A+synthesis%2C+structure+activity+relationship+and+biological+activity&doi=10.1021%2Fjm200570p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity</span></div><div class="casAuthors">Reddy, M. V. Ramana; Venkatapuram, Padmavathi; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Cosenza, Stephen C.; Robell, Kimberly A.; Akula, Balaiah; Hoffman, Benjamin S.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6254-6276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer.  Accordingly, there is an increasing awareness of this novel nonenzymic target for cancer therapeutics.  We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells.  The development of styrylbenzylsulfone derivs. followed logically from a tumor cell cytotoxicity screen performed in our lab. that did not have an a priori target profile.  Modifications of some of the precursor mols. led to lead optimization with regard to tumor cell cytotoxicity.  In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (I) (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) assocd. with aberrant expression of cyclin D proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyWp-VIWe7rVg90H21EOLACvtfcHk0li2Ft-cv4m_nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP&md5=216de055e27dc53794018fc1416bc62f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm200570p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200570p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DB.%2BS.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520clinical%2520stage%2520multi%2520kinase%2520inhibitor%2520sodium%2520%2528E%2529-2-%257B2-Methoxy-5-%255B%25282%25E2%2580%25B2%252C%25204%25E2%2580%25B2%252C%25206%25E2%2580%25B2-trimethoxystyrylsulfonyl%2529methyl%255D%2520phenylamino-%2520acetate%2520%2528ON%252001910.Na%2529%253A%2520synthesis%252C%2520structure%2520activity%2520relationship%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6254%26epage%3D6276%26doi%3D10.1021%2Fjm200570p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gumireddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papathi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">275</span>â <span class="NLM_lpage">286</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2005.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ccr.2005.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=15766665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFCqu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=275-286&author=K.+Gumireddyauthor=M.+V.+R.+Reddyauthor=S.+C.+Cosenzaauthor=R.+B.+Nathanauthor=S.+J.+Bakerauthor=N.+Papathiauthor=J.+Jiangauthor=J.+Hollandauthor=E.+P.+Reddy&title=ON01910%2C+a+non-ATP-competitive+small+molecule+inhibitor+of+Plk1%2C+is+a+potent+anticancer+agent&doi=10.1016%2Fj.ccr.2005.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent</span></div><div class="casAuthors">Gumireddy, Kiranmai; Reddy, M. V. Ramana; Cosenza, Stephen C.; Nathan, R. Boomi; Baker, Stacey J.; Papathi, Nabisa; Jiang, Jiandong; Holland, James; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Elevated expression of polo-like kinase-1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results in their mitotic arrest and apoptosis.  Here we describe the profile of ON01910, a small mol. inhibitor of Plk1 activity, which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis.  This compd. was not ATP-competitive, but competed for the substrate binding site of the enzyme.  In vivo, this compd. did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.  ON01910 showed strong synergy with several chemotherapeutic agents, often inducing complete regression of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSUR7gRV8hAbVg90H21EOLACvtfcHk0ljsdjeBgUg6aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFCqu70%253D&md5=d93f0f896b0471550b9c163c175402b8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DNathan%26aufirst%3DR.%2BB.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DPapathi%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DON01910%252C%2520a%2520non-ATP-competitive%2520small%2520molecule%2520inhibitor%2520of%2520Plk1%252C%2520is%2520a%2520potent%2520anticancer%2520agent%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D275%26epage%3D286%26doi%3D10.1016%2Fj.ccr.2005.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ndagi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlongo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soliman, M.</span></span> <span> </span><span class="NLM_article-title">Metal complexes in cancer therapy â an update from drug design perspective</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.2147/dddt.s119488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.2147%2Fdddt.s119488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28424538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=599-616&author=U.+Ndagiauthor=N.+Mhlongoauthor=M.+Soliman&title=Metal+complexes+in+cancer+therapy+%E2%80%93+an+update+from+drug+design+perspective&doi=10.2147%2Fdddt.s119488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Metal complexes in cancer therapy - an update from drug design perspective</span></div><div class="casAuthors">Ndagi, Umar; Mhlongo, Ndumiso; Soliman, Mahmoud E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">599-616</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">In the past, metal-based compds. were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge.  With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compds. used in the treatment of cancers was witnessed.  This forms the foundation for the modern era of the metal-based anticancer drugs.  Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, are the mainstay of the metal-based compds. in the treatment of cancer, but the delay in the therapeutic accomplishment of other metal-based compds. hampered the progress of research in this field.  Recently, however, there has been an upsurge of activities relying on the structural information, aimed at improving and developing other forms of metal-based compds. and nonclassical platinum complexes whose mechanism of action is distinct from known drugs such as cisplatin.  In line with this, many more metal-based compds. have been synthesized by redesigning the existing chem. structure through ligand substitution or building the entire new compd. with enhanced safety and cytotoxic profile.  However, because of increased emphasis on the clin. relevance of metal-based complexes, a few of these drugs are currently on clin. trial and many more are awaiting ethical approval to join the trial.  In this review, we seek to give an overview of previous reviews on the cytotoxic effect of metal-based complexes while focusing more on newly designed metal-based complexes and their cytotoxic effect on the cancer cell lines, as well as on new approach to metal-based drug design and mol. target in cancer therapy.  We are optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrltxUp021QdrVg90H21EOLACvtfcHk0ljsdjeBgUg6aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7bI&md5=3ef5ff6ea1338c3c47fb10901a18c4c8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2147%2Fdddt.s119488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fdddt.s119488%26sid%3Dliteratum%253Aachs%26aulast%3DNdagi%26aufirst%3DU.%26aulast%3DMhlongo%26aufirst%3DN.%26aulast%3DSoliman%26aufirst%3DM.%26atitle%3DMetal%2520complexes%2520in%2520cancer%2520therapy%2520%25E2%2580%2593%2520an%2520update%2520from%2520drug%2520design%2520perspective%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D599%26epage%3D616%26doi%3D10.2147%2Fdddt.s119488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span> <span> </span><span class="NLM_article-title">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kB</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>396</i></span>,  <span class="NLM_fpage">76</span>â <span class="NLM_lpage">84</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.canlet.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28323031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=396&publication_year=2017&pages=76-84&author=T.-S.+Kangauthor=W.+Wangauthor=H.-J.+Zhongauthor=Z.-Z.+Dongauthor=Q.+Huangauthor=S.+W.+F.+Mokauthor=C.-H.+Leungauthor=V.+K.+W.+Wongauthor=D.-L.+Ma&title=An+anti-prostate+cancer+benzofuran-conjugated+iridium%28III%29+complex+as+a+dual+inhibitor+of+STAT3+and+NF-kB&doi=10.1016%2Fj.canlet.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-ÎºB</span></div><div class="casAuthors">Kang, Tian-Shu; Wang, Wanhe; Zhong, Hai-Jing; Dong, Zhen-Zhen; Huang, Qi; Mok, Simon Wing Fai; Leung, Chung-Hang; Wong, Vincent Kam Wai; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">396</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-84</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four benzofuran-conjugated iridium(III) or rhodium (III)-based metal complexes are synthesized to screen as an inhibitor of STAT3 activity in prostate cancer cells.  All complexes show the high stability and soly. in the biol. system.  In this study, an iridium(III) complex engages STAT3 and NF-ÎºB to inhibit their translocation and transcriptional activities.  Moreover, complex 1 shows more potential antiproliferative activity against DU145 cells and suppresses tumor growth in a prostate cancer xenograft mouse without observable adverse effects.  Complex 1 may provide the basis for developing new therapeutic strategy in vivo and in vitro for the treatment of advanced prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGS7qZTHhEVrVg90H21EOLACvtfcHk0ljsdjeBgUg6aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslOnsrk%253D&md5=d410face71ded9bdd70b16ad00eb8b11</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.-S.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DDong%26aufirst%3DZ.-Z.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DLeung%26aufirst%3DC.-H.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.-L.%26atitle%3DAn%2520anti-prostate%2520cancer%2520benzofuran-conjugated%2520iridium%2528III%2529%2520complex%2520as%2520a%2520dual%2520inhibitor%2520of%2520STAT3%2520and%2520NF-kB%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D396%26spage%3D76%26epage%3D84%26doi%3D10.1016%2Fj.canlet.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4756</span>â <span class="NLM_lpage">4763</span>, <span class="refDoi">Â DOI: 10.1039/c7sc00311k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc7sc00311k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28959398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=4756-4763&author=L.-J.+Liuauthor=W.+Wangauthor=S.-Y.+Huangauthor=Y.+Hongauthor=G.+Liauthor=S.+Linauthor=J.+Tianauthor=Z.+Caiauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Inhibition+of+the+Ras%2FRaf+interaction+and+repression+of+renal+cancer+xenografts+in+vivo+by+an+enantiomeric+iridium%28III%29+metal-based+compound&doi=10.1039%2Fc7sc00311k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span></div><div class="casAuthors">Liu, Li-Juan; Wang, Wanhe; Huang, Shi-Ying; Hong, Yanjun; Li, Guodong; Lin, Sheng; Tian, Jinglin; Cai, Zongwei; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4756-4763</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Targeting protein-protein interactions (PPIs) offers tantalizing opportunities for therapeutic intervention for the treatment of human diseases.  Modulating PPI interfaces with org. small mols. has been found to be exceptionally challenging, and few candidates have been successfully developed into clin. drugs.  Meanwhile, the striking array of distinctive properties exhibited by metal compds. renders them attractive scaffolds for the development of bioactive leads.  Here, we report the identification of iridium(III) compds. as inhibitors of the H-Ras/Raf-1 PPI.  The lead iridium(III) compd. 1 exhibited potent inhibitory activity against the H-Ras/Raf-1 interaction and its signaling pathway in vitro and in vivo, and also directly engaged both H-Ras and Raf-1-RBD in cell lysates.  Moreover, 1 repressed tumor growth in a mouse renal xenograft tumor model.  Intriguingly, the Î-enantiomer of 1 showed superior potency in the biol. assays compared to Î-1 or racemic 1.  These compds. could potentially be used as starting scaffolds for the development of more potent Ras/Raf PPI inhibitors for the treatment of kidney cancer or other proliferative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr81r1n5s7wkrVg90H21EOLACvtfcHk0lgcue5ovTGt4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D&md5=b1c8c88211bab7eca780eb33b35dc772</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc7sc00311k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc7sc00311k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-Y.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DInhibition%2520of%2520the%2520Ras%252FRaf%2520interaction%2520and%2520repression%2520of%2520renal%2520cancer%2520xenografts%2520in%2520vivo%2520by%2520an%2520enantiomeric%2520iridium%2528III%2529%2520metal-based%2520compound%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D4756%26epage%3D4763%26doi%3D10.1039%2Fc7sc00311k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span> <span> </span><span class="NLM_article-title">Chirality in metal-based anticancer agents</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4017</span>â <span class="NLM_lpage">4026</span>, <span class="refDoi">Â DOI: 10.1039/c8dt00089a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc8dt00089a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29479608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeltbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=4017-4026&author=Y.+Wangauthor=H.+Huangauthor=Q.+Zhangauthor=P.+Zhang&title=Chirality+in+metal-based+anticancer+agents&doi=10.1039%2Fc8dt00089a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Chirality in metal-based anticancer agents</span></div><div class="casAuthors">Wang, Yi; Huang, Huaiyi; Zhang, Qianling; Zhang, Pingyu</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4017-4026</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Chiral natural biol. mols., such as nucleic acids and proteins, guide the research of chiral compds.  Chiral metal-based drugs are currently an interesting and rapidly growing field in anticancer research.  This perspective focuses on chiral metal compds. with application in cancer chemotherapy.  The different chiral metal-based anticancer agents and the extent to which the chiral resoln. affects their biol. properties are discussed.  This perspective will aid the design of new potent and efficient chiral metal-based anticancer drugs that exploit their unique properties combined with their potential selectivity toward targeted chiral biomols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDzj4YMeZDbVg90H21EOLACvtfcHk0lgcue5ovTGt4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeltbw%253D&md5=1ff36b7b4aa03ae760a0a2da549f67cb</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2Fc8dt00089a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc8dt00089a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DP.%26atitle%3DChirality%2520in%2520metal-based%2520anticancer%2520agents%26jtitle%3DDalton%2520Trans.%26date%3D2018%26volume%3D47%26spage%3D4017%26epage%3D4026%26doi%3D10.1039%2Fc8dt00089a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oun, R.</span></span> <span> </span><span class="NLM_article-title">The status of platinum anticancer drugs in the clinic and in clinical trials</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">8113</span>â <span class="NLM_lpage">8127</span>, <span class="refDoi">Â DOI: 10.1039/c0dt00292e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc0dt00292e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=20593091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8113-8127&author=N.+J.+Wheateauthor=S.+Walkerauthor=G.+E.+Craigauthor=R.+Oun&title=The+status+of+platinum+anticancer+drugs+in+the+clinic+and+in+clinical+trials&doi=10.1039%2Fc0dt00292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The status of platinum anticancer drugs in the clinic and in clinical trials</span></div><div class="casAuthors">Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">8113-8127</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas, myelomas and melanoma.  Unfortunately its continued use is greatly limited by severe dose limiting side effects and intrinsic or acquired drug resistance.  Over the last 30 years, 23 other platinum-based drugs have entered clin. trials with only two (carboplatin and oxaliplatin) of these gaining international marketing approval, and another three (nedaplatin, lobaplatin and heptaplatin) gaining approval in individual nations.  During this time there have been more failures than successes with the development of 14 drugs being halted during clin. trials.  Currently there are four drugs in the various phases of clin. trial (satraplatin, picoplatin, Lipoplatin and ProLindac).  No new small mol. platinum drug has entered clin. trials since 1999 which is representative of a shift in focus away from drug design and towards drug delivery in the last decade.  In this perspective article we update the status of platinum anticancer drugs currently approved for use, those undergoing clin. trials and those discontinued during clin. trials, and discuss the results in the context of where we believe the field will develop over the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqSuqxBzUTjbVg90H21EOLACvtfcHk0lgcue5ovTGt4w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOhsrnO&md5=bfa2fef3a7c3c4a3122a0fa60e45f804</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2Fc0dt00292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0dt00292e%26sid%3Dliteratum%253Aachs%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26aulast%3DWalker%26aufirst%3DS.%26aulast%3DCraig%26aufirst%3DG.%2BE.%26aulast%3DOun%26aufirst%3DR.%26atitle%3DThe%2520status%2520of%2520platinum%2520anticancer%2520drugs%2520in%2520the%2520clinic%2520and%2520in%2520clinical%2520trials%26jtitle%3DDalton%2520Trans.%26date%3D2010%26volume%3D39%26spage%3D8113%26epage%3D8127%26doi%3D10.1039%2Fc0dt00292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florea, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¼sselberg, D.</span></span> <span> </span><span class="NLM_article-title">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1351</span>â <span class="NLM_lpage">1371</span>, <span class="refDoi">Â DOI: 10.3390/cancers3011351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.3390%2Fcancers3011351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=24212665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1351-1371&author=A.-M.+Floreaauthor=D.+B%C3%BCsselberg&title=Cisplatin+as+an+anti-tumor+drug%3A+cellular+mechanisms+of+activity%2C+drug+resistance+and+induced+side+effects&doi=10.3390%2Fcancers3011351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span></div><div class="casAuthors">Florea, Ana-Maria; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1351-1371</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Platinum complexes are clin. used as adjuvant therapy of cancers aiming to induce tumor cell death.  Depending on cell type and concn., cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms.  Addnl., cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways.  Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression.  Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochem. mechanism of action.  While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant.  Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair.  To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers.  Thus, understanding of the biochem. mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7eCBHQ5T5rVg90H21EOLACvtfcHk0lgNhy0qaeqcuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D&md5=368b8ef25e06a41747ec0940872966b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3390%2Fcancers3011351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3011351%26sid%3Dliteratum%253Aachs%26aulast%3DFlorea%26aufirst%3DA.-M.%26aulast%3DB%25C3%25BCsselberg%26aufirst%3DD.%26atitle%3DCisplatin%2520as%2520an%2520anti-tumor%2520drug%253A%2520cellular%2520mechanisms%2520of%2520activity%252C%2520drug%2520resistance%2520and%2520induced%2520side%2520effects%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26spage%3D1351%26epage%3D1371%26doi%3D10.3390%2Fcancers3011351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabik, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance and toxicity associated with platinating agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.ctrv.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ctrv.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17084534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=9-23&author=C.+A.+Rabikauthor=M.+E.+Dolan&title=Molecular+mechanisms+of+resistance+and+toxicity+associated+with+platinating+agents&doi=10.1016%2Fj.ctrv.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance and toxicity associated with platinating agents</span></div><div class="casAuthors">Rabik, Cara A.; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Platinating agents, including cisplatin, carboplatin, and oxaliplatin, have been used clin. for nearly 30 years as part of the treatment of many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma.  The cytotoxic lesion of platinating agents is thought to be the platinum intrastrand crosslink that forms on DNA, although treatment activates a no. of signal transduction pathways.  Treatment with these agents is characterized by resistance, both acquired and intrinsic.  This resistance can be caused by a no. of cellular adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and increased levels of DNA repair or DNA tolerance.  Here we investigate the pathways that treatment with platinating agents activate, the mechanisms of resistance, potential candidate genes involved in the development of resistance, and assocd. clin. toxicities.  Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclin. data that has clin. relevance generated over the past five years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxn13FCg9DbVg90H21EOLACvtfcHk0lgNhy0qaeqcuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D&md5=9d5cc75e635b074a03a11c2f67c7914b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRabik%26aufirst%3DC.%2BA.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520and%2520toxicity%2520associated%2520with%2520platinating%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D9%26epage%3D23%26doi%3D10.1016%2Fj.ctrv.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanellato, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fregonese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelosi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platts, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative activity of a series of cisplatinbased Pt(IV)-acetylamido/carboxylato prodrugs</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5300</span>â <span class="NLM_lpage">5309</span>, <span class="refDoi">Â DOI: 10.1039/c5dt04905a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc5dt04905a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=26903367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1agur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=5300-5309&author=M.+Raveraauthor=E.+Gabanoauthor=I.+Zanellatoauthor=F.+Fregoneseauthor=G.+Pelosiauthor=J.+A.+Plattsauthor=D.+Osella&title=Antiproliferative+activity+of+a+series+of+cisplatinbased+Pt%28IV%29-acetylamido%2Fcarboxylato+prodrugs&doi=10.1039%2Fc5dt04905a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs</span></div><div class="casAuthors">Ravera, Mauro; Gabano, Elisabetta; Zanellato, Ilaria; Fregonese, Federico; Pelosi, Giorgio; Platts, James A.; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5300-5309</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The authors report studies of a novel series of Pt(IV) complexes exhibiting an asym. combination of acetylamido and carboxylato ligands in the axial positions.  The authors demonstrate efficient synthesis of a series of analogs, differing in the alkyl chain length and hence lipophilicity, from a stable acetylamido/hydroxido complex formed by reaction of cisplatin with peroxyacetimidic acid (PAIA).  NMR spectroscopy and x-ray crystallog. confirm the identity of the resulting complexes, and highlight subtle differences in the structure and stability of acetylamido complexes compared to the equiv. acetato complexes.  Redn. of acetylamido complexes, whether achieved chem. or electro-chem., is significantly more difficult than that of acetate complexes, resulting in lower antiproliferative activity for shorter-chain complexes.  For those with longer chains and hence greater cell uptake, this difference is negated and acetylamido complexes are as active as acetato analogs, both exhibiting antiproliferative potency (1/IC50) against A2780 ovarian cancer cells similar to that of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeDevbWiPRS7Vg90H21EOLACvtfcHk0lgNhy0qaeqcuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1agur4%253D&md5=f19910d04a38e1701fedfdb48a71b7d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1039%2Fc5dt04905a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc5dt04905a%26sid%3Dliteratum%253Aachs%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DZanellato%26aufirst%3DI.%26aulast%3DFregonese%26aufirst%3DF.%26aulast%3DPelosi%26aufirst%3DG.%26aulast%3DPlatts%26aufirst%3DJ.%2BA.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DAntiproliferative%2520activity%2520of%2520a%2520series%2520of%2520cisplatinbased%2520Pt%2528IV%2529-acetylamido%252Fcarboxylato%2520prodrugs%26jtitle%3DDalton%2520Trans.%26date%3D2016%26volume%3D45%26spage%3D5300%26epage%3D5309%26doi%3D10.1039%2Fc5dt04905a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of cisplatin resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>â <span class="NLM_lpage">1883</span>, <span class="refDoi">Â DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+mechanisms+of+cisplatin+resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0lgNhy0qaeqcuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520mechanisms%2520of%2520cisplatin%2520resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Chalcoplatin, a dual-targeting and p53 activator-containing anticancer Pt(IV) prodrug with unique mode of action</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6301</span>â <span class="NLM_lpage">6304</span>, <span class="refDoi">Â DOI: 10.1039/c4cc10409a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1039%2Fc4cc10409a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=25644651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslelsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=6301-6304&author=L.+Maauthor=R.+Maauthor=Y.+Wangauthor=X.+Zhuauthor=J.+Zhangauthor=H.+C.+Chanauthor=X.+Chenauthor=W.+Zhangauthor=S.-K.+Chiuauthor=G.+Zhu&title=Chalcoplatin%2C+a+dual-targeting+and+p53+activator-containing+anticancer+Pt%28IV%29+prodrug+with+unique+mode+of+action&doi=10.1039%2Fc4cc10409a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action</span></div><div class="casAuthors">Ma, Lili; Ma, Rong; Wang, Yiping; Zhu, Xiaoyue; Zhang, Junliang; Chan, Hoi Ching; Chen, Xianfeng; Zhang, Wenjun; Chiu, Sung-Kay; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">6301-6304</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells.  Mechanistic investigation was carried out on this dual-targeting Pt(IV) prodrug, chalcoplatin.  The prodrug effectively entered cancer cells and arrested the cell cycle at the S and G2/M phases, distinctive of that from cisplatin.  Chalcoplatin significantly induced p53 activation as well as the subsequent apoptosis pathways.  This unique mode of action renders chalcoplatin remarkably cytotoxic and makes this compd. among the first examples of a Pt(IV) prodrug that directly interacts with the downstream pathway after the formation of Pt-DNA lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5te1PhnZbxLVg90H21EOLACvtfcHk0lgD-O9EHaulOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslelsr8%253D&md5=19b60de49f0552793f3e87ca8f2efa16</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc4cc10409a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4cc10409a%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DChiu%26aufirst%3DS.-K.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DChalcoplatin%252C%2520a%2520dual-targeting%2520and%2520p53%2520activator-containing%2520anticancer%2520Pt%2528IV%2529%2520prodrug%2520with%2520unique%2520mode%2520of%2520action%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D6301%26epage%3D6304%26doi%3D10.1039%2Fc4cc10409a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, R. T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2546</span>â <span class="NLM_lpage">2554</span>, <span class="refDoi">Â DOI: 10.1021/ja411811w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja411811w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslarsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=2546-2554&author=Y.+Yuanauthor=R.+T.+K.+Kwokauthor=B.+Z.+Tangauthor=B.+Liu&title=Targeted+theranostic+platinum%28IV%29+prodrug+with+a+built-in+aggregation-induced+emission+light-up+apoptosis+sensor+for+noninvasive+early+evaluation+of+its+therapeutic+responses+in+situ&doi=10.1021%2Fja411811w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Theranostic Platinum(IV) Prodrug with a Built-In Aggregation-Induced Emission Light-Up Apoptosis Sensor for Noninvasive Early Evaluation of Its Therapeutic Responses in Situ</span></div><div class="casAuthors">Yuan, Youyong; Kwok, Ryan T. K.; Tang, Ben Zhong; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2546-2554</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted drug delivery to tumor cells with minimized side effects and real-time in situ monitoring of drug efficacy is highly desirable for personalized medicine.  In this work, we report the synthesis and biol. evaluation of a chemotherapeutic Pt(IV) prodrug whose two axial positions are functionalized with a cyclic arginine-glycine-aspartic acid (cRGD) tripeptide for targeting integrin Î±vÎ²3 overexpressed cancer cells and an apoptosis sensor which is composed of tetraphenylsilole (TPS) fluorophore with aggregation-induced emission (AIE) characteristics and a caspase-3 enzyme specific Asp-Glu-Val-Asp (DEVD) peptide.  The targeted Pt(IV) prodrug can selectively bind to Î±vÎ²3 integrin overexpressed cancer cells to facilitate cellular uptake.  In addn., the Pt(IV) prodrug can be reduced to active Pt(II) drug in cells and release the apoptosis sensor TPS-DEVD simultaneously.  The reduced Pt(II) drug can induce the cell apoptosis and activate caspase-3 enzyme to cleave the DEVD peptide sequence.  Due to free rotation of the phenylene rings, TPS-DEVD is nonemissive in aq. media.  The specific cleavage of DEVD by caspase-3 generates the hydrophobic TPS residue, which tends to aggregate, resulting in restriction of intramol. rotations of the Ph rings and ultimately leading to fluorescence enhancement.  Such noninvasive and real-time imaging of drug-induced apoptosis in situ can be used as an indicator for early evaluation of the therapeutic responses of a specific anticancer drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcarQMtyRDprVg90H21EOLACvtfcHk0lgD-O9EHaulOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslarsQ%253D%253D&md5=722226adf51710b50744cdbb6ea35565</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja411811w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja411811w%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DKwok%26aufirst%3DR.%2BT.%2BK.%26aulast%3DTang%26aufirst%3DB.%2BZ.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DTargeted%2520theranostic%2520platinum%2528IV%2529%2520prodrug%2520with%2520a%2520built-in%2520aggregation-induced%2520emission%2520light-up%2520apoptosis%2520sensor%2520for%2520noninvasive%2520early%2520evaluation%2520of%2520its%2520therapeutic%2520responses%2520in%2520situ%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D2546%26epage%3D2554%26doi%3D10.1021%2Fja411811w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ammar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveendran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benita, S.</span></span> <span> </span><span class="NLM_article-title">A lipophilic Pt(IV) oxaliplatin derivative enhances antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9035</span>â <span class="NLM_lpage">9046</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00955</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00955" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9035-9046&author=A.+A.+Ammarauthor=R.+Raveendranauthor=D.+Gibsonauthor=T.+Nassarauthor=S.+Benita&title=A+lipophilic+Pt%28IV%29+oxaliplatin+derivative+enhances+antitumor+activity&doi=10.1021%2Facs.jmedchem.6b00955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00955%26sid%3Dliteratum%253Aachs%26aulast%3DAmmar%26aufirst%3DA.%2BA.%26aulast%3DRaveendran%26aufirst%3DR.%26aulast%3DGibson%26aufirst%3DD.%26aulast%3DNassar%26aufirst%3DT.%26aulast%3DBenita%26aufirst%3DS.%26atitle%3DA%2520lipophilic%2520Pt%2528IV%2529%2520oxaliplatin%2520derivative%2520enhances%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9035%26epage%3D9046%26doi%3D10.1021%2Facs.jmedchem.6b00955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">211</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.09.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.09.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29031068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=211-220&author=Z.+Xuauthor=W.+Huauthor=Z.+Wangauthor=S.+Gou&title=Platinum%28IV%29+prodrugs+multiply+targeting+genomic+DNA%2C+histone+deacetylases+and+PARP-1&doi=10.1016%2Fj.ejmech.2017.09.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1</span></div><div class="casAuthors">Xu, Zichen; Hu, Weiwei; Wang, Zhimei; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">211-220</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Several Pt(IV) prodrugs contg. SAA, a histone deacetylases inhibitor, were designed and prepd. for multiply targeting genomic DNA, histone deacetylases and PARP-1.  The resulting Pt(IV) prodrug had significantly strong antiproliferative activity against the tested cancer cell lines, esp. SAA1, derived from the conjugation of cisplatin and SAA, had potent ability to overcome cisplatin resistance.  Under the combined action of DNA platination and inhibition of HDACs and PARP-1 activity, the cytotoxic activity of SAA1 was 174-fold higher than cisplatin against cisplatin-resistant SGC7901/CDDP cancer cells.  The mechanism of action of SAA1 was preliminarily investigated, in which cellular uptake, cell apoptosis and cell cycle arrest as well as western blot anal. were made by treating SAA1 with SGC7901/CDDP cells.  Besides, HDACs inhibition activity and PARP-1 enzyme inhibition of SAA1 were also studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpassqM0HVpH7Vg90H21EOLACvtfcHk0lgD-O9EHaulOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrnJ&md5=87982d0f22d37dc9d13628a44d0e2703</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.074%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DPlatinum%2528IV%2529%2520prodrugs%2520multiply%2520targeting%2520genomic%2520DNA%252C%2520histone%2520deacetylases%2520and%2520PARP-1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D211%26epage%3D220%26doi%3D10.1016%2Fj.ejmech.2017.09.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BarnÃ©s, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haskel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">39</span>â <span class="NLM_lpage">49</span>, <span class="refDoi">Â DOI: 10.1021/bc070031k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc070031k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=39-49&author=S.+Mukhopadhyayauthor=C.+M.+Barn%C3%A9sauthor=A.+Haskelauthor=S.+M.+Shortauthor=K.+R.+Barnesauthor=S.+J.+Lippard&title=Conjugated+platinum%28IV%29-peptide+complexes+for+targeting+angiogenic+tumor+vasculature&doi=10.1021%2Fbc070031k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature</span></div><div class="casAuthors">Mukhopadhyay, Sumitra; Barnes, Carmen M.; Haskel, Ariel; Short, Sarah M.; Barnes, Katie R.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-49</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The integrins Î±vÎ²3 and Î±vÎ²5 and the membrane-spanning surface protein aminopeptidase N (APN) are highly expressed in tumor-induced angiogenesis, making them attractive targets for therapeutic intervention.  Both integrins and APN recognize a broad range of peptides contg. RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) motifs, resp.  Here, we describe the design, synthesis, and characterization of a series of mono- and difunctionalized platinum(IV) complexes in which a conjugated peptide motif, contg. RGD, (CRGDC)c, (RGDfK)c, or NGR, is appended as a "tumor-homing device" to target tumor endothelial cells selectively over healthy cells. Platinum(IV)-peptide complexes with nonspecific amino acids or peptide moieties were prepd. as controls.  Concn.-response curves of these compds. were evaluated against primary proliferating endothelial cells and tumor cell lines and compared to those of cisplatin, a well-described platinum-based chemotherapeutic agent.  The Pt(IV)-RGD conjugates were highly and specifically cytotoxic to cell lines contg. Î±vÎ²3 and Î±vÎ²5, approaching the activity of cisplatin.  The Pt(IV)-NGR complexes were less active than Pt(IV)-RGD-contg. compds. but more active than nonspecific Pt-peptide controls.  Integrin Î±vÎ²3 mediated, at least in part, the anti-proliferative effect of a Pt(IV)-RGD conjugate, as demonstrated by a decreased inhibitory response when endothelial cells were either (1) incubated with an excess of Î±vÎ²3/Î±vÎ²5-specific RGD pentapeptides or (2) transfected with RNAi for Î²3, but not Î²1, integrins.  These results suggest a rational approach to improved chemotherapy with Pt(IV)-peptide conjugates by selective drug delivery to the tumor compartment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl92LLNxja-rVg90H21EOLACvtfcHk0liTx0ezhio9eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVWhtbzJ&md5=d12897f15d2582321ee037868e81c87c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fbc070031k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc070031k%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DBarn%25C3%25A9s%26aufirst%3DC.%2BM.%26aulast%3DHaskel%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DBarnes%26aufirst%3DK.%2BR.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DConjugated%2520platinum%2528IV%2529-peptide%2520complexes%2520for%2520targeting%2520angiogenic%2520tumor%2520vasculature%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D39%26epage%3D49%26doi%3D10.1021%2Fbc070031k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Construction of dual stimuli-responsive platinum(IV) hybrids with NQO1 targeting ability and overcoming cisplatin resistance</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2191</span>â <span class="NLM_lpage">2200</span>, <span class="refDoi">Â DOI: 10.1021/acs.inorgchem.8b03386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.8b03386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12qs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2191-2200&author=L.+Fangauthor=X.+Qinauthor=J.+Zhaoauthor=S.+Gou&title=Construction+of+dual+stimuli-responsive+platinum%28IV%29+hybrids+with+NQO1+targeting+ability+and+overcoming+cisplatin+resistance&doi=10.1021%2Facs.inorgchem.8b03386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance</span></div><div class="casAuthors">Fang, Lei; Qin, Xiaodong; Zhao, Jian; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2191-2200</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quinone oxidoreductase isoenzyme I (NQO1) is a cytoprotective two-electron-specific reductase that highly expresses in various cancer cells.  Taking NQO1 as the target, we herein report three hybrid compds. from Pt(IV) complexes and a quinone propionic acid unit.  The mechanism studies showed that the hybrids could be activated by both NQO1 and ascorbic acid to release the cytotoxic Pt(II) unit, exhibiting a dual stimuli-responsive character.  In the pharmacol. studies, complexes 2 and 3 presented higher antitumor activity than cisplatin.  More importantly, the hybrid could also overcome cisplatin resistance due to the NQO1 targeting ability, improved cellular uptake, and/or different action mechanism.  Significantly, complex 3 contg. a coumarin moiety could be effectively activated in NQO1-overexpressed cancer cells to "turn on" fluorescence, showing a promising visual effect in cancer cells.  In vivo study revealed that both 2 and 3 exhibited higher antitumor efficacy than cisplatin in the A549 xenograft mouse model at an equimolar dose to cisplatin.  In all, the hybrids may serve as promising NQO1-targeting anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmTZGLtzJprVg90H21EOLACvtfcHk0liTx0ezhio9eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12qs7s%253D&md5=a85adfa507e6e09031d51218ef6e7326</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.8b03386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.8b03386%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DConstruction%2520of%2520dual%2520stimuli-responsive%2520platinum%2528IV%2529%2520hybrids%2520with%2520NQO1%2520targeting%2520ability%2520and%2520overcoming%2520cisplatin%2520resistance%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D2191%26epage%3D2200%26doi%3D10.1021%2Facs.inorgchem.8b03386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Conjugation of Pt(IV) complexes with chlorambucil to overcome cisplatin resistance via a â³joint actionâ³ mode toward DNA</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.05.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.05.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=28586717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2017&pages=167-175&author=X.+Qinauthor=L.+Fangauthor=F.+Chenauthor=S.+Gou&title=Conjugation+of+Pt%28IV%29+complexes+with+chlorambucil+to+overcome+cisplatin+resistance+via+a+%E2%80%B3joint+action%E2%80%B3+mode+toward+DNA&doi=10.1016%2Fj.ejmech.2017.05.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA</span></div><div class="casAuthors">Qin, Xiaodong; Fang, Lei; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Two platinum(IV) complexes were designed and prepd. by conjugation of cisplatin and oxaliplatin units with a DNA-damaging agent, chlorambucil, resp.  By taking a joint action to enhance the damage of DNA, the conjugates displayed potent antitumor activity against all the tested cancer cell lines comparable to cisplatin and oxaliplatin, and notably could overcome cisplatin resistance at certain degree.  Complex [Pt(NH3)2Cl2(OCO(CH2)3-p-C6H4-N(CH2CH2Cl)2)] (I), a hybrid of cisplatin and chlorambucil, arrested the cell cycle at the S and G2 phases, distinctive from those of cisplatin and oxaliplatin.  Apoptosis studies revealed that complex 4 could induce cell apoptosis significantly in both SGC7901 and SGC7901/CDDP cells.  Moreover, further investigation indicated that complex I suppressed the drug resistance by the improvement of the platinum uptake and the inhibition of PARP-1 protein.  These results show that the "joint action" on DNA is an effective strategy to overcome cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovGAma6fthdLVg90H21EOLACvtfcHk0liTx0ezhio9eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmt73P&md5=c1bfa5b72c30b2df08d4124b8bd34f44</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.056%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DConjugation%2520of%2520Pt%2528IV%2529%2520complexes%2520with%2520chlorambucil%2520to%2520overcome%2520cisplatin%2520resistance%2520via%2520a%2520%25E2%2580%25B3joint%2520action%25E2%2580%25B3%2520mode%2520toward%2520DNA%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D137%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.ejmech.2017.05.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>â <span class="NLM_lpage">2148</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+a+dual-targeting+and+tubulin+inhibitor+containing+antitumor+Pt%28IV%29+moiety+with+a+unique+mode+of+action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0lj0sFGoLR_qFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520a%2520dual-targeting%2520and%2520tubulin%2520inhibitor%2520containing%2520antitumor%2520Pt%2528IV%2529%2520moiety%2520with%2520a%2520unique%2520mode%2520of%2520action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lien, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-F.</span></span> <span> </span><span class="NLM_article-title">Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">385</span>â <span class="NLM_lpage">395</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2012.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.bcp.2012.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=23142712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnu7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=385-395&author=C.-C.+Hsuauthor=J.-C.+Lienauthor=C.-W.+Changauthor=C.-H.+Changauthor=S.-C.+Kuoauthor=T.-F.+Huang&title=Yuwen02f1+suppresses+LPS-induced+endotoxemia+and+adjuvant-induced+arthritis+primarily+through+blockade+of+ROS+formation%2C+NFkB+and+MAPK+activation&doi=10.1016%2Fj.bcp.2012.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFkB and MAPK activation</span></div><div class="casAuthors">Hsu, Chun-Chieh; Lien, Jin-Cherng; Chang, Chia-Wen; Chang, Chien-Hsin; Kuo, Sheng-Chu; Huang, Tur-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">385-395</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phagocytes release inflammatory mediators to defense harmful stimuli upon bacterial invasion, however, excessive inflammatory reaction leads to tissue damage and manifestation of pathol. states.  Therefore, targeting on uncontrolled inflammation seems feasible to control numerous inflammation-assocd. diseases.  Under the drug screening process of synthetic diphenylpyrazole derivs., we discovered compd. yuwen02f1 possesses anti-inflammatory effects in decreasing the release of pro-inflammatory cytokines including TNFÎ± and IL-6, nitric oxide, reactive oxygen species (ROS) as well as inhibiting migration of LPS-stimulated phagocytes.  In addn., we obsd. that the mol. mechanism of yuwen02f1-mediated anti-inflammation is assocd. with decreasing phosphorylation of MAPK mols. including ERK1/2, JNK and p38, and attenuating translocation of p47phox and p67phox to the cell membrane.  Yuwen02f1 also reverses IÎºBÎ± degrdn. and attenuates the expression of NFÎºB-related downstream inducible enzymes like iNOS and COX-2.  Furthermore, we found that yuwen02f1 attenuates some pathol. syndromes of LPS-induced sepsis and adjuvant-induced arthritis in mice, as evidenced by decreasing the cytokine prodn., reversing thrombocytopenic syndrome, protecting the mice from tissue injury in septic mice, and attenuating paw edema in arthritic mice as well.  These results suggest that yuwen02f1 is a potential anti-inflammatory agent for alleviating syndromes of acute and chronic inflammatory diseases as evidenced by attenuating the generation of cytokines and down-regulating the expression of iNOS and COX-2 through the blockade of ROS generation and NADPH oxidase, NFÎºB and MAPK activation pathways in LPS-stimulated phagocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0PHxiILK5XrVg90H21EOLACvtfcHk0lj0sFGoLR_qFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnu7jK&md5=ed0d620f43912d7c37ec04cf5279cb72</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DC.-C.%26aulast%3DLien%26aufirst%3DJ.-C.%26aulast%3DChang%26aufirst%3DC.-W.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DKuo%26aufirst%3DS.-C.%26aulast%3DHuang%26aufirst%3DT.-F.%26atitle%3DYuwen02f1%2520suppresses%2520LPS-induced%2520endotoxemia%2520and%2520adjuvant-induced%2520arthritis%2520primarily%2520through%2520blockade%2520of%2520ROS%2520formation%252C%2520NFkB%2520and%2520MAPK%2520activation%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D385%26epage%3D395%26doi%3D10.1016%2Fj.bcp.2012.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1021</span>â <span class="NLM_lpage">1027</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2017.11.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ejmech.2017.11.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=29232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1021-1027&author=K.-J.+Wuauthor=H.-J.+Zhongauthor=G.+Liauthor=C.+Liuauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Structure-based+identification+of+a+NEDD8-activating+enzyme+inhibitor+via+drug+repurposing&doi=10.1016%2Fj.ejmech.2017.11.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34cR"><div class="casContent"><span class="casTitleNuber">34c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing</span></div><div class="casAuthors">Wu, Ke-Jia; Zhong, Hai-Jing; Li, Guodong; Liu, Chenfu; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1021-1027</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">NEDD8-activating enzyme (NAE) is an essential player of the NEDD8 conjugation pathway that regulates protein degrdn.  Meanwhile, drug repurposing is a cost-efficient strategy to identify new therapeutic uses for existing scaffolds.  In this report, mitoxantrone (1) was repurposed as an inhibitor of NAE by virtual screening of an FDA-approved drug database.  Compd. 1 inhibited NAE activity in cell-free and cell-based systems with high selectivity and was competitive with ATP.  Furthermore, compd. 1 induced apoptosis of colorectal adenocarcinoma cancer cells through inhibiting the degrdn. of the neddylation substrate p53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUAq1axDoEP7Vg90H21EOLACvtfcHk0lj0sFGoLR_qFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsr3I&md5=c9d129e8a7887bcdc3e77cdc27e4fdbf</span></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.101%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.-J.%26aulast%3DZhong%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DStructure-based%2520identification%2520of%2520a%2520NEDD8-activating%2520enzyme%2520inhibitor%2520via%2520drug%2520repurposing%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2Fj.ejmech.2017.11.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span> <span> </span><span class="NLM_article-title">Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">999</span>â <span class="NLM_lpage">1014</span>, <span class="refDoi">Â DOI: 10.1080/15548627.2016.1166318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1080%2F15548627.2016.1166318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=27124102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVWgsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=999-1014&author=Q.+Huangauthor=L.+Zhanauthor=H.+Caoauthor=J.+Liauthor=Y.+Lyuauthor=X.+Guoauthor=J.+Zhangauthor=L.+Jiauthor=T.+Renauthor=J.+Anauthor=B.+Liuauthor=Y.+Nieauthor=J.+Xing&title=Increased+mitochondrial+fission+promotes+autophagy+and+hepatocellular+carcinoma+cell+survival+through+the+ROS-modulated+coordinated+regulation+of+the+NFKB+and+TP53+pathways&doi=10.1080%2F15548627.2016.1166318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34dR"><div class="casContent"><span class="casTitleNuber">34d</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways</span></div><div class="casAuthors">Huang, Qichao; Zhan, Lei; Cao, Haiyan; Li, Jibin; Lyu, Yinghua; Guo, Xu; Zhang, Jing; Ji, Lele; Ren, Tingting; An, Jiaze; Liu, Bingrong; Nie, Yongzhan; Xing, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">999-1014</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Mitochondrial morphol. is dynamically remodeled by fusion and fission in cells, and dysregulation of this process is closely implicated in tumorigenesis.  However, the mechanism by which mitochondrial dynamics influence cancer cell survival is considerably less clear, esp. in hepatocellular carcinoma (HCC).  In this study, we systematically investigated the alteration of mitochondrial dynamics and its functional role in the regulation of autophagy and HCC cell survival.  Furthermore, the underlying mol. mechanisms and therapeutic application were explored in depth.  Mitochondrial fission was frequently upregulated in HCC tissues mainly due to an elevated expression ratio of DNM1L to MFN1, which significantly contributed to poor prognosis of HCC patients.  Increased mitochondrial fission by forced expression of DNM1L or knockdown of MFN1 promoted the survival of HCC cells both in vitro and in vivo mainly by facilitating autophagy and inhibiting mitochondria-dependent apoptosis.  We further demonstrated that the survival-promoting role of increased mitochondrial fission was mediated via elevated ROS prodn. and subsequent activation of AKT, which facilitated MDM2-mediated TP53 degrdn., and NFKBIA- and IKK-mediated transcriptional activity of NFKB in HCC cells.  Also, a crosstalk between TP53 and NFKB pathways was involved in the regulation of mitochondrial fission-mediated cell survival.  Moreover, treatment with mitochondrial division inhibitor-1 significantly suppressed tumor growth in an in vivo xenograft nude mice model.  Our findings demonstrate that increased mitochondrial fission plays a crit. role in regulation of HCC cell survival, which provides a strong evidence for this process as drug target in HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfIjpHitJclbVg90H21EOLACvtfcHk0lifm0muQLNzqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVWgsbc%253D&md5=944ea7dc2bf6d7b43ffe54a44656bf42</span></div><a href="/servlet/linkout?suffix=cit34d&amp;dbid=16384&amp;doi=10.1080%2F15548627.2016.1166318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2016.1166318%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLyu%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DNie%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DJ.%26atitle%3DIncreased%2520mitochondrial%2520fission%2520promotes%2520autophagy%2520and%2520hepatocellular%2520carcinoma%2520cell%2520survival%2520through%2520the%2520ROS-modulated%2520coordinated%2520regulation%2520of%2520the%2520NFKB%2520and%2520TP53%2520pathways%26jtitle%3DAutophagy%26date%3D2016%26volume%3D12%26spage%3D999%26epage%3D1014%26doi%3D10.1080%2F15548627.2016.1166318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nishanth, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jyotsna, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlager, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddanna, P.</span></span> <span> </span><span class="NLM_article-title">Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFÎºB signaling pathway</span>. <i>Nanotoxicology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">502</span>â <span class="NLM_lpage">516</span>, <span class="refDoi">Â DOI: 10.3109/17435390.2010.541604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.3109%2F17435390.2010.541604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=21417802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1egurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=502-516&author=R.+P.+Nishanthauthor=R.+G.+Jyotsnaauthor=J.+J.+Schlagerauthor=S.+M.+Hussainauthor=P.+Reddanna&title=Inflammatory+responses+of+RAW+264.7+macrophages+upon+exposure+to+nanoparticles%3A+role+of+ROS-NF%CE%BAB+signaling+pathway&doi=10.3109%2F17435390.2010.541604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34eR"><div class="casContent"><span class="casTitleNuber">34e</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory responses of RAW 264.7 macrophages upon exposure to nanoparticles: role of ROS-NFÎºB signaling pathway</span></div><div class="casAuthors">Nishanth, Reddy P.; Jyotsna, Radhika G.; Schlager, John J.; Hussain, Saber M.; Reddanna, Pallu</div><div class="citationInfo"><span class="NLM_cas:title">Nanotoxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">502-516</span>CODEN:
                <span class="NLM_cas:coden">NANOGK</span>;
        ISSN:<span class="NLM_cas:issn">1743-5404</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Recent advances in particle-forming chemistries used for developing nanotechnol. has not only widened novel applications for nanoscale materials but also has provided significant concern regarding their biol. effects.  The present study investigates the inflammatory responses of RAW 264.7 mouse macrophages exposed to nanoparticles (NPs, 5 Î¼g/mL) of varied sizes including silver (Ag), aluminum (Al), carbon black (CB), carbon coated silver (CAg) and gold (Au).  A significant increase in IL-6, reactive oxygen species (ROS) generation, nuclear translocation of nuclear factor-kappa B (NF-ÎºB), induction of cyclooxygenase-2 (COX-2), and tumor necrosis factor-alpha (TNF-Î±) expression was obsd. in macrophages with max. response found in cells exposed to Ag NPs followed by Al, CB and CAg.  These pro-inflammatory effects of NPs were dependent on size and duration of exposure and comparable to those induced by lipopolysaccharide (LPS), a known inflammatory mediator.  Au NPs, on the other hand, induced small but significant inflammatory responses in macrophages upon prolonged exposure.  These studies reveal that Ag NPs exhibit higher propensity in inducing inflammation, mediated by ROS and NF-ÎºB signaling pathways and leading to the induction of COX-2, TNF-Î± and IL-6.  However, no such prominent pro-inflammatory responses were obsd. with Au NPs, suggesting their bio-compatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBXe19-iFdMLVg90H21EOLACvtfcHk0lifm0muQLNzqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1egurY%253D&md5=fa78ce9bbf060611afdc45b7a92611b9</span></div><a href="/servlet/linkout?suffix=cit34e&amp;dbid=16384&amp;doi=10.3109%2F17435390.2010.541604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F17435390.2010.541604%26sid%3Dliteratum%253Aachs%26aulast%3DNishanth%26aufirst%3DR.%2BP.%26aulast%3DJyotsna%26aufirst%3DR.%2BG.%26aulast%3DSchlager%26aufirst%3DJ.%2BJ.%26aulast%3DHussain%26aufirst%3DS.%2BM.%26aulast%3DReddanna%26aufirst%3DP.%26atitle%3DInflammatory%2520responses%2520of%2520RAW%2520264.7%2520macrophages%2520upon%2520exposure%2520to%2520nanoparticles%253A%2520role%2520of%2520ROS-NF%25CE%25BAB%2520signaling%2520pathway%26jtitle%3DNanotoxicology%26date%3D2011%26volume%3D5%26spage%3D502%26epage%3D516%26doi%3D10.3109%2F17435390.2010.541604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">751</span>â <span class="NLM_lpage">758</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2012.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.molcel.2012.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=23352452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=751-758&author=A.+K.+Freemanauthor=D.+A.+Rittauthor=D.+K.+Morrison&title=Effects+of+Raf+dimerization+and+its+inhibition+on+normal+and+disease-associated+Raf+signaling&doi=10.1016%2Fj.molcel.2012.12.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling</span></div><div class="casAuthors">Freeman, Alyson K.; Ritt, Daniel A.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Raf kinases are essential for normal Ras-Raf-MEK-ERK pathway signaling, and activating mutations in components of this pathway are assocd. with a variety of human cancers, as well as the related developmental disorders Noonan, LEOPARD, and cardiofaciocutaneous syndromes.  Although the Raf kinases are known to dimerize during normal and disease-assocd. Raf signaling, the functional significance of Raf dimerization has not been fully elucidated.  Here, using mutational anal. and a peptide inhibitor, we show that dimerization is required for normal Ras-dependent Raf activation and for the biol. function of disease-assocd. Raf mutants with moderate, low, or impaired kinase activity.  However, dimerization is not needed for the function of B-Raf mutants with high catalytic activity, such as V600E-B-Raf.  Importantly, we find that a dimer interface peptide can effectively block Raf dimerization and inhibit Raf signaling when dimerization is required for Raf function, thus identifying the Raf dimer interface as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_CXtQf2fRqbVg90H21EOLACvtfcHk0lifm0muQLNzqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCqtr8%253D&md5=7c8dfaa1a8c01cd4d87cbd8ef364df8d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2012.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2012.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DA.%2BK.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DEffects%2520of%2520Raf%2520dimerization%2520and%2520its%2520inhibition%2520on%2520normal%2520and%2520disease-associated%2520Raf%2520signaling%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D49%26spage%3D751%26epage%3D758%26doi%3D10.1016%2Fj.molcel.2012.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wildtype and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16364920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wildtype+and+mutant+B-RAF+activate+C-RAF+through+distinct+mechanisms+involving+heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span></div><div class="casAuthors">Garnett, Mathew J.; Rana, Sareena; Paterson, Hugh; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-969</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The protein kinase B-Raf is mutated in approx. 7% of human cancers.  Most mutations are activating, but, surprisingly, a small no. have reduced kinase activity.  However, the latter can still stimulate cellular signaling through the MEK-ERK pathway because they activate the related family member C-Raf.  We examd. the mechanism underlying C-Raf activation by B-Raf.  We show that C-Raf is activated in the cytosol in a Ras-independent manner that requires activation segment phosphorylation and binding of 14-3-3 to C-Raf.  We show that wild-type B-Raf forms a complex with C-Raf in a Ras-dependent manner, whereas the mutants bind independently of Ras.  Importantly, we show that wild-type B-Raf can also activate C-Raf.  Our data suggest that B-Raf activates C-Raf through a mechanism involving 14-3-3 mediated heterooligomerization and C-Raf transphosphorylation.  Thus, we have identified a B-Raf-C-Raf-MEK-ERK cascade that signals not only in cancer but also in normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcr3ut9vW0NrVg90H21EOLACvtfcHk0liJn1HIY5iINg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D&md5=5db9fcc0a36f7670fcd3e92b399ed0de</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWildtype%2520and%2520mutant%2520B-RAF%2520activate%2520C-RAF%2520through%2520distinct%2520mechanisms%2520involving%2520heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rushworth, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">Regulationand role of Raf-1/B-Raf heterodimerization</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2262</span>â <span class="NLM_lpage">2272</span>, <span class="refDoi">Â DOI: 10.1128/mcb.26.6.2262-2272.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1128%2Fmcb.26.6.2262-2272.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=16508002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=2262-2272&author=L.+K.+Rushworthauthor=A.+D.+Hindleyauthor=E.+O%E2%80%99Neillauthor=W.+Kolch&title=Regulationand+role+of+Raf-1%2FB-Raf+heterodimerization&doi=10.1128%2Fmcb.26.6.2262-2272.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and role of Raf-1/B-Raf heterodimerization</span></div><div class="casAuthors">Rushworth, Linda K.; Hindley, Alison D.; O'Neill, Eric; Kolch, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2262-2272</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway participates in the control of many fundamental cellular processes including proliferation, survival, and differentiation.  The pathway is deregulated in up to 30% of human cancers, often due to mutations in Ras and the B-Raf isoform.  Raf-1 and B-Raf can form heterodimers, and this may be important for cellular transformation.  Here, we have analyzed the biochem. and biol. properties of Raf-1/B-Raf heterodimers.  Isolated Raf-1/B-Raf heterodimers possessed a highly increased kinase activity compared to the resp. homodimers or monomers.  Heterodimers between wild-type Raf-1 and B-Raf mutants with low or no kinase activity still displayed elevated kinase activity, as did heterodimers between wild-type B-Raf and kinase-neg. Raf-1.  In contrast, heterodimers contg. both kinase-neg. Raf-1 and kinase-neg. B-Raf were completely inactive, suggesting that the kinase activity of the heterodimer specifically originates from Raf and that either kinase-competent Raf isoform is sufficient to confer high catalytic activity to the heterodimer.  In cell lines, Raf-1/B-Raf heterodimers were found at low levels.  Heterodimerization was enhanced by 14-3-3 proteins and by mitogens independently of ERK.  However, ERK-induced phosphorylation of B-Raf on T753 promoted the disassembly of Raf heterodimers, and the mutation of T753 prolonged growth factor-induced heterodimerization.  The B-Raf T753A mutant enhanced differentiation of PC12 cells, which was previously shown to be dependent on sustained ERK signaling.  Fine mapping of the interaction sites by peptide arrays suggested a complex mode of interaction involving multiple contact sites with a main Raf-1 binding site in B-Raf encompassing T753.  In summary, our data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiol. activation process and that the heterodimer has distinct biochem. properties that may be important for the regulation of some biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4CMv4bNtn7Vg90H21EOLACvtfcHk0liJn1HIY5iINg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xislygtb0%253D&md5=2826875a4a2509255bb203ec154be080</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2Fmcb.26.6.2262-2272.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Fmcb.26.6.2262-2272.2006%26sid%3Dliteratum%253Aachs%26aulast%3DRushworth%26aufirst%3DL.%2BK.%26aulast%3DHindley%26aufirst%3DA.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DRegulationand%2520role%2520of%2520Raf-1%252FB-Raf%2520heterodimerization%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2006%26volume%3D26%26spage%3D2262%26epage%3D2272%26doi%3D10.1128%2Fmcb.26.6.2262-2272.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khamisy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span> <span> </span><span class="NLM_article-title">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">28</span>, <span class="refDoi">Â DOI: 10.1016/s0092-8674(04)00206-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2FS0092-8674%2804%2900206-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=15066279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=17-28&author=J.+I.+Loizouauthor=S.+F.+El-Khamisyauthor=A.+Zlatanouauthor=D.+J.+Mooreauthor=D.+W.+Chanauthor=J.+Qinauthor=S.+Sarnoauthor=F.+Meggioauthor=L.+A.+Pinnaauthor=K.+W.+Caldecott&title=The+protein+kinase+CK2+facilitates+repair+of+chromosomal+DNA+single-strand+breaks&doi=10.1016%2Fs0092-8674%2804%2900206-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span></div><div class="casAuthors">Loizou, Joanna I.; El-Khamisy, Sherif F.; Zlatanou, Anastasia; Moore, David J.; Chan, Douglas W.; Qin, Jun; Sarno, Stefania; Meggio, Flavio; Pinna, Lorenzo A.; Caldecott, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CK2 was the first protein kinase identified and is required for the proliferation and survival of mammalian cells.  Here, we have identified an unanticipated role for CK2.  We show that this essential protein kinase phosphorylates the scaffold protein XRCC1 and thereby enables the assembly and activity of DNA single-strand break repair protein complexes in vitro and at sites of chromosomal breakage.  Moreover, we show that inhibiting XRCC1 phosphorylation by mutation of the CK2 phosphorylation sites or preventing CK2 activity using a highly specific inhibitor ablates the rapid repair of cellular DNA single-strand breaks by XRCC1.  These data identify a direct role for CK2 in the repair of chromosomal DNA strand breaks and in maintaining genetic integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqiQqOcdOwurVg90H21EOLACvtfcHk0liJn1HIY5iINg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D&md5=494c5eb7c11f74d080dc07ebc17eda77</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900206-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900206-5%26sid%3Dliteratum%253Aachs%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DEl-Khamisy%26aufirst%3DS.%2BF.%26aulast%3DZlatanou%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DThe%2520protein%2520kinase%2520CK2%2520facilitates%2520repair%2520of%2520chromosomal%2520DNA%2520single-strand%2520breaks%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fs0092-8674%2804%2900206-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabik, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of resistance and toxicity associated with platinating agents</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.ctrv.2006.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.ctrv.2006.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=17084534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=9-23&author=C.+A.+Rabikauthor=M.+E.+Dolan&title=Molecular+mechanisms+of+resistance+and+toxicity+associated+with+platinating+agents&doi=10.1016%2Fj.ctrv.2006.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance and toxicity associated with platinating agents</span></div><div class="casAuthors">Rabik, Cara A.; Dolan, M. Eileen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-23</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Platinating agents, including cisplatin, carboplatin, and oxaliplatin, have been used clin. for nearly 30 years as part of the treatment of many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma.  The cytotoxic lesion of platinating agents is thought to be the platinum intrastrand crosslink that forms on DNA, although treatment activates a no. of signal transduction pathways.  Treatment with these agents is characterized by resistance, both acquired and intrinsic.  This resistance can be caused by a no. of cellular adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and increased levels of DNA repair or DNA tolerance.  Here we investigate the pathways that treatment with platinating agents activate, the mechanisms of resistance, potential candidate genes involved in the development of resistance, and assocd. clin. toxicities.  Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclin. data that has clin. relevance generated over the past five years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLxn13FCg9DbVg90H21EOLACvtfcHk0liJn1HIY5iINg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVartrw%253D&md5=9d5cc75e635b074a03a11c2f67c7914b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2006.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2006.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DRabik%26aufirst%3DC.%2BA.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520and%2520toxicity%2520associated%2520with%2520platinating%2520agents%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2007%26volume%3D33%26spage%3D9%26epage%3D23%26doi%3D10.1016%2Fj.ctrv.2006.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saris, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Vaart, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rietbroek, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloramaert, F.</span></span> <span> </span><span class="NLM_article-title">In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2763</span>â <span class="NLM_lpage">2769</span>, <span class="refDoi">Â DOI: 10.1093/carcin/17.12.2763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1093%2Fcarcin%2F17.12.2763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=9006117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADyaK2sXos1Sltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1996&pages=2763-2769&author=C.+P.+Sarisauthor=P.+M.+van+de+Vaartauthor=R.+C.+Rietbroekauthor=F.+Bloramaert&title=In+vitro+formation+of+DNA+adducts+by+cisplatin%2C+lobaplatin+and+oxaliplatin+in+calf+thymus+DNA+in+solution+and+in+cultured+human+cells&doi=10.1093%2Fcarcin%2F17.12.2763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells</span></div><div class="casAuthors">Saris, C. P.; van de Vaart, P. J. M.; Rietbroek, R. C.; Blommaert, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2763-2769</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Two interesting representatives of a new generation of platinum-based cytostatic drugs that are currently being tested in clin. trials are lobaplatin [1,2-diaminomethylcyclobutane platinum(II) lactate] and oxaliplatin [1,2-diaminocyclohexane platinum (II) oxalate].  Since little is known about the DNA adduct formation of these compds., the authors studied their formation in DNA in vitro in calf thymus DNA and in cells.  The major adducts formed in vitro were the Pt-GG and Pt-Ag intrastrand crosslinks.  The latter adducts could be detected using a recently developed 32P-postlabeling method.  Using both this assay and at. absorption spectroscopy, it was shown that there is a substantially higher rate of the in vitro adduct formation by cisplatin, compared with lobaplatin and oxaliplatin.  Platinum concns. required to obtain 90% cell kill during a 2 h incubation of A2780 cells were 15 Î¼M for cisplatin and oxaliplatin and 22 Î¼M for lobaplatin.  Using an antiserum originally raised against cisplatin-treated DNA, the authors were also able to detect platinum-DNA adducts induced by lobaplatin and oxaliplatin.  Maximal nuclear staining for all three compds. was obsd. after a 4 h post-incubation period.  The nuclear staining level induced by cisplatin was about 10-fold higher than after lobaplatin and oxaliplatin treatment.  GG and AG adducts, measured by 32P-postlabeling, also showed max. levels at about 4 h after cisplatin, lobaplatin and oxaliplatin, resp.  The ratios of GG over AG intrastrand crosslinks in the A2780 cells were not significantly different for the various compds.  In conclusion, the 32P-postlabeling technique has been shown to be appropriate for adduct anal., not only for the classical Pt compds. cisplatin and carboplatin but also for novel platinum compds. like lobaplatin and oxaliplatin.  Results indicated large differences in reactivity of the latter compds. to DNA in vitro, compared with cisplatin.  This difference was smaller in cells, suggesting enhancement of adduct formation by certain cellular mechanisms and/or compds.  From these studies, no conclusions can be drawn with resp. to the cytotoxicity of the different Pt-GG and Pt-Ag intrastrand crosslinks formed by these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqR-jeAv0gIrVg90H21EOLACvtfcHk0lixvDS1hKMzuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXos1Sltg%253D%253D&md5=c1b398e21c11c9fa5da5a79e39298270</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2F17.12.2763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252F17.12.2763%26sid%3Dliteratum%253Aachs%26aulast%3DSaris%26aufirst%3DC.%2BP.%26aulast%3Dvan%2Bde%2BVaart%26aufirst%3DP.%2BM.%26aulast%3DRietbroek%26aufirst%3DR.%2BC.%26aulast%3DBloramaert%26aufirst%3DF.%26atitle%3DIn%2520vitro%2520formation%2520of%2520DNA%2520adducts%2520by%2520cisplatin%252C%2520lobaplatin%2520and%2520oxaliplatin%2520in%2520calf%2520thymus%2520DNA%2520in%2520solution%2520and%2520in%2520cultured%2520human%2520cells%26jtitle%3DCarcinogenesis%26date%3D1996%26volume%3D17%26spage%3D2763%26epage%3D2769%26doi%3D10.1093%2Fcarcin%2F17.12.2763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stennett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibellini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-GalÃ¡n, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiestner, A.</span></span> <span> </span><span class="NLM_article-title">ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1979</span>â <span class="NLM_lpage">1991</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-11-2113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1158%2F1078-0432.ccr-11-2113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=22351695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOlsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1979-1991&author=C.+M.+Chapmanauthor=X.+Sunauthor=M.+Roschewskiauthor=G.+Aueauthor=M.+Farooquiauthor=L.+Stennettauthor=F.+Gibelliniauthor=D.+Arthurauthor=P.+P%C3%A9rez-Gal%C3%A1nauthor=A.+Wiestner&title=ON+01910.Na+is+selectively+cytotoxic+for+chronic+lymphocytic+leukemia+cells+through+a+dual+mechanism+of+action+involving+PI3K%2FAKT+inhibition+and+induction+of+oxidative+stress&doi=10.1158%2F1078-0432.ccr-11-2113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress</span></div><div class="casAuthors">Chapman, Colby M.; Sun, Xiameng; Roschewski, Mark; Aue, Georg; Farooqui, Mohamed; Stennett, Lawrence; Gibellini, Federica; Arthur, Diane; Perez-Galan, Patricia; Wiestner, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1979-1991</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Chronic lymphocytic leukemia (CLL), a malignancy of mature B cells, is incurable with chemotherapy.  Signals from the microenvironment support leukemic cell survival and proliferation and may confer chemotherapy resistance.  ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome.  Our aim was to analyze the efficacy of ON 01910.Na against CLL cells in vitro and investigate the mol. effects of this drug on tumor biol.  Exptl. Design: Cytotoxicity of ON 01910.Na against CLL cells from 34 patients was detd. in vitro with flow cytometry of cells stained with Annexin V and CD19.  Global gene expression profiling on Affymetrix microarrays, flow cytometry, Western blotting, and cocultures with stroma cells were used to delineate ON 01910.Na mechanism of action.  RESULTS: ON 01910.Na induced apoptosis in CLL B cells without significant toxicity against T cells or normal B cells.  ON 01910.Na was equally active against leukemic cells assocd. with a more aggressive disease course [Ig heavy-chain variable region unmutated, adverse cytogenetics] than against cells without these features.  Gene expression profiling revealed two main mechanisms of action: PI3K/AKT inhibition and induction of ROS that resulted in an oxidative stress response through activating protein 1 (AP-1), c-jun-NH2-terminal kinase, and ATF3 culminating in the upregulation of NOXA.  ROS scavengers and shRNA mediated knockdown of ATF3- and NOXA-protected cells from drug-induced apoptosis.  ON 01910.Na also abrogated the prosurvival effect of follicular dendritic cells on CLL cells and reduced SDF-1-induced migration of leukemic cells.  CONCLUSIONS: These data support the clin. development of ON 01910.Na in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHq7SJ_-_G0LVg90H21EOLACvtfcHk0lixvDS1hKMzuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOlsr8%253D&md5=befc3ea20445bc4c39da0f19074d4b34</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-11-2113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-11-2113%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DC.%2BM.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DAue%26aufirst%3DG.%26aulast%3DFarooqui%26aufirst%3DM.%26aulast%3DStennett%26aufirst%3DL.%26aulast%3DGibellini%26aufirst%3DF.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DP%25C3%25A9rez-Gal%25C3%25A1n%26aufirst%3DP.%26aulast%3DWiestner%26aufirst%3DA.%26atitle%3DON%252001910.Na%2520is%2520selectively%2520cytotoxic%2520for%2520chronic%2520lymphocytic%2520leukemia%2520cells%2520through%2520a%2520dual%2520mechanism%2520of%2520action%2520involving%2520PI3K%252FAKT%2520inhibition%2520and%2520induction%2520of%2520oxidative%2520stress%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D1979%26epage%3D1991%26doi%3D10.1158%2F1078-0432.ccr-11-2113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations</span>. <i>J. Formosan Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">599</span>â <span class="NLM_lpage">611</span>, <span class="refDoi">Â DOI: 10.1016/s0929-6646(09)60380-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fs0929-6646%2809%2960380-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19666347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKmsLjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=599-611&author=C.-Y.+Liuauthor=C.-F.+Leeauthor=Y.-H.+Wei&title=Role+of+reactive+oxygen+species-elicited+apoptosis+in+the+pathophysiology+of+mitochondrial+and+neurodegenerative+diseases+associated+with+mitochondrial+DNA+mutations&doi=10.1016%2Fs0929-6646%2809%2960380-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of reactive oxygen species-elicited apoptosis in the pathophysiology of mitochondrial and neurodegenerative diseases associated with mitochondrial DNA mutations</span></div><div class="casAuthors">Liu, Chun-Yi; Lee, Cheng-Feng; Wei, Yau-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Formosan Medical Association</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">599-611</span>CODEN:
                <span class="NLM_cas:coden">JFASEO</span>;
        ISSN:<span class="NLM_cas:issn">0929-6646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier (Singapore) Pte Ltd.</span>)
        </div><div class="casAbstract">A review.  A wide spectrum of pathogenic mutations of mitochondrial DNA (mtDNA) has been demonstrated to cause mitochondrial dysfunction and overprodn. of reactive oxygen species (ROS), in relation to mitochondrial and neurodegenerative diseases.  Our previous studies have shown that large-scale deletions of mtDNA not only serve as an indicator of oxidative damage, but also result in greater susceptibility of human cells to apoptosis triggered by UV irradn. and other apoptotic stimuli.  In this review, we focus on the involvement of mtDNA-mutation-assocd. oxidative stress and susceptibility to apoptosis in the pathophysiol. of mitochondrial and neurodegenerative diseases.  Different lines of research have provided concordant data to suggest that the mtDNA-mutation-elicited energy insufficiency and enhanced oxidative stress and damage lead to cell dysfunction, and increase the susceptibility of affected cells to apoptosis in patients with these diseases.  Moreover, accumulating exptl. evidence has shown that antioxidant therapy is a good strategy for decreasing intracellular ROS and alleviating oxidative-stress-induced apoptosis in cells of patients that harbor pathogenic mtDNA mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfnZBRyvsj67Vg90H21EOLACvtfcHk0lixvDS1hKMzuw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKmsLjP&md5=1a4ccf4fec0113ee06e8251158f8e0f5</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1016%2Fs0929-6646%2809%2960380-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0929-6646%252809%252960380-6%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.-Y.%26aulast%3DLee%26aufirst%3DC.-F.%26aulast%3DWei%26aufirst%3DY.-H.%26atitle%3DRole%2520of%2520reactive%2520oxygen%2520species-elicited%2520apoptosis%2520in%2520the%2520pathophysiology%2520of%2520mitochondrial%2520and%2520neurodegenerative%2520diseases%2520associated%2520with%2520mitochondrial%2520DNA%2520mutations%26jtitle%3DJ.%2520Formosan%2520Med.%2520Assoc.%26date%3D2009%26volume%3D108%26spage%3D599%26epage%3D611%26doi%3D10.1016%2Fs0929-6646%2809%2960380-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of mitochondria targeted Flavoneânaphthalimideâpolyamine conjugates with antimetastatic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2071</span>â <span class="NLM_lpage">2083</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2071-2083&author=F.+Daiauthor=Q.+Liauthor=Y.+Wangauthor=C.+Geauthor=C.+Fengauthor=S.+Xieauthor=H.+Heauthor=X.+Xuauthor=C.+Wang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+mitochondria+targeted+Flavone%E2%80%93naphthalimide%E2%80%93polyamine+conjugates+with+antimetastatic+activity&doi=10.1021%2Facs.jmedchem.6b01846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Mitochondria-Targeted Flavone-Naphthalimide-Polyamine Conjugates with Antimetastatic Activity</span></div><div class="casAuthors">Dai, Fujun; Li, Qian; Wang, Yuxia; Ge, Chaochao; Feng, Chenyang; Xie, Songqiang; He, Haoying; Xu, Xiaojuan; Wang, Chaojie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2071-2083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 90% of cancer-assocd. deaths result from disseminated tumors, indicating the ineffectiveness of current therapies and the imperative need of antimetastatic drugs.  A novel pharmacophore with flavonoid and naphthalimide moieties was constructed by using a fragment-based drug design and a series of eight flavone-naphthalimide-polyamine conjugates were synthesized.  In vitro evaluation revealed that compd. I with a homospermidine motif displayed better cell selectivity between cancerous and normal liver cells than amonafide did.  The in vivo assays on two hepatocellular carcinoma (HCC) models verified that I potently suppressed pulmonary metastasis with improved organ indexes compared to amonafide.  Various expts. showed that I as a potential fluorescent chem. probe could target the mitochondria.  Preliminary investigation into the mechanism of action of I indicated that it might harness a polyamine transporter for cell entrance, localize in the mitochondria, selectively cause reactive oxygen species (ROS) overprodn. in hepatoma cells instead of normal liver cells, and finally lead to HCC cell apoptosis and migration inhibition via multiple ROS-mediated signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVnOVDRABi27Vg90H21EOLACvtfcHk0lihBGQxLc1LvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSqt7s%253D&md5=de5add465c72748224b38fd9a153f131</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01846%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520mitochondria%2520targeted%2520Flavone%25E2%2580%2593naphthalimide%25E2%2580%2593polyamine%2520conjugates%2520with%2520antimetastatic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2071%26epage%3D2083%26doi%3D10.1021%2Facs.jmedchem.6b01846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.</span></span> <span> </span><span class="NLM_article-title">Cancer cell killing via ROS: To increase or decrease, that is the question</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1875</span>â <span class="NLM_lpage">1884</span>, <span class="refDoi">Â DOI: 10.4161/cbt.7.12.7067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.4161%2Fcbt.7.12.7067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=18981733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Glt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1875-1884&author=J.+Wangauthor=J.+Yi&title=Cancer+cell+killing+via+ROS%3A+To+increase+or+decrease%2C+that+is+the+question&doi=10.4161%2Fcbt.7.12.7067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell killing via ROS: to increase or decrease, that is the question</span></div><div class="casAuthors">Wang, Jie; Yi, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1875-1884</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Reactive oxygen species (ROS) act as a second messenger in cell signaling and are essential for various biol. processes in normal cells.  Any aberrance in redox balance may relate to human pathogenesis including cancers.  Since ROS are usually increased in cancer cells due to oncogene activation, relative lack of blood supply or other variances and ROS do involve in initiation, progression and metastasis of cancers, ROS are considered oncogenic.  Ironically, ROS prodn. is a mechanism shared by all non-surgical therapeutic approaches for cancers, including chemotherapy, radiotherapy and photodynamic therapy, due to their implication in triggering cell death, therefore ROS are also used to kill cancer cells.  Because of the double-edged sword property of ROS in detg. cell fate, both pro- or anti-oxidant therapies have been proposed for treatments of cancers.  Based on either side, a no. of drugs, agents and approaches are developed or in the progress of development, some of which have shown clin. promise.  This review summarizes the current understanding on ROS-manipulation strategies in cancer treatment and underlying mechanisms.  ROS-producing or -eliminating agents and the potential drugs in this aspect are categorized.  An effort is made in particular to discuss the paradox in the rationales of two opposite ROS-manipulation strategies and the concerns for their use.  Selectivity between tumor and non-tumor cells may depend on difference of their redox environments.  A combinational set of cellular parameters including redox status, antioxidant enzymes expression, cell signaling and transcription factor activation profiles, namely "redox signaling signature", is waiting for being developed in order to choose ROS-elevating or ROS-depleting therapy specific to certain type of cancer cells.  In clin. setting individualized choice of an optimal ROS-manipulation therapy may require accurate and convenient measurements for ROS as well as "redox signaling signature" for prediction of efficacy and systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-R3JAlagNIbVg90H21EOLACvtfcHk0lihBGQxLc1LvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Glt7g%253D&md5=61838888fcbc11271f6474919d572cde</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.4161%2Fcbt.7.12.7067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.7.12.7067%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DJ.%26atitle%3DCancer%2520cell%2520killing%2520via%2520ROS%253A%2520To%2520increase%2520or%2520decrease%252C%2520that%2520is%2520the%2520question%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1875%26epage%3D1884%26doi%3D10.4161%2Fcbt.7.12.7067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clerkin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naughton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quiney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotter, T. G.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of ROS modulated cell survival during carcinogenesis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">30</span>â <span class="NLM_lpage">36</span>, <span class="refDoi">Â DOI: 10.1016/j.canlet.2008.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1016%2Fj.canlet.2008.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=18372105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2008&pages=30-36&author=J.+S.+Clerkinauthor=R.+Naughtonauthor=C.+Quineyauthor=T.+G.+Cotter&title=Mechanisms+of+ROS+modulated+cell+survival+during+carcinogenesis&doi=10.1016%2Fj.canlet.2008.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ROS modulated cell survival during carcinogenesis</span></div><div class="casAuthors">Clerkin, J. S.; Naughton, R.; Quiney, C.; Cotter, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  There is increasing evidence within the literature that the decreased susceptibility of tumor cells to stimuli that induce apoptosis can be linked to their inherently increased redox potential.  The review primarily focuses on the PI3-kinase/Akt pathway, and the multiple points along this signalling pathway that may be redox regulated.  The PI3-kinase/Akt pathway can influence a cells' sensitivity to death inducing signals, through direct manipulation of apoptosis regulating mols. or by regulating the activity of key transcription factors.  Proteins involved in the control of apoptosis that are directly regulated by the PI3-kinase/Akt pathway include caspase-9, Bad and the transcription factor GSK-3Î².  Lately, it is becoming increasingly obvious that phosphatases are a major counter balance to the PI3-kinase/Akt pathway.  Phosphatases such as PP2A and PP1Î± can dephosphorylate signalling mols. within the PI3-kinase/Akt pathway, blocking their activity.  It is the balance between the kinase activity and the phosphatase activity that dets. the presence and strength of the PI3-kinase/Akt signal.  This is why any protein modifications that hinder dephosphorylation can increase the tumors survival advantage.  One such modification is the oxidn. of the sulphydryl group in key cysteine residues present within the active site of the phosphatases.  This highlights the link between the increased redox stress in tumors with the PI3-kinase/Akt pathway.  This review will discuss the various sources of reactive oxygen species within a tumor and the effect of these radicals on the PI3-kinase/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfmcBwEYdkbbVg90H21EOLACvtfcHk0lihBGQxLc1LvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKlu7c%253D&md5=b5dd40feb838ad74d7a22bdba45a52fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DClerkin%26aufirst%3DJ.%2BS.%26aulast%3DNaughton%26aufirst%3DR.%26aulast%3DQuiney%26aufirst%3DC.%26aulast%3DCotter%26aufirst%3DT.%2BG.%26atitle%3DMechanisms%2520of%2520ROS%2520modulated%2520cell%2520survival%2520during%2520carcinogenesis%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D266%26spage%3D30%26epage%3D36%26doi%3D10.1016%2Fj.canlet.2008.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusatis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheelhouse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulesza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hidalgo, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">610</span>â <span class="NLM_lpage">618</span>, <span class="refDoi">Â DOI: 10.1038/onc.2008.424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fonc.2008.424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=19029951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7zM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=610-618&author=A.+Jimenoauthor=A.+Chanauthor=G.+Cusatisauthor=X.+Zhangauthor=J.+Wheelhouseauthor=A.+Solomonauthor=F.+Chanauthor=M.+Zhaoauthor=S.+C.+Cosenzaauthor=M.+R.+Reddyauthor=M.+A.+Rudekauthor=P.+Kuleszaauthor=R.+C.+Donehowerauthor=E.+P.+Reddyauthor=M.+Hidalgo&title=Evaluation+of+the+novel+mitotic+modulator+ON+01910.Na+in+pancreatic+cancer+and+preclinical+development+of+an+ex+vivo+predictive+assay&doi=10.1038%2Fonc.2008.424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay</span></div><div class="casAuthors">Jimeno, A.; Chan, A.; Cusatis, G.; Zhang, X.; Wheelhouse, J.; Solomon, A.; Chan, F.; Zhao, M.; Cosenza, S. C.; Ramana Reddy, M. V.; Rudek, M. A.; Kulesza, P.; Donehower, R. C.; Reddy, E. P.; Hidalgo, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">610-618</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The purpose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy.  Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xenografts.  ON 01910.Na showed equiv. activity to gemcitabine against pancreatic cancer cell lines in vitro.  The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1.  These markers were optimized for a fine-needle aspirate ex vivo rapid assay.  Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility.  Next, nine patient-derived tumors from the PancXenoBank were profiled using the assay developed in cell lines and treated with ON 01910.Na for 28 days.  Two cases were cataloged as potential responders and seven as resistant.  There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response.  Of the seven tumors of predictive resistant, only one was sensitive to ON 01910.Na.  In addn., there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment.  The novel mitotic inhibitor, ON 01910.Na, showed activity in preclin. model of pancreatic cancer.  A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeiRhg4c6sqLVg90H21EOLACvtfcHk0liwRn2eceA7oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7zM&md5=ad45c01db1c55597ea204767e63cd262</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.424%26sid%3Dliteratum%253Aachs%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DCusatis%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWheelhouse%26aufirst%3DJ.%26aulast%3DSolomon%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DM.%2BR.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DKulesza%26aufirst%3DP.%26aulast%3DDonehower%26aufirst%3DR.%2BC.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520novel%2520mitotic%2520modulator%2520ON%252001910.Na%2520in%2520pancreatic%2520cancer%2520and%2520preclinical%2520development%2520of%2520an%2520ex%2520vivo%2520predictive%2520assay%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D610%26epage%3D618%26doi%3D10.1038%2Fonc.2008.424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohrens, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzinger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang-Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKoy, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozols, R. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of a cis-diamrninedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">414</span>â <span class="NLM_lpage">418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=3539322" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1987&pages=414-418&author=B.+C.+Bohrensauthor=T.+C.+Hamiltonauthor=H.+Masudaauthor=K.+R.+Grotzingerauthor=J.+Whang-Pengauthor=K.+G.+Louieauthor=T.+Knutsenauthor=W.+M.+McKoyauthor=R.+C.+Youngauthor=R.+F.+Ozols&title=Characterization+of+a+cis-diamrninedichloroplatinum%28II%29-resistant+human+ovarian+cancer+cell+line+and+its+use+in+evaluation+of+platinum+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBohrens%26aufirst%3DB.%2BC.%26aulast%3DHamilton%26aufirst%3DT.%2BC.%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DGrotzinger%26aufirst%3DK.%2BR.%26aulast%3DWhang-Peng%26aufirst%3DJ.%26aulast%3DLouie%26aufirst%3DK.%2BG.%26aulast%3DKnutsen%26aufirst%3DT.%26aulast%3DMcKoy%26aufirst%3DW.%2BM.%26aulast%3DYoung%26aufirst%3DR.%2BC.%26aulast%3DOzols%26aufirst%3DR.%2BF.%26atitle%3DCharacterization%2520of%2520a%2520cis-diamrninedichloroplatinum%2528II%2529-resistant%2520human%2520ovarian%2520cancer%2520cell%2520line%2520and%2520its%2520use%2520in%2520evaluation%2520of%2520platinum%2520analogues%26jtitle%3DCancer%2520Res.%26date%3D1987%26volume%3D47%26spage%3D414%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amos, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twentyman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1316</span>â <span class="NLM_lpage">1323</span>, <span class="refDoi">Â DOI: 10.1038/bjc.1993.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=10.1038%2Fbjc.1993.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=8099807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGht7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=1316-1323&author=H.+Coleyauthor=W.+Amosauthor=P.+Twentymanauthor=P.+Workman&title=Examination+by+laser+scanning+confocal+fluorescence+imaging+microscopy+of+the+subcellular+localisation+of+anthracyclines+in+parent+and+multidrug+resistant+cell+lines&doi=10.1038%2Fbjc.1993.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localization of anthracyclines in parent and multidrug resistant cell lines</span></div><div class="casAuthors">Coley, H. M.; Amos, W. B.; Twentyman, P. R.; Workman, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1316-23</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">This study highlights the usefulness of laser scanning confocal microscopy in the examn. of subcellular disposition of anthracyclines in tumor cell lines.  The distribution of anthracycline compds. has been studied in two pairs of parental and multidrug resistant (MDR) cell lines.  For the parental EMT6 mouse mammary tumor cell line EMT6/P treated with doxorubicin (DOX) the anthracycline fluorescence was shown to be predominantly nuclear but with some particulate cytoplasmic fluorescence and very low levels of plasma membrane staining.  In the same expts. much fainter fluorescence was seen for the EMT5/AR 1.0 MDR subline which hyperexpresses P-glycoprotein.  The loss of nuclear fluorescence was comparatively greater than loss of cytoplasmic fluorescence.  For the human large cell lung cancer line COR-L23/P cellular DOX disposition was markedly nuclear with nuclear membrane staining and diffuse cytoplasmic fluorescence.  For the MDR line COR-L23/R, which lacks P-glycoprotein expression, DOX fluorescence was reduced in the nucleus compared with the parental line, but an intense area of perinuclear staining was seen consistent with localization to the Golgi app.  The morpholinyl-substituted analog MR-DOX achieved very similar subcellular distribution in both parental and MDR lines, consistent with its retention of activity in the latter.  The presence of verapamil during anthracycline exposure increased the intensity of fluorescence in the MDR lines, particularly in the nucleus.  Relatively little effect was seen in the parental lines.  Confocal microscopy provides high resoln. images of the subcellular distribution of anthracyclines in parent and MDR cell lines.  Differences in drug disposition in various cell lines may provide insights into the mechanism of multidrug resistance and suggest strategies for its therapeutic circumvention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6AjVNm_Dl_LVg90H21EOLACvtfcHk0liwRn2eceA7oQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGht7k%253D&md5=5b836e6e7a5a747139831af60f18d2c8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1993.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1993.244%26sid%3Dliteratum%253Aachs%26aulast%3DColey%26aufirst%3DH.%26aulast%3DAmos%26aufirst%3DW.%26aulast%3DTwentyman%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DExamination%2520by%2520laser%2520scanning%2520confocal%2520fluorescence%2520imaging%2520microscopy%2520of%2520the%2520subcellular%2520localisation%2520of%2520anthracyclines%2520in%2520parent%2520and%2520multidrug%2520resistant%2520cell%2520lines%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1993%26volume%3D67%26spage%3D1316%26epage%3D1323%26doi%3D10.1038%2Fbjc.1993.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01223">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62361"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01223?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01223</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Table of IC<sub>50</sub> values in vitro of tested compounds against multidrug-resistant cancer lines, expression of P-glycoprotein (P-gp) in CDDP/DOX-resistant cancer cell lines, charts of stability of compound <b>29</b> and the release of CDDP and compound <b>26</b> under reduction of ascorbic acid and under acidic condition, figure and data of standard curve of <b>26</b>, HPLC analysis on the release of <b>26</b> in A549 cells, MST assays and CETSAs of <b>26</b> and <b>29</b>, western blotting analysis of the effect on BRAF and BRAF/CRAF complexes induced by <b>29</b>, table of IC<sub>50</sub> values of <b>26</b>, <b>29</b>, and CDDP at 24 h. A549 apoptosis induced by <b>29</b> by IC<sub>50</sub> concentration in 72 h, DNA damage assays and ROS assays induced by <b>29</b>, UV and fluorescence spectra of <b>26</b> and <b>29</b>, western blotting analysis of Pin 1 protein induced by <b>29</b>, table of antitumor activity of compound <b>29</b> on A549 xenograft models, and figures of HR-MS, <sup>1</sup>H, <sup>13</sup>C NMR spectra, and HPLC chromatograms (<b>18â23</b>, <b>27â29</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_001.pdf">jm9b01223_si_001.pdf (4.01 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01223/suppl_file/jm9b01223_si_002.csv">jm9b01223_si_002.csv (2.31 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01223&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01223%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-1%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01223" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aac7ef96e3c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
